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Hip fractures are one of the most common and debilitating injuries in older adults. Older 
adults who sustain a hip fracture are more likely to have increased mortality and morbidity 
with reduced quality of life. This, combined with slow recovery times, can lead to a need for 
entry to aged care facilities. 
Considerable work has been undertaken to investigate risk factors for hip fracture in the wider 
clinical research. This study built on that work and aims to identify risk factors for hip 
fracture in older adults with complex needs in the New Zealand context, based on questions 
from the interRAI home care (interRAI-HC) assessment. The interRAI-HC assessment is a 
standardised comprehensive clinical assessment typically given to people aged 65 years and 
older to assess areas of need that each person has. From the determined risk factors, a hip 
fracture risk score was developed to identify individuals who are more likely to sustain a hip 
fracture in the two years following their assessment.  
Two sets of interRAI-HC data were used in this study. The initial dataset (September 2012 to 
June 2015) was randomly split into two datasets. Two-thirds of the data was used to explore 
risk factors for hip fracture and to develop a risk score. A competing risk regression was used 
to determine which variables were significantly associated with hip fracture and were to be 
included in the hip fracture risk scores. The remaining one-third of the initial dataset was used 
to perform cross-validation of the developed scores, evaluating how well the scores predicted 
hip fracture events not used in the creation of the scores. Separate scores for males and 
females were created due to their different risk profiles. The predictive power of each score 
was assessed using Receiver Operator Characteristic (ROC) curves and their associated area 
under the curve (AUC) at various candidate thresholds. The scores developed were further 
validated with the second, more recent, set of interRAI-HC assessments (November 2015 to 
June 2018). 
Factors associated with hip fracture for the whole interRAI-HC assessment cohort were age, 
sex, ethnicity, falls, mental function varies, wandering, body mass index (BMI), tobacco use, 
Parkinson's disease, and dyspnoea (shortness of breath). For males, the risk factors associated 
with hip fracture were age, Parkinson's disease, and dyspnoea. For females, the factors 
associated with hip fracture were age, ethnicity, wandering, BMI, tobacco use, and dyspnoea. 
The male's score had an AUC of 0.586 (95% CI: 0.548 to 0.625), and the female's score had 
an AUC of 0.615 (95% CI: 0.593 to 0.637). When retesting using the more recent dataset, the 
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male's score had an AUC of 0.611 (95% CI: 0.594 to 0.629) and the female’s score had an 
AUC of 0.624 (95% CI: 0.612 to 0.636). 
The scores developed here were modestly predictive of hip fracture risk for a New Zealand 
interRAI-HC cohort. The results of this thesis provide a good foundation for the development 
of a more sensitive and specific hip fracture prediction model. With further development, the 
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The world population is ageing including that of New Zealand (1, 2), and with this 
comes higher numbers of age-related illnesses and injuries. With the rise in these age-
related conditions, health delivery services and hospital beds are under increasing 
pressures and demands. In response, international organisations, such as the World 
Health Organization (WHO), and government agencies, such as the New Zealand 
Ministry of Health (MoH), have instigated and re-developed policies to better manage 
older people’s health. A key strategy in countering these pressures and demands is 
around prevention. 
Hip fractures are one of the most common and debilitating injuries in older adults, and 
can lead to premature death, disability and length recovery. 
This thesis will focus on hip fractures in older people, and seeks to develop a score 
utilising data from a standardised comprehensive geriatric assessment tool to predict 
and, hopefully when implemented, reduce the associated mortality and morbidity. This 
introduction chapter gives an overview of hip fractures, including typical care and 
treatment for hip fractures in New Zealand. The second section of this chapter provides 
more detail on the phenomenon of ageing populations in New Zealand and the world, 
and the third section explores different policies about ageing and how this thesis fits 
within those policy aims. The fourth section details current methods of hip fracture 
prevention. The fifth section gives an overview of interRAI and how it used in 
healthcare in New Zealand and around the world. The sixth section discusses the aims 
and objectives of this thesis, and the seventh section then provides a brief description of 
each chapter of the thesis. 
 
1.1 Hip Fractures 
A hip fracture is defined as a break in the upper section of the femur. There are two 
types of hip fractures; intrascapular (cervical hip) fractures, and extracapsular 
(trochanteric) fractures (3, 4). Hip fractures are classed as osteoporotic fractures when 
they are caused by low bone mineral density (BMD). Osteoporotic fractures also 
commonly occur in the vertebra, wrist, humerus, rib, pelvis, clavicle, scapula, sternum, 
and tibia and fibula (3, 5). 
2 
 
1.1.1 Types of Hip Fracture 
Clinical classification of hip fractures in New Zealand uses the International Statistical 
Classification of Diseases, Tenth Revision, Australian Modification (ICD-10 AM) 
classifications in the S72 range of specification. Table 1 lists the ICD codes and the 
area of fracture they represent. 
 
Table 1 ICD-10 AM classifications for hip fracture 
Area of fracture ICD Code 
S72.0 Fracture of head and neck of femur 
S72.1 Pertrochanteric fracture 
S72.2 Subtrochanteric fracture of femur 
S72.3 Fracture of shaft of femur 
S72.4 Fracture of lower end of femur 
S72.8 Other fracture of femur 
S72.9 Unspecified fracture of femur 
 
1.1.2 Burden of Hip Fracture 
Hip fractures are a debilitating injury and one of the most common injuries in older 
adults, particularly in those aged 80 years and older (6). Older adults who sustain a hip 
fracture are likely to have a reduced quality of life (QoL) after recovery. Approximately 
50% of those who have a hip fracture will regain the ability to walk unaided, but with 
many of these people not regaining full mobility (7). Additionally, approximately 60% 
of people who have a hip fracture will require ongoing help with activities of daily 
living (ADLs) such as bathing, dressing, or toileting (8, 9). 
Hip fractures have been linked to higher rates of mortality and higher rates of entry into 
aged residential care (ARC) facilities (10-12). In New Zealand it has been estimated 
that approximately 25% of adults aged 65 years and older who have hip fractures will 
enter ARC facilities, while another 25% will die prematurely (7). Hip fractures are 
rarely the single cause of premature death, but a combination of the hip fracture, age, 
sex, and co-morbidities have been found to be significantly associated with mortality 
(13). Walker et al. found that men had a higher rate of mortality after fracture than 
women, and individuals aged 85 years and older had higher rates of mortality after 
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fracture than those aged between 60 and 64 years (12). They also found that between 
1988 and 1992 there was an 8% rate of death within 35 days of fracture, and 24% 
within one year of sustaining a hip fracture (12). 
Additionally, studies have found that individuals who sustain a hip fracture are at an 
increased risk of sustaining a second subsequent fracture, compared to those who have 
not had a hip fracture (14, 15). A recent Australian study found that one in eleven 
individuals who had a hip fracture would have a second subsequent fracture (16). 
There is also a high financial burden associated with hip fracture. For example, in the 
United States of America (US), hip fractures accounted for 14% of all fractures in 
2005, but represented 72% of the total fracture related costs (17, 18). In 2016, there 
were 3,750 people admitted to hospital in New Zealand for a hip fracture arising from a 
fall, which cost the health system approximately $171 million (19, 20). A typical hip 
fracture that requires a stay in hospital of up to three weeks costs approximately 
$47,000 in 2019. If there are complications arising from the hip fracture which lead to 
the individual being released to an ARC facility after their hospital stay, the associated 
costs are closer to $135,000 (9). 
1.1.3 Treatment and Care of Hip Fractures in New Zealand 
New Zealand has District Health Boards (DHB) who are responsible for providing 
health care services in specific areas of the country. DHBs are organisations responsible 
for providing health and disability support within a specific geographic area of New 
Zealand. There are currently 20 DHBs in New Zealand (21) and some of them may 
have slightly different treatment plans for hip fracture. The New Zealand MoH has a set 
of guidelines outlining the standard process for hip fracture treatment. The MoH is the 
government advisory department that provides health information, and plans and funds 
public health services. The MoH also provides guidelines and monitors each of the 
DHBs but the DHBs can still differ in their treatment practices within those guidelines 
(22). Further, people admitted to hospital with a hip fracture have differing levels of 
fitness so their treatment plans may differ even when treated within the same DHB. 
When a person has a hip fracture in New Zealand, they are typically admitted to the 
emergency department of a hospital. In the normal course of events, the hospital staff 
will work with the patient to determine what is wrong and the best course of treatment 
based on their findings. X-rays of the hip are performed and hospital staff may also test 
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the patient’s blood and perform chest X-rays to check for any heart or lung problems 
that may affect decisions made about surgery. While these tests are being undertaken, a 
patient will be given painkillers, or other medications, if needed. Depending on the 
severity of the fracture, some patients will go straight to surgery from the emergency 
department, and others will be transferred to an orthopaedic ward. In the orthopaedic 
ward a full medical assessment will be done to determine the patient’s health and how 
fit they are for surgery (23). Before surgery the patient will meet with an anaesthetist 
and surgeon to discuss any details about the operation. There will also be a nursing 
team who will perform checks to assess the patient’s comfort, blood pressure, body 
temperature, and heart rate. The anaesthetist will then administer anaesthetic, and the 
surgery will be performed. After the surgery, the patient will be transferred to a 
recovery room where their condition will be assessed to ensure the patient is not 
suffering any ill effects from the surgery. When the patient is doing well, they are 
transferred to a hip fracture or orthopaedic ward. After the patient is returned to the 
ward post-surgery, the recovery and rehabilitation stages begin. Patients typically spend 
a few days or weeks in hospital for rehabilitation to regain strength. A team of 
specialists such as nurses, physiotherapists, occupational therapists, and social workers 
work with the patient to tailor a recovery plan. Part of the recovery plan will involve 
determining whether the patient requires extra help at home such as specialised 
equipment to reduce falls, further medical checks, or access to community-based 
exercise classes (23). 
To ensure that a high standard of care is provided to anyone suffering a hip fracture, the 
Australian and New Zealand Hip Fracture Registry (ANZHFR) audits a number of 
hospitals in Australia and New Zealand using both patient level and hospital level data 
to assess seven focus areas to ensure a high quality of hip fracture care in hospitals (24). 
As part of its annual audit, in 2018 the ANZHFR gathered information on hip fracture 
treatment from 56 hospitals, 15 of which were in New Zealand. A total of 9,408 records 
on individual hip fractures (2,291 from New Zealand, 7,117 from Australia) were used 
for this report. Patients whose data were used for the audit were limited to individuals 
over 50 years of age who had fractured their hip from a minimal trauma injury (e.g., 




According to the audit, approximately 50% of hospitals in New Zealand document 
performing a pain assessment within 30 minutes of presenting to the emergency 
department, and 38% of patients are receiving painkillers within the first 30 minutes of 
arriving or while travelling to hospital. The rate of pain management using nerve blocks 
has been improving in New Zealand hospitals, with 61% of hip fracture patients in 
2018 receiving nerve blocks compared with 58% in 2017 and 51% in 2016. In New 
Zealand, 24% of patients are assessed by a geriatrician before their surgery. 
Approximately, 80% of patients undergo surgery within the first 48 hours of them 
presenting to hospital. In the cases where patients had to transfer from one hospital to 
another for the surgery, the average time to surgery was 54 hours. The average length 
of stay in the emergency department was 5 hours. The day after surgery, 87% of 
patients are given the opportunity to mobilise and 93% of patients have unrestricted 
weight-bearing immediately after surgery. Approximately 80% of patients were 
followed up 120 days after presentation to hospital, and of those who were followed up, 
23% stated they had returned to their pre-fracture level of mobility. Approximately 
74% of hip fracture patients in New Zealand underwent a falls-risk assessment during 
their hospital stay. Bone protection medication was prescribed to 25% of New Zealand 
hip fracture patients when they were discharged from hospital. Among New Zealand 
hip fracture patients who had a 120-day follow up, 38% were still taking bone 
protection medication (25).  
1.1.4 Incidence of Hip Fracture 
1.1.4.1 Worldwide 
Hip fracture incidence rates vary worldwide. A systematic review by Kanis et al. 
grouped countries into three categories of risk: high, moderate, and low incidence (26). 
The categories were based on the rates of fracture per 100,000 people/year. High 
incidence of fracture was defined as >300 in women, or >150, or >250 for both men 
and women. Regions with a high incidence of fracture included Northern, South 
Western, and Central Europe, countries in the Middle East, and some Asian countries 
such as Singapore, Japan, and Korea. Moderate instance was defined as 200-300 in 
women, 100-150 in men, or 150-250 in men and women. Moderate risk regions 
included Australia, New Zealand, China, Argentina, India, and North America. Low 
instances were <200 in women, <100, or <150 in both men and women. Low-risk 
regions included South East Asia, Latin America, and Africa (26). A study conducted 
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in the United Kingdom based on general practice data estimated that the lifetime risk of 
a female sustaining a hip fracture is 11.4% and for a male it is 3.1% (27). 
1.1.4.2 New Zealand 
Langley et al. identified hip fracture incidence rates in New Zealand for individuals 
aged 50 years and over from 1974 to 2007. After adjusting for age, , the incidence rate 
per 100,000 people/year was estimated to be approximately 100 for men in 1974, 
increasing to 150 in 2007. Compared to males, females had a higher incidence of 400 in 
1974; this rate increased to 490 in 1987 but declined thereafter to 370 in 2007 (28).  
The Langley study compared incidence rates across 5-year age groups by examining 
the rate ratio relative to a 50-54-year-old baseline group (28). (28). For males, the rate 
ratio increased with increasing age to a maximum rate ratio of 12 for the 95-99-year-old 
age group. There were similar trends among females, with the maximum rate ratio of 
10 observed for the 90-94-year-old age group (28). An earlier study on hip fracture risk 
among older people found that for both men and women, once they reached 90 years of 
age, their hip fracture risk did not increase with further ageing (29). Following from 
these results, Langley et al. estimated the incidence rates of hip fractures in 2025 
among those aged 65 years and older. They used two different approaches to estimate 
hip fracture trends, to allow for two different possible ways the trends could continue 
into the future. The first scenario assumed a constant rate of hip fracture incidence from 
2003 to 2025, and the second scenario, used the observed trend and assumed it would 
continue to 2025. The total number of hip fractures for males in 2007 was 799 and for 
females it was 2,250. This first scenario predicted an overall decrease in the annual 
number of hip fractures with an estimate of 649 fractures for males, and 1,232 hip 
fractures in females for the year 2025. The second scenario predicted an increase in the 
total number of hip fractures with an estimate of 2,439 hip fractures in males, and 4,395 
estimated hip fractures in males, for the year 2025 (28). 
A paper published in 1995 reported on the hip fracture incidence rates in Māori (New 
Zealand’s indigenous ethnic group) and non-Māori people aged 60 years and older (30). 
Their results found that non-Māori females had the highest rate of hip fractures (827 
per 100,000 people from 1989-1991), and Māori males had the lowest rate of hip 
fracture (197 per 100,000 people from 1989-1991) (30). When comparing the rates 
from 1989-1991 to previous hip fracture incidence rates from 1973-1975, Barber et al. 
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noted there was no significant increase in hip fracture rates for Māori male, but there 
were significant increases for non-Māori males, Māori females, and non-Māori females 
(30). Table 2 below, shows a comparison of the hip fracture rates for each group. 
Table 2 Age standardised rates of hip fracture per 100,000 of population comparison by years 
 Hip fracture rates 1973-
1975 (95% CI) 
Hip fracture rates 1989-
1991 (95% CI) 
Māori Male 149 (89-208) 197 (117-243) 
Non-Māori Male 162 (151-173) 288 (269-295) 
Māori Female 239 (147-331) 516 (355-566) 
Non-Māori Female 493 (476-510) 827 (795-832) 
 
Health Quality and Safety Care New Zealand (HQSC) collects data on falls in people 
aged 50 years and older (20). The data can be used to identify anyone who had a hip 
fracture due to a fall. The data comes from hospital inpatient and outpatient collections, 
the Accident Compensation Corporation (ACC), DHB shared services, and the 
Pharmaceutical Collection. (ACC is a New Zealand organisation which provides 
financial support to anyone who has suffered an accidental injury in New Zealand. The 
Pharmaceutical Collection is a data warehouse that contains the claim and payments 
information for subsidised dispensing.) The latest report was from 2016 and identifies a 
total of 3,750 people who were admitted to hospital for a hip fracture in that year with 
an average rate of 2.4 fractures per 1,000 people/year. Hip fracture rates increased with 
age, with 49% of fractures occurring in people aged 85 years and older (20). They 
found that women had higher rates of hip fracture than men, but these figures were not 
age adjusted. Māori are New Zealand’s indigenous people and represent 16.5% of the 
population, and they often have differing outcomes and corresponding healthcare needs 
in many areas of healthcare. People who identified as European/Other ethnicity had a 
higher rate of hip fracture (2.8 per 1,000 people) than people who identified as one of 
the other three ethnicity groups specified in the study: Māori, Pacific people, and Asian 
(all with a rate of 0.8 per 1,000 people). The HQSC report also stated that hip fracture 
rates have not significantly changed since 2011 but no figures were given (20). 
The ANZHFR 2018 audit across 15 different hospitals in New Zealand from 1 January 
2017 to 31 December 2017 identified 2,291 people who had a hip fracture. Of those 
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2,291 people, 70% were female and the average age of patients was 84 years. Most hip 
fracture patients identified as European ethnicity (approximately 80%) with 3.6% of 
individuals identifying as Māori and Pacific people. Most people were living at home 
(72%) at the time of sustaining their hip fracture and 39% of people were identified as 
having dementia or impaired cognition (25).  
There appears to be an increase in the absolute hip fracture incidence around the world, 
including in New Zealand, when not standardising for age. One possible reason for this 
increase in hip fracture incidence could be that people are living longer - with an 
increasing number of older adults, there would be an expected increase in the rate of 
hip fracture. 
 
1.2 Ageing Population 
The world’s population is ageing (31, 32). In lower income countries, this is primarily 
due to lower rates of mortality in younger people, while in higher income countries, this 
is predominantly due to lower rates of mortality in older people (31). The ageing 
population has led to older adults (people aged 65 years and older) being the fastest 
growing age group around the world (31). It is estimated that from 2015 to 2050, the 
world population of people aged 60 years and older is expected to rise from 901 million 
to 2.1 billion (32). Additionally, the global population of people over 80 years old is 
expected to increase from 125 million in 2015 to 434 million in 2050. With an ageing 
population, there is an associated increase in risk of illnesses and greater health care 
requirements. The incidence of hip fracture is increasing, which leads to more people 
requiring health care services to treat hip fractures. Increased focus on health care now 
could help implement preventive measures to ensure that those who are living longer 
are doing so as healthy individuals. The WHO recognises the need for a greater focus 
on ensuring older people are not just living longer, but are living good and healthy lives 
(31, 33). 
New Zealand’s population is no exception to the global trend and is also ageing. This 
nation had 700,000 people aged 65 years and older in 2016; a number that is estimated 
to increase to around 1.32 to 1.42 million by 2043 (34). The population of those aged 
85 years and older is expected to increase from 83,000 in 2016 to between 239,000 and 
284,000 in 2043 (34).  
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These projected increases will have a major impact on the health care system as current 
service delivery is predicted to be unsustainable in the long-term if nothing is done. A 
change in delivery will be required to account for an increase in older people’s health 
services (35). With this change in health service delivery, there may be an increase in 
the cost of health care; however it has been noted that if preventive measures can be 
implemented in time, population ageing may not lead to significantly higher 
expenditure (36). Different organisations around the world have developed health 
policies to work towards better health care plans suited for an ageing population; 
section 1.3 below outlines some of the policies developed. The New Zealand 
government have also had several agencies developing policies to ensure that older 
person’s health is a top priority (37-39). It is important to understand the biomedical, 
social, and any other issues that may arise due to an ageing population so that they may 
be treated, and older adults can have a high QoL as they age. 
 
1.3 Policies and Health Care Services Relating to Ageing and Hip 
Fractures  
1.3.1 World Health Organization Ageing Strategy 
In response to the ageing population and the need for changes to the current health care 
service delivery models, in 2016 the World Health Assembly adopted a global strategy 
and action plan to ensure that adults were not only living longer, but they were also 
living healthier lives (31, 33). The action plan has five strategic objectives. The first 
objective is to take action to promote healthy ageing in every country. This involves a 
plan to establish national frameworks, strengthen the capacities of countries to develop 
evidence-based policies, and to combat ageism by providing better understanding about 
ageing. The second objective is to develop age-friendly environments. This includes 
encouraging older adults to have the freedom to make their own decisions and engage 
more with the community and promoting action across multiple sectors to ensure an age 
friendly environment at all levels. The third objective is to align health systems to the 
needs of the older people by developing health systems for capacity and functional 
ability, providing access to affordable age specific clinical care, and ensuring all health 
professionals are trained and educated on older people’s health. The fourth objective is 
to develop sustainable and equitable systems for long-term care, by constantly 
improving a long-term care system, establishing a strong workforce and supported 
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caregivers, and to ensure a high quality of person-centred long-term care. The final 
objective is to improve measurement, monitoring, and research on health ageing by 
having a consistent way of measuring, analysing, describing, and monitoring healthy 
ageing, strengthening research capacities and encouraging innovative research, and 
producing research around healthy ageing (33). 
1.3.2 New Zealand’s Ageing Strategy 
New Zealand is a signatory to the WHO Global Health and Ageing Strategy and has 
developed policies on healthy ageing in alignment with WHO’s guidelines. The MoH 
developed the Healthy Ageing Strategy to ensure that older people will live long, 
healthy lives and receive appropriate end-of-life care (39). The Healthy Ageing 
Strategy is informed by other health strategies such as the New Zealand Health 
Strategy, which was developed for all New Zealanders (37, 38), the New Zealand 
Disability Strategy (40), and several other New Zealand based policies relevant to 
healthy ageing, including Māori and Pacific health policies. The New Zealand Healthy 
Ageing Strategy has taken a life-course approach because ageing well begins when an 
individual is young and still developing, and adopting healthy habits early can lead to a 
healthier individual at an older age (39). 
The Healthy Ageing Strategy has five key areas of focus to ensure healthy ageing for 
all New Zealanders. The first key area is ageing well, which is a strategy dedicated to 
focusing on physical and mental health throughout an individual’s life, developing 
resilience, achieving equity among different ethnic groups, improving the physical, 
social, and environmental aspects of ageing, and supporting age-friendly communities. 
The second area of focus is acute and restorative care including accuracy of admissions, 
developing co-ordination between different hospital specialties, making sure hospitals 
are safe for all users including those with dementia, and aiding with recovery, both in 
hospital and out in the community. The third area of focus is on living well with long-
term conditions, ensuring that clinicians and social workers have the tools to help 
individuals with long-term conditions as well as giving the individuals themselves the 
resources to be able to ensure they have the support they need. The fourth focus area is 
support for people with high and complex needs, ensuring a high quality of in-home 
services and aged care services are available, in addition to support for the families. 
The final focus area is respectful end-of -life care ensuring the preferences of 
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individuals are respected, that families also have access to support at this time, and a 
high standard of palliative care (39). 
The Healthy Ageing Strategy is relevant to this thesis, as the research presented focuses 
on ageing well, and support for people with high and complex needs by developing a 
hip fracture risk score to assess how likely an individual is to sustain a hip fracture over 
a 2-year period. Individuals identified as being at an elevated risk of hip fracture may 
then be given extra support to try and reduce the risk of hip fracture. 
1.3.3 Osteoporosis New Zealand Strategic Plan 2017-2020 
Osteoporosis is a major risk factor for fracture. Osteoporosis New Zealand is an 
organisation that was founded in 1999 with the goal of increasing both public and 
government awareness of osteoporosis (41). Since then, Osteoporosis New Zealand has 
expanded their goals to include improving the lives of anyone who has osteoporosis, 
and to prevent fractures caused by osteoporosis (42). In 2012, Osteoporosis New 
Zealand published Bone Care 2020, a document which outlines why there is a need to 
implement a systematic approach to hip fracture care and prevention in New Zealand 
(43). The first objective is to develop a hip fracture registry to improve outcomes and 
the quality of care delivered after a hip fracture. The second objective is to prevent 
second hip fractures by providing adequate care services for patients who are in 
hospital with a hip fracture. The third objective is to prevent first hip fractures by 
working with general practitioners (GPs) to assess an individual’s risk of hip fracture. 
The fourth objective is to deliver consistent public health messages about how to 
maintain a healthy lifestyle and reduce the risk of fractures (7).  
The Osteoporosis New Zealand Strategic Plan was developed in 2016, following on 
from the guidelines established in Bone Care 2020. The Strategic Plan expanded upon 
the objectives outlined in Bone Care 2020 to establish six objectives targeted at 
different population groups and awareness programmes were developed for each 
objective, to educate the public about osteoporosis and related injuries(7). Table 3 




Table 3 Osteoporosis New Zealand Strategic Plan objectives and their corresponding programmes 
Target Group Objectives Programmes 
Hip fracture patients Improve outcomes and quality 
of care by developing a hip 
fracture registry 
Develop the New Zealand Hip 
Fracture Registry 
Other fracture patients Treat the first fracture and 
provide access to fracture 
liaison services to reduce the 
risk of a second fracture 
Push each DHB to adopt 
fracture liaison services 
People at risk of first 
fracture 
GPs to assess fracture risk of 
patients in their practice 
Develop first Fracture 
Prevention Programmes 
Adults age 65 years and 
older 
Deliver messages about health 
to the public about 
maintaining physical fitness 
Public awareness campaigns 
Adults aged 19-64 years Deliver public health 
messages about adopting a 
healthy lifestyle 
Public awareness campaigns 
Children up to age 18 
years 
Deliver public health 
messages about achieving 
healthy bone mass 
Public awareness campaigns 
 
Since the publication of the strategic plan, a hip fracture registry has been developed in 
conjunction with the ANZHFR and the HQSC (https://www.hipfracture.co.nz) (25). 
Fracture liaison services have been implemented in DHBs, and a study was published 
in 2016 about the experiences of the Waitemata DHB employing fracture liaison 
services (44). Additionally, in 2017 the ANZHFR published the Clinical Guidance on 
the Diagnosis and Management of Osteoporosis in New Zealand, which is a tool 
developed to guide clinicians in the prevention and treatment of osteoporotic fractures 
(45). The third objective of the Osteoporosis New Zealand strategic plan is directly 
related to the aims of this thesis, which include assessing the fracture risk of patients, 
while the guidelines have been developed for use with GPs in their practice, this thesis 
aims to assess the hip fracture risk of all community-dwelling older adults who undergo 
an interRAI-home care (HC) assessment in New Zealand. More information on the 




1.4 Hip Fracture Prevention 
1.4.1 Prevention 
Hip fractures are serious injuries and focus on prevention is a top priority for many 
health providers around the world (46, 47). Common hip fracture prevention strategies 
include reducing the risk of falls in the home, increasing daily exercise, management of 
health and medication, and maintaining bone health (46). Hip protection devices are 
also sometimes used as a preventive measure. They can be either a plastic case or soft 
padding that covers an individual’s hip to reduce the chance of a hip fracture resulting 
from a fall (47). 
There are currently no active programmes in New Zealand specifically aimed at 
reducing hip fractures (43). In some instances where orthogeriatric care is available, 
patients who are hospitalised with a hip fracture will be provided with osteoporosis 
medications to help prevent a second fracture (43). Osteoporosis New Zealand are 
currently developing a First Fracture Prevention Programme. While there are no active 
programmes focused on hip fractures specifically, there is a falls prevention 
programme, Reducing Harm from Falls. This programme was developed in 2012, and 
updated in 2017, with the aim of reducing the number of falls and fall-related injuries in 
the population, including hip fracture. The programme has several toolkits and 
guidelines available online for clinicians to access (9). The focus of the programme is 
on education across ten topics, including the impact of falls, assessing risk of falls, 
ensuring safe environments, medications, and improving strength and balance (48). 
1.4.2 Risk Factors for Hip Fracture 
Research has been carried out to identify risk factors for hip fracture. This is done so 
that targeted prevention programmes can be developed to reduce a person’s risk of hip 
fracture. Falls are the most common risk factor associated with hip fracture, and other 
risk factors for hip fracture include osteoporosis, gender, and older age (15). A detailed 
discussion of risk factors for hip fracture can be found in Chapter Two. 
1.4.3 Prediction Models 
There have been many prediction models developed to identify individuals who have 
an elevated risk of hip fracture so that interventions may be put in place to reduce the 
risk of fractures. The prediction models incorporate multiple risk factors associated 
with hip fracture or falls. Often, the prediction models will give a result based on the 
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number of risk factors a person has; the more risk factors an individual has, the more 
likely they are to be at a high risk of fracture. An example of such a prediction model is 
the Garvan fracture risk calculator, which is one of the more commonly used hip 
fracture prediction scores. Items included in the Garvan fracture risk calculator are sex, 
age, fractures since the age of 50 years, and falls in the last 12 months, with an option 
to include a BMD measurement (49). Other prediction tools that have been developed 
are the FRAX (50), Qfracture (51), and Van Staa (52). 
Chapter Two contains a detailed discussion of different hip fracture prediction models, 
including the variables used and how well they predict hip fracture risk. 
 
1.5 InterRAI as a Health Care Service 
In conjunction with the New Zealand Ageing Strategy, the New Zealand Guidelines 
Group (NZGG) developed guidelines for clinical assessment processes for older people. 
The NZGG is an organisation established to aid in the promotion of effective health and 
disability services. The purpose of the guidelines was to deliver recommendations for 
appropriate and effective assessment processes for identifying social, personal, 
functional, and clinical needs of older people (53). Older people in New Zealand 
generally refers to individuals aged 65 years and older as this is the retirement age of 
many New Zealanders. In addition to the guidelines, the NZGG performed an audit of 
current assessment processes and found there was a disparity between the expectations 
for assessments and the way that assessments were conducted. It was decided by the 
NZGG that the use of a comprehensive evidence-based and standardised assessment 
tool would be a way to ensure the assessment processes matched the needs outlined by 
the NZGG (53). A review of potential assessment tools was conducted, which included 
four comprehensive tools, six overview tools, and two screening tools. The interRAI 
Home Care tool (interRAI-HC) was among those explored and was rated highly (54). 
In 2004, five DHBs piloted the interRAI-HC (55). The pilot programme was considered 
a success, and it was decided that interRAI-HC would be rolled out on a national level. 
Since 2012, it has been mandated for all individuals aged 65 years and older requiring 
publicly-funded health care services, including publicly-funded ARC. To enter a 
publicly-funded ARC, all adults must undergo an interRAI-HC assessment (56). From 
2015 it was also mandated that everyone in an aged care facility would receive the 
15 
 
interRAI long-term care facility (interRAI-LTCF) assessment every six months, or if 
their health changes significantly before that time, to ensure the healthcare needs of the 
residents are assessed on a regular basis (57). 
InterRAI is an international group dedicated to providing comprehensive clinical 
assessments across multiple areas of health. There are over 20 different interRAI 
assessments in use around the world with focuses ranging from new-born babies, to 
mental health, to assessments for older people, and to people under palliative care. In 
New Zealand, the interRAI assessments currently in use are the contact (CA), 
community health (CHA), home care (HC), long-term care (LTCF), and palliative care 
(PC) assessments. Each assessment contains a set of core items, shared across different 
assessments and a set of unique questions for use with specific assessments. For 
example, the LTCF assessment has questions about the type of activities a resident is 
involved in. 
The CA is a simple screening tool used to assess the severity of an individual’s needs, 
and whether they require a more comprehensive needs assessment such as the HC. The 
CA consists of core questions and in some cases expands to include extra questions 
based on an individual’s answers. For example, if an individual has cognitive issues 
their assessment will include extra questions to determine the severity of any cognitive 
impairment they may have. 
The CHA is designed for use in the community, and like the CA can incorporates 
question branching to include extra questions if needed, for example there is an assisted 
living addition available for the CHA to be included when an individual is in an 
assisted living facility. 
The HC is a comprehensive clinical assessment tool designed to evaluate the health 
needs of community-dwelling individuals. The LTCF is a comprehensive assessment 
designed for use in aged care facilities as a way of assessing the strengths and needs of 
an individual. The PC is an assessment of the strengths, needs, and preferences of older 
adults requiring palliative care (58). 
A summary of the assessment types can be found in Table 4. The LTCF and HC 
assessments are mandated in New Zealand for anyone seeking publicly funded health 
services. More information on how interRAI assessments are conducted (specifically - 
the HC assessment) can be found in chapter three. Large numbers of assessments are 
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undertaken each year in New Zealand and can be linked with other health data using a 
unique identifier given to each individual. More information on how the data is linked 
can be found in 3.2. 
Table 4 Summary of interRAI assessments used in New Zealand  
Assessment Target demographic 
CA Non-complex community dwelling individuals 
CHA Anyone in community with a specific care need 
HC Complex community-dwelling individuals 
LTCF People living in aged care residential care facilities 
PC People requiring palliative care 
 
1.6 Aim and Objectives 
The aim of this research was to develop a hip fracture prediction tool to be used for 
individuals who undergo an interRAI-HC assessment in New Zealand, as discussed in 
the interRAI as a health care services section above. The first objective was to identify 
risk factors associated with hip fracture. The second objective was to use the risk 
factors identified to develop a prediction score. 
 
1.7 Thesis Structure 
The remainder of this thesis has been structured using eight chapters together with 
supplementary materials at its conclusion. Chapter One has given a brief overview of 
hip fractures and how they impact older adults. There was also a brief explanation of 
how there is likely to be an increase in hip fractures due to an ageing population. The 
aim of this thesis was described. The second chapter provides an in-depth exploration 
and critique of the literature on hip fracture risk and provides a discussion on how this 
thesis can improve upon current studies of hip fracture risks in older people. The 
literature review also describes the gap in the literature that this thesis aims to fill. The 
third chapter explains the methodology. The chapter provides the justification for 
using a competing risk regression model for analysis and provides an explanation of 
how the hip fracture score will be developed. Chapter Four provides a brief overview 
of the dataset used for analysis. This chapter includes information on the data tidying 
process and basic descriptive statistics such as the mean age of the cohort, and 
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frequency of hip fractures within the dataset. The fifth chapter reports on analysis 
following on from the results of the score replication section in chapter three to build a 
competing risk regression model, based on the previous results and additional questions 
from the home care assessment. Chapter Six uses the results of the preceding two 
chapters to construct a hip fracture risk score. Scores calculated are then broken into 
two groups indicating low and high risk of fracture. This chapter goes into depth on the 
creation and optimisation of a hip fracture risk score that can be used to determine who 
is at an elevated risk of sustaining hip fractures. In Chapter Seven, the score is 
externally validated using a more recent version of the interRAI-HC dataset. It is a 
repeat analysis of the previous chapter to see how well the model predicts hip fracture 
risk for an external cohort. The final chapter (Chapter Eight) is an overview, and 
details strengths and weaknesses of various parts of the study. This chapter also 




2 Literature Review 
2.1 Introduction  
There is a large array of literature pertaining to hip fractures, including incidence of hip 
fracture, risk factors associated with hip fracture, outcomes after hip fracture, and 
effective methods for treatment and recovery after hip fracture. 
This chapter explores the literature in relation to the research goals of this thesis. 
Firstly, an examination of the literature around hip fracture risk will aid in identifying 
potential risk factors to include in analysis. Secondly, an exploration of the literature 
around hip fracture risk scores will help to identify methods and variables used to 
predict hip fracture risk in people. Finally, a breakdown of possible methods for use in 
clinical prediction models will provide insight into potential statistical methods to apply 
when developing a hip fracture risk score. A small section at the end of the chapter 
provides insight into how this thesis fits into the current body of knowledge regarding 
hip fracture risk, and the gap this research will fill. 
 
2.2 Methods 
Literature was systematically searched for across the Ovid Medline, and Google 
Scholar databases. The initial Ovid Medline search included articles from 1946 to 2019, 
but a later search only included articles from 2009 onwards to identify papers published 
within the last 10 years. The Google Scholar search was narrowed down to publications 
from 2009 to 2019. The literature searches were conducted in three parts. The first part 
was a search for literature on known risk factors for hip fracture. Key search terms used 
for this section were (hip fracture OR femur fracture) AND (older adults OR elderly) 
AND (risk factors). The second search was used to identify fracture scores and indexes 
relating to hip fracture. Key words used for this search were (hip fracture OR femur 
fracture OR osteoporotic fracture) AND (older adults OR elderly), AND (risk score 
OR prediction model OR Risk Assessment). Inclusion criteria for identifying relevant 
studies were: (i) studies including “older adults” as the cohort of interest (most studies 
included age 65 years and older as “older adults” but some early papers identified 
individuals 50 years and older as “older adults”); (ii) studies exploring potential risk 
factors for hip fracture; (iii) studies developing prediction models for hip fracture; and 
(iv) published in the English language. Relevance was evaluated based on the title and 
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abstract of all studies found in the database. The third and final search conducted was to 
identify statistical methods that may be used to develop prediction models. The 
statistical methods were identified from the methods of the papers identified in the first 
two searches. Additional information about each of the methods was found in statistical 
textbooks. References within each article of interest were also examined to identify 
further articles of interest for each of the three parts. Peer-reviewed journal articles, 
including systematic reviews were included, editorials and grey literature were 
excluded. 
Alerts for the key term risk factors for hip fracture were set up on Google Scholar in 
March 2019 and manual literature searches were conducted periodically from June 
2016 to September 2019 to identify any newly published papers that might have been 
of significance. All records of interest were collected in EndNote X9.2. Figure 1 below 
outlines the article selection criteria following the Preferred Reporting Items for 





Figure 1 Flow diagram detailing selection criteria for literature review 
 
2.3 Risk Factors for Hip Fracture 
Risk factors for hip fracture have been studied extensively. Risk factors can cover a 
wide variety of domains, such as falls, fractures, bone strength, age, sex, ethnicity, 
cognition, body mass index (BMI), environment, lifestyle factors, co-morbidities, 
medicine, and exercise. Each type of risk factor listed can be associated with hip 
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Falls are the biggest cause of osteoporotic fractures and there are several reasons why 
an individual may fall (60). Environment can affect falls risk; for example, living in a 
house with poor lighting, loose carpets, or small pieces of furniture, which can be 
tripping hazards, can lead to an increase in the number of falls (61). Cognition can also 
impact falls, as people with cognitive impairments such as dementia are more likely to 
be on medications that make them dizzy or lead to postural instability (62). Some 
medications can cause dizziness, which can lead to an increase in falls; for example, 
benzodiazepines are associated with falls (63). There are many other medical 
conditions that can more directly lead to falls, such as diabetes mellitus, which may 
cause an individual to experience dizziness (60). Exercise is associated with falls where 
those who are more physically fit are less likely to fall (64). This could be due to 
stronger muscles, better balance, and faster reflexes (64).  
Lifestyle factors such as smoking cigarettes and alcohol abuse have been linked to 
reduced bone mass, which increases the risk of fracture (61). Additionally, alcohol 
consumption has been found to be associated with an increase in falls risk in women; 
this is most likely from males and females having different alcohol metabolisms where 
females may be more susceptible to impaired cognition and physical functioning (65). 
BMI has been linked to fractures; those who have a low BMI are more likely to have a 
hip fracture than people with higher BMI (66). This is possibly due to those with lower 
BMI having less tissue surrounding the bones and when a fall occurs, a smaller 
individual is likely to have less cushioning from a fall and be more likely to fracture 
their bones (67). 
There are several associations between bone health and other risk factors for hip 
fracture. Age and sex are both correlated with bone health (60). Females tend to be at a 
greater risk of osteoporosis than males, particularly after menopause (60, 68). For both 
males and females, the older a person gets, the weaker their bones tend to be (68). 
There can also be differences in bone structure and bone density across different ethnic 
groups as found by Chin et al. amongst premenopausal women of Polynesian, Asian, 
and European descent (69). Use of some medications such as corticosteroids can reduce 
bone mineral density (BMD) (70). Regular exercise can increase bone mass which can 
help prevent bone fracture in older adults (71). 
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Different ethnic groups have different BMI distributions in their populations. This 
results from musculature varying across ethnic groups and the apparent variances in the 
body fat composition in the populations of different ethnic groups (72, 73). Figure 2 
below is a conceptual framework derived from the literature to help the reader 
understand how the literature fits together. The list below is not a comprehensive list of 
all the risk factors associated with hip fracture, but it does capture the main domains. 












The biggest risk factor for hip fracture identified in the literature is falls (60, 74-78). Early 
research indicated that approximately 90% of hip fractures were caused by falling (79). Issues 
that can lead to falls include balance problems, dizziness, and vision problems (60). Several of 
the kinds of risk factors for hip fracture are related to falls as shown in Figure 2. 
2.3.2 Fractures 
Fractures can themselves contribute to hip fracture risk. Many studies have shown that having 
a hip fracture or another type of osteoporotic fracture can increase the chance of sustaining a 
subsequent fracture (16). After an individual sustains a vertebral fracture, their risk of 
sustaining a hip fracture increases by a factor of 2.5 compared to those who have not had a 
vertebral fracture (61). Similarly, when an individual has already suffered a hip fracture, the 
risk of a subsequent hip fracture increases by a factor of 2.3 compared to those who have not 
had a hip fracture (61). A new hip fracture can occur on either side of the body so there is a 
chance that an individual could sustain two or more hip fractures in a lifetime. According to 
research conducted by Shroder et al., the risk of sustaining a third hip fracture is 
approximately 8.6 per 1,000 men and 9.8 per 1,000 women, per year (80). 
2.3.3 Bone Strength 
Reduced bone strength due to low BMD and osteoporosis are other contributing factors to hip 
fracture (61, 81). Osteoporosis is a disease where the bone becomes more fragile due to 
deterioration of bone tissue, and this can increase the chance of a fracture (3). Researchers 
exploring the effect of BMD on hip fracture risk found there was a strong relationship 
between BMD and hip fracture (61, 82). Wainwright et al. conducted a study to identify risk 
factors for hip fracture in women over 65 years old without osteoporosis and found lower 
BMD in the hip was associated with hip fractures (83). Bone shape can also be associated 
with hip fracture risk (61). An individual with a long hip axis is more likely to have a hip 
fracture than someone with a short hip axis (61). 
2.3.4 Age and Sex 
Demographic factors such as age and sex can also be related to hip fracture. Females tend to 
have a higher age adjusted risk of hip fracture, particularly as they are more likely to suffer 
from osteoporosis, diminished bone density, and other complications post-menopause (61, 68, 
84, 85). Male-specific studies reported that males who sustain a hip fracture were generally 
younger than females (86, 87). This is possibly because females tend to live longer and may 
have hip fractures at an older age (88). Females on the other hand tended to have lower BMD, 
be older in age, and have higher rates of osteoporosis (61). 
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All of the hip fracture studies reviewed found that older individuals have a higher chance of 
sustaining a hip fracture than younger individuals (60, 61, 75). It is estimated that worldwide, 
hip fracture incidence rates will rise by 1%-3% per year due to the ageing population (89, 90). 
Ageing is associated with reduced BMD due to changing bone structure and therefore 
increases the risk of hip fracture (91). Older people also have reduced muscle mass and 
impaired reflexes, which may make them more likely to fall and sustain a fracture (61). 
2.3.5 Ethnicity 
Ethnic differences have been found to influence hip fracture risk. Studies have shown that 
white or European individuals tend to be at a higher risk of fracture than a number of different 
ethnic groups (61, 69). An early study by Chin et al. identified Asian people as having shorter 
femoral necks and they postulated this may be a reason why Asian people tend to have a 
lower rate of hip fracture than that of Europeans (69). Their results also found that Polynesian 
people have longer femoral necks than those of European people, but Polynesians still have 
lower rates of hip fracture than Europeans. Chin et al. suggests that Polynesians may have 
higher BMD that may contribute to them having fewer hip fractures (69). Hamdy et al. noted 
that white and Hispanic Americans had similar fracture risk to each other while black and 
Asian individuals tended to have a reduced risk of hip fracture (61). The updated Qfracture 
study conducted by Hippisley-Cox et al. found that ethnicity was related to hip fracture in 
both males and females (92). Specifically, those who identified as white were at an elevated 
risk of fracture compared to other ethnic groups such as Indian, Pakistani, Bangladeshi, 
Chinese, other Asian, black African, and black Caribbean (92). Ethnic differences were also 
found to be associated with hip fracture risk in studies conducted by Berry et al. which found 
that white race was associated with an increased hip fracture risk (76). 
In New Zealand, hip fracture rates are higher in European/other ethnic groups than in Māori, 
Asian, and Pacific people (20). The age-standardised hip fracture rates per 1,000 people aged 
50 years and older in New Zealand were 0.8 for Māori, Pacific people, and Asians, and 2.8 for 
European/other people (20). An earlier study examining hip fracture rates in New Zealand 
found that Māori males had the lowest number of fractures compared to female Māori and 
male/female non-Māori (30). 
2.3.6 Cognition 
Cognition, or more specifically cognitive impairment, has been found to be associated with 
fracture risk (75, 76, 93). Wandering is a trait often associated with impaired cognition, and it 
has been found to increase the risk of hip fracture, particularly in older people living in aged 
care facilities (76, 94). In addition to wandering, the Berry et al. study examining hip fracture 
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in aged care facilities found that people who were easily distracted were likely to have a hip 
fracture, and for each increase of 1 point on the cognitive performance scale (CPS), an 
individual’s risk of fracture increased by approximately 3% (76). The CPS is a measure used 
at the end of an interRAI assessment to evaluate a person’s level of cognition, with a score 
ranging from 0 (intact) to 6 (very severe impairment) (95). A German study comparing the 
risk of hip fracture in people with dementia versus those without dementia found that people 
who had a diagnosis of dementia were at an increased risk of hip fracture (96). Bohlken et al. 
also found that people with dementia who lived in aged care homes were more likely to have 
a hip fracture than those who lived at home (96). Two recent studies looking at risk of 
subsequent hip fracture after an initial fracture found that people with dementia were more 
likely to sustain a second hip fracture, and they were also more likely to die within 30 days of 
the initial fracture (16, 97). 
2.3.7 BMI 
BMI is a measure calculated from an individual’s body mass divided by the square of the 
body height, expressed as kg/m2 and is used as a general rule to categorise people into groups: 
underweight (BMI <18.5), normal (18.5 > BMI > 30), overweight (30 > BMI >34.9) , and 
obese (BMI >35) (98). BMI is related to hip fracture risk in two ways. People who are 
underweight tend to have a higher risk of hip fracture than those in the higher BMI categories 
(66, 68, 76, 99, 100). Bean et al. examined 50 women with hip fractures and found that those 
with lower body mass seemed more likely to be at risk of fracture; when skeletal size (the size 
of the bones in a person’s body) was considered, body mass was not associated with hip 
fracture risk (101). Their findings suggest that skeletal size or muscle weakness (a lack of 
muscle strength), and not body mass, may be the reason for hip fracture, although their 
sample size was very small so further study around skeletal size would be useful for 
confirming these findings (101). 
Several studies have also noted that many people who are overweight have a reduced risk of 
hip fracture (99, 102). People with higher BMI tend to have a higher body fat percentage and 
this extra padding around the hip area could protect an individual from fractures after a fall 
(67). Another suggestion posited by Hla et al. is that an increased strain on the bones from the 
increased weight can help to increase the BMD, therefore the person is less likely to fracture 
their hip (103). Women with higher BMI tend to have greater levels of adipose tissue; when 





People with different living arrangements have also been found to have differing risk profiles. 
Chen et al. identified there was a difference in risk profiles between community-dwelling and 
institutionalised older people (105). Each group of individuals had different risk profiles as 
they were subject to different environments and had differing health needs (51, 75, 105, 106). 
One study from New Zealand examined the difference in hip fracture rates between 
community-dwelling and institutionalised older people and found that individuals living in 
institutions such as aged care facilities were at a higher risk of hip fracture than those living at 
home (29). Additionally, Hippisley-Cox et al. found, that for males, living in care facilities 
was a significant risk factor for hip fracture (92). Wilson et al. found that the type of residence 
was associated with hip fracture risk; their study noted that people living in mobile homes 
were at an increased risk of hip fracture compared to individuals living in a house, duplex, or 
town house (93). However, this could be related to factors associated with living in a mobile 
home, such as more tripping hazards. 
An individual’s home environment may be hazardous and can lead to hip fracture. Hazardous 
environments can include items such as clutter around the house, no hand holds in bathrooms, 
loose rugs, no stair rails, poor lighting, and uneven outdoor pathways on the property (78, 
107). A New Zealand study of falls risk examined reasons for falls resulting in hip fractures 
among 780 people. They found that 84.4% of the falls happened in the home and 13.1% 
happened away from home. Approximately 25% of the falls that occurred in the home had 
some form of object contribution (108). A case-control study conducted by Clemson et al. 
found nine specific hazards were associated with an increased risk of hip fracture; these were: 
doormats, floor mats in areas of high use such as hallways, internal stairs, seating, poor 
bedroom lighting, bathtubs, bathmats, and toilets (109).  
Socioeconomic factors have also been attributed to hip fracture risk. A Swedish study noted 
that employment, household income, and type of housing were associated with risk factor for 
postmenopausal women aged 50-81 years old (110). A study from the UK on risk factors for 
hip fracture found, that for males, the level of deprivation was associated with hip fracture 
risk, where those who were most deprived had a higher incidence of hip fracture (111). 
Additional studies have also noted that people who have a lower income level had a higher 
risk of hip fracture (112, 113). 
2.3.9 Lifestyle Factors 
Lifestyle factors such as smoking and alcohol consumption can affect a person’s risk of hip 
fracture. Many studies have shown that smoking tobacco can increase an individual’s risk of 
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hip fracture (75, 86, 114). Tobacco use can lead to a decrease in BMD (115, 116). 
Additionally, smokers tend to have inadequate dietary intake, particularly in terms of calcium 
and vitamin D, which are essential for healthy bones (61). 
Alcohol use has also been found to be associated with hip fracture risk (61, 117). One study 
found that alcohol consumption was associated with an increase in falls among women (65). 
Alcohol can also affect the BMD and lead to weaker bones, particularly in heavy drinkers 
(115, 118). Alcohol can also interact with medications leaving an individual with reduced 
cognitive function, thereby increasing their risk of falls (61). 
2.3.10 Co-Morbidities 
A variety of health conditions have been linked to an increased risk of hip fracture. Chronic 
obstructive pulmonary disorder (COPD) and Parkinson’s disease are two particular diseases 
that have been linked to an increased risk of hip fracture (16, 61, 119-121). A 2010 study by 
Dam et al. found older men with COPD or asthma were likely to have lower BMD than 
people who did not have either disease (119). It has been noted in other studies that 
individuals who have asthma, particularly those who are treated with corticosteroids, are at an 
increased risk of osteoporosis and fractures related to osteoporosis (122-124). People with 
Parkinson’s disease tend to be unsteady on their feet, which may lead to an increase in falls 
risk. Individuals with rheumatoid arthritis have also been found to be at risk of hip fracture 
(125-127). However individuals with osteoarthritis were less likely to have a hip fracture due 
to limited mobility (75, 76). Diabetes has also been associated with hip fracture risk (16, 76). 
Postural hypotension, stroke, Alzheimer’s disease, and arrhythmias may increase the risk of 
falls, which can, in turn, increase the risk for hip fracture (60, 128). 
Liang et al. conducted a meta-analysis of 13 studies to explore whether there was an 
association between cardiovascular disease and heart failure (129). The results showed there 
was a positive association between cardiovascular disease and hip fracture (129). Cancer 
patients have also been found to have an increased risk of hip fracture (60, 130). Edwards et 
al. identified that most older cancer patients had osteoporosis or low bone mass, which put 
them at a high risk of having a hip fracture (130). Their study included multiple types of 
cancer including breast, lung, and gastrointestinal cancers. Chen et al. found the risk of falls 
and fractures increased in postmenopausal women after they received a breast cancer 
diagnosis (131). A Swedish study found that older men undergoing androgen deprivation 
therapy for the treatment of prostate cancer developed osteoporosis and were at a high risk of 
sustaining a hip fracture compared to patients who were not undergoing androgen deprivation 
therapy for cancer treatment, and also compared to those who had no diagnosis of cancer 
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(132). A Danish study also found an increased risk of hip fracture among men with a 
diagnosis of prostate cancer and also among those who were undergoing androgen deprivation 
therapy (87). 
2.3.11 Medications 
Medications such as the use of corticosteroids have been identified as a risk factor for hip 
fracture (51, 81, 92, 102, 133-135). Taking corticosteroids can lead to a reduced BMD which 
increases an individual’s risk of hip fracture (70). Corticosteroids are commonly used to treat 
symptoms of COPD and asthma (136). Several studies have shown that corticosteroid use is a 
risk factor for hip fracture among people with COPD (137, 138). Additional studies have 
found psychotropic medications and medications for cardiovascular issues have been noted to 
be associated with an increased falls risk (139). 
Loop diuretics such as furosemide can increase the chance of hip fracture, particularly in men, 
as loop diuretics can increase urinary excretion of calcium, which leads to reduced BMD 
(140). However, this mechanism could also be due to confounding co-morbidities and/or 
hypotension (140). 
Both the FRS and FRAiL studies explored whether medications had an impact on hip fracture 
risk for interRAI-LTCF cohorts; both studies found that the medications they explored were 
not significantly associated with hip fracture risk (76, 94). 
To date, there have been two studies identifying specific medications that were associated 
with an increased risk of fracture among older New Zealanders (141, 142). The first, by 
Jamieson et al., determined there was a significant relationship between hip fracture risk and 
drug burden index drugs (sedative and anticholinergic medications) (141). In the second 
study, Nishtala et al. identified there was an increased risk of hip fracture associated with use 
of the sleeping pill Zopiclone (142). 
2.3.12 Exercise 
Physical activity has been linked with hip fracture risk (68, 86, 102, 143-150). Some studies 
have found that those who participate more in physical activity are less likely to sustain a hip 
fracture than those who do little to no physical activity (68, 86, 143, 144). A comparison of 
different levels of physical performance in older men found that those who had poor physical 
performance were more likely to sustain a hip fracture than those who were more physically 
fit (146). Their findings showed that men who had poor physical performance in at least three 
tasks were approximately 3 times (Hazard Ratio (HR) :3.14, 95% CI: 1.46, 6.73) more likely 
to sustain a hip fracture than men who had higher physical performance capacity (146). A 
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Swedish study examined the effect of different levels of physical activity on hip fracture risk 
and found there was no association between hip fractures and the amount of time spent on 
work-related physical activity or total physical activity. However, time spent on general 
household activities and leisure-time physical activity may decrease an adult’s risk of hip 
fracture (145). Particularly, people who spent less than one hour per week performing 
household activities had an 85% higher risk (HR: 1.85, 95% CI: 1.01,3.38) of hip fracture 
than people who spent ≥6 hours per week on the same activities (145). Trimpou et al. also 
identified that engaging in leisure-time activities had a reduced risk of hip fracture than those 
who did not engage in any leisure-time activities (HR: 0.83, 95% CI: 0.71, 0.97)(150). They 
also found that work related activities were not associated with hip fracture (150). Høidrup et 
al. identified that women who were moderately physically active for 2-4 hours per week had a 
decreased risk in hip fracture (HR: 0.72, 95% CI: 0.59, 0.89) (144). 
Some studies showed that implementing exercise programmes had a reduced impact on hip 
fracture risk. A Finnish study explored whether combined resistance and balance-jumping 
training for older adults had a lasting impact on reducing falls and fracture rates (149). Their 
study found that over five years of follow-up, those who participated in the exercise training 
had 51% less falls (Relative Risk (RR): 0.49, 95% CI: 0.25,0.98) and 74% less fractures (RR: 
0.26, 95% CI: 0.07, 0.97) than those who did not participate in the exercise programme (149). 
Additionally, a study conducted by Nikander et al. found that odd-impact exercises (soccer 
and squash) could be good for increasing the strength of the femoral neck which could reduce 
the risk of hip fracture (147). Nordström et al. also noted that individuals who participated in 
odd-impact exercises (ice-hockey and soccer) had stronger femoral necks in later life than 
those who did not compete in such sports (148). Regular exercise can increase bone strength 
by placing stress on the bones which helps stimulate bone strength and reduce the risk of 
fractures (151, 152). Additionally, exercise can help to improve balance leading to a reduction 
in falls and fall-related fractures (151, 153). 
Additionally, exercise in early life is important for reaching peak bone mass (154-157). 
Andreoli et al. conducted a study to explore the long-term effects of BMD in postmenopausal 
ex-athletes (158). Their study found there was minimal difference between the BMD in ex-
athletes and younger athletes, suggesting the benefits of physical activity performed in youth 
are maintained in later life (158). A meta-analysis by Karlsson et al. showed that exercise 
during an individual’s formative years has long-term benefits for skeletal strength, which can 




2.4 Fracture Scores and Indexes 
There are many risk factors associated with hip fracture as explored in the previous section. It 
is also important to note that there is a cumulative effect when one or more of the risk factors 
associated with hip fracture is found in an individual (160). For example, someone who has 
one risk factor such as low BMI would be less likely to have a hip fracture than an individual 
who has multiple risk factors such as low BMI, history of falls, older age, and osteoporosis. 
Researchers have made use of the cumulative nature of risk factors to develop models to 
identify individuals who may be at an elevated risk of hip fracture such as the FRAX and 
Garvan scores (49, 50). Many of the risk factor models are applied in a clinical setting to aid 
with hip fracture prevention. Once an individual’s risk of hip fracture has been calculated, the 
assessors can implement prevention practices to help reduce a person’s risk of fracture for 
those at high or medium risk. 
This section explores 11 different risk scores developed between 2001 and 2017, for use in 
predicting hip fractures, and explains why they were developed, the methods used to develop 
the score, and the risk factors used in each prediction tool. 
2.4.1 FRAX 
One of the most well-known tools for assessing hip fracture risk is the FRAX (Fracture risk 
assessment tool) score, developed by the researchers at the University of Sheffield in 2008 
(50, 161). The FRAX score was developed using Poisson regression. Hip fracture incidence 
data was taken from a study by Singer et al. (162); however, the study did not make clear how 
this data was applied to the total cohort. Items included in the FRAX score are age, sex, 
weight, height, previous fracture, a parent fracturing a hip, being a current smoker, using 
glucocorticoids, rheumatoid arthritis, osteoporosis, alcohol consumption, and femoral neck 
BMD (50). The FRAX score is used to determine the ten-year probability of hip fracture and 
other major osteoporotic fractures such as a spinal fracture (50, 161).  
Criticisms of the FRAX score include that it is for a general cohort of men and women aged 
40 years and older and may be too general to help people in specific age groups or situations 
such as those requiring home help. It could be a good screening tool to identify people who 
have some risk of hip fracture within the next ten years, but a more targeted score could be 
better for providing insight into health care and prevention programs for an individual with 
more specific health needs, such as those aged 65 years and older. Additional information, 





The bone fracture risk calculator, more commonly known as the Garvan tool, was developed 
in 2007 as a tool for predicting the 5- and 10-year risk of hip fracture in primary care settings 
(49). The Garvan was developed using a cohort of 1,028 females, and 740 males aged 60 
years and older living in the city of Dubbo, Australia. Within the cohort there were 127 
(6.5%) people who sustained a hip fracture, and 96 (4.9%) of these were sustained by females 
(49). 
Cox proportional hazards models were used to assess the risk factors for hip fracture, and a 
nomogram was created to predict hip fracture risk. A nomogram is a graphical way of 
presenting data. In this instance, the nomogram consists of separate lines for each item used to 
calculate hip fracture risk. Each line is a scale that corresponds to a certain number of points 
(163). The first item in the Garvan tool is age in years and a vertical line is drawn from the 
age of a person being assessed to the corresponding number of points to determine how many 
points that person receives for that specific risk factor. For example, a female aged 87 years 
old would receive a total of 20 points. This process is repeated for each item to obtain the 
number of points that correspond to those items. Once this has been done for all items in the 
tool, the points are added together and a vertical line is drawn from the total number of points 
to two scales at the bottom of the nomogram indicating the 5- and 10-year risk of hip fracture 
for the individual being evaluated. The items included in the Garvan tool are age, BMD T-
scores (which is a measure of bone density), previous fracture, and any falls in the last 12 
months. Nomograms were developed separately for males and females.  
The Area Under the Curve (AUC) for the Garvan model was 0.85 for both males and females, 
indicating the model has strong predictability (164). An AUC of 0.5 means there is an 
approximately 50% chance the test will accurately identify whether an individual is positive 
or negative and an AUC of 1 means the score perfectly identifies who is positive and who is 
negative (165). An internal validation was also conducted using a bootstrapping method 
where 1,000 sub-samples of 150 individuals of the whole sample were resampled with 
replacement, and analysed to see how well the Garvan tool can predict fracture in a different 
sample. The AUC for the Receiver Operator Characteristics curve (ROC) for the female 
model was 0.7 and for males it was 0.65 (49).  
The Garvan score was developed with a small sample size compared to other fracture scores, 
and it was specific to one city in Australia, which suggests it may not be generalisable to a 
worldwide population as each population may have differences that mean some risk factors 
are more prevalent than others in those specific countries. The Garvan uses BMD that requires 
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the individual to undergo a clinical test to determine; this may be hard to do for every patient. 
There are a variety of risk factors; several that have been commonly found in the literature 
suggesting the score may capture people who may be overlooked if just one or two risk 
factors were tested for.  
The nomogram method of calculation seems cumbersome given that the score could be easily 
calculated by developing a computer calculation where the required numbers are input into a 
calculation tool and the associated 5- and 10-year risk of hip fracture is returned once the 
input is completed. The Garvan Institute website now has an online tool (not mentioned in the 
original paper) using the same algorithm for calculating the 5- and 10-year risk, which will 
make it easier for clinicians to use (https://www.garvan.org.au/promotions/bone-fracture-
risk/calculator/).  
2.4.3 QFracture 
The QFracture scores were two scores developed in 2009 to estimate the 10-year risk of hip 
fracture and the 10-year risk of osteoporotic fracture (vertebral, distal radius (wrist), and hip 
fractures) in GP practice patients in England and Wales. The age of participants ranged from 
30 to 85 years. The study cohort was separated into a derivation and a validation dataset. The 
derivation dataset consisted of 1,183,663 females and 1,174,232 males, and the validation 
cohort consisted of 642,153 females and 633,764 males. In the derivation cohort, there were 
24,350 (2.1%) osteoporotic fractures and 9,302 (0.39%) hip fractures in females, and 7,934 
(0.34%) osteoporotic fractures and 5,424 (0.23%) hip fractures in males.  
Cox proportional hazards models were used to identify risk factors associated with hip 
fracture and osteoporotic fractures. Separate risk profiles were identified for males and 
females. The significant risk factors associated with osteoporotic fractures in females were 
use of hormone replacement therapy (HRT), smoking status, alcohol use, parental history of 
osteoporosis, rheumatoid arthritis, cardiovascular disease, type 2 diabetes, asthma, tricyclic 
antidepressants, corticosteroid use, history of falls, menopause symptoms, age, chronic liver 
disease, gastrointestinal malabsorption, BMI, and endocrine disorders. When exploring these 
variables in relation to hip fracture, use of HRT, menopausal symptoms, parental history of 
osteoporosis, malabsorption, and other endocrine disorders were not associated with hip 
fracture (51). 
Significant factors associated with both osteoporotic fracture and hip fracture alone were age, 
BMI, smoking status, alcohol use, rheumatoid arthritis, cardiovascular disease, type 2 
diabetes, asthma, use of tricyclic antidepressants, history of falls, liver disease, and 
34 
 
corticosteroid use. All variables associated with fracture were included in the final models for 
prediction. When validating the QFracture scores, it was found the hip fracture score 
performed better than the osteoporotic fracture scores in both males and females. The AUC 
for osteoporotic fracture scores was 0.788 (95% CI: 0.786, 0.790) in females, and 0.688 (95% 
CI: 0.684, 0.692) in males. The AUC from the ROC for the hip fracture scores was 0.890 
(95% CI: 0.889, 0.892) in females and 0.856 (95% CI: 0.851, 0.860) in males (51). 
There is a large cohort for both the derivation and validation samples, suggesting there is 
likely to be better statistical power and precision in estimates. All the items used in the 
QFracture score are easy to determine from asking the patient and do not require complicated 
clinical tests to calculate. The age range used for developing the QFracture score was 30-85 
years, which gives an estimate of fracture for a wider age range. This model may not be good 
at predicting the risk of fracture in people aged older than 85 years. 
2.4.4 QFracture Updated 
In 2012, an updated version of the QFracture score was developed using routinely collected 
data from thousands of GPs across the United Kingdom (UK). The decision to update the 
score was based on recommendations from the National Institute for Health Excellence 
(NICE) (92). NICE provides guidance on health care in the UK. Suggestions included 
expanding the age range of patients and including ethnicity information. The scores were 
designed for estimating the 10-year risk of osteoporotic fracture (this time with proximal 
humerus fractures included) and hip fracture. Additional potential items were added to the 
model and more items were found to be significantly associated with fracture risk. 
The data were separated into a derivation cohort (3,142,673 patients) and a validation cohort 
(1,583,373 patients). Within the derivation cohort there were 59,772 (1.9%) people who 
sustained a fracture, and within the validation cohort there were 28,685 (1.8%) people who 
sustained a fracture. A Cox Proportional hazards model was used to assess risk factors for 
fracture using the derivation cohort. Risk factors for osteoporotic fracture in females were 
age, BMI, ethnicity, alcohol consumption, smoking status, COPD, asthma, cancer, 
cardiovascular disease, dementia, epilepsy, history of falls, chronic liver disease, Parkinson’s 
disease, rheumatoid arthritis, systemic lupus erythematosus, chronic renal disease, diabetes 
(type 1 and type 2), previous fracture, endocrine disorders, gastrointestinal malabsorption, 
antidepressant use, corticosteroids, HRT, and parental history of hip fracture, and for hip 
fractures the risk factors were the same as for osteoporotic fracture except for gastrointestinal 
malabsorption and parental history of hip fracture.  
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For males, the risk factors were similar to those of the females but being in a residential care 
facility was also significant and endocrine problems was not. All significant factors for 
osteoporotic fracture were also significantly associated with hip fracture except for 
gastrointestinal absorption. The AUC from the ROC for osteoporotic fracture in females was 
0.790 (95% CI: 0.787, 0.793) and for hip fracture was 0.893 (95% CI: 0.890, 0.896). For 
males the AUC for osteoporotic fracture was 0.711 (95% CI: 0.703, 0.719) and for hip 
fractures it was 0.875 (95% CI: 0.868, 0.883) The updated Qfracture scores tested better than 
the original Qfracture scores, and, again, the hip fracture score had better calibration and 
discrimination than the osteoporotic fracture scores (92). 
The original Qfracture score was created using individuals aged 30-85 years old, and the 
updated score considers the older adults and ranges in age from 30-100 years old. The score 
had a large cohort and a large derivation cohort, which allowed for more statistical power. 
Cross-validation was used, which allows for testing the score on a dataset that was not 
directly used for development. A Cox proportional hazards model was used, and a competing 
risks model may be a better option as it would account for deaths as a competing event. There 
is an online tool available for use with the QFracture Updated algorithm at 
http://qfracture.org. 
2.4.5 FRACTURE Index 
The FRACTURE Index is a clinical assessment score used to assess the 5-year risk of 
osteoporotic fracture in postmenopausal women developed in 2001 in the USA (84). The 
FRACTURE index was developed to be simple to calculate in a clinical setting by using a 
small number of variables. The cohort consisted of 7,782 women who were recruited across 
multiple health care databases such as health plan information and registered voter lists. 
Within the cohort there were a total of 231 (3.0%) people who sustained a hip fracture (84). 
Variables included in the model are age, BMD (optional), fracture after age 50 years, maternal 
hip fracture after age 50 years, weight less than or equal to 57 kg (125 pounds), smoking 
status, and use of arms to stand up from a chair (84). There was a strong relationship between 
the FRACTURE index and incidence of hip fracture. The AUC from the ROC for the model 
was 0.714 without BMD and 0.766 with BMD (84). No confidence intervals were reported in 
the published paper.  
The FRACTURE score is developed for a specific cohort of postmenopausal women and is 
good for informing the clinicians and patients about their risk of fracture, which can help in 
determining which preventative strategies to implement for which people to best reduce 
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osteoporotic fractures. The specific cohort is also a disadvantage as it means the score may 
not necessarily work for other people; for instance, it would not work for predicting hip 
fracture risk in males. The cohort were healthy individuals, and anyone with complex health 
care needs may have a different risk profile, therefore the score may not work as well for 
those people. 
2.4.6 FRAMO 
The Fracture and Mortality (FRAMO) Index was developed in 2004 in Sweden to predict the 
risk of fracture and mortality in women aged 70 years and older (166). The cohort consisted 
of 1,248 women recruited from rural health care areas in Sweden. Within the cohort a total 
number of 31 (1.2%) women sustained a hip fracture. The FRAMO Index was developed to 
identify women who may be at high risk of vertebral and non-vertebral (including hip) 
fractures so that preventive measures can be taken to lower this risk. The score was developed 
using a small number of questions to be easily used as part of routine clinical assessments 
(166). 
The items included in the index were age, weight, previous fragility fracture (hip, lower arm, 
upper arm, or vertebrae fracture), and using arms to rise out of a chair. Both logistic 
regression and Cox proportional hazards models were employed to assess which variables 
were associated with hip fracture. The AUC of the index was 0.72 (95% CI: 0.64, 0.81) for 
hip fracture and 0.75 (95% CI: 0.71, 0.79) for mortality (166). 
The score was specifically developed for older females and may not be generalisable to other 
people. There are only four items used in the score and all are easy to obtain from the 
individual, which makes it easy to calculate a score. The size of the cohort used for 
development of the score was small so it is likely that a larger cohort could have yielded a 
more predictive model. 
2.4.7 FRISC 
The Fracture and Immobilisation Score (FRISC) is a prediction model developed for adults in 
Japan to assess the risk of fracture and immobilisation (167). It was developed to identify risk 
factors in a Japanese population and to identify an individual’s risk of fracture (both hip and 
other osteoporotic fracture). Patients were recruited while in hospital. The score was 
developed in 2010 using adults aged 40-79 years old. The cohort consisted of 1,787 people 
and 44 hip fractures occurred over a one-year period (167). 
Items used in the FRISC were age, weight, BMD, prior fracture, osteoporosis, dementia, 
menopausal status, and back pain. Poisson regression models were used for analysis. The 
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FRISC was validated using data from two different areas of Japan, Miyama and Taiji, where 
the AUC of the FRISC was 0.727 (95% CI: 0.660, 0.794) (167). 
This score was developed specifically for postmenopausal women in Japan and may not be 
generalisable to another audience. The sample size was small, and the score was not validated 
on any other datasets. The AUC was above 0.7 which suggests it is good for predicting hip 
fractures for the target cohort. 
2.4.8 Van Staa 
The Van Staa is a clinical tool developed to predict the 5-year risk of fracture (hip, vertebral, 
and other osteoporotic fracture) in postmenopausal women aged 50 years and older (52). The 
purpose of the Van Staa tool was to identify long-term risks of hip fracture in postmenopausal 
women. The development cohort consisted of 366,104 women living in the UK. There were a 
total of 6,453 (1.8%) hip fracture events. Patient information for the study was obtained from 
The Health Improvement Network (THIN) database of medical records from UK GP patients 
(52). 
Items included in the Van Staa assessment are age, BMI, previous fractures, falls, smoking 
status, medication use, early menopause, chronic disease, and medication for the central 
nervous system. Risk factors were identified using Cox proportional hazards models. The 
AUC was 0.84 for hip fracture, 0.69 for vertebral fracture, and 0.60 for other osteoporotic 
fracture (52). Confidence intervals of the AUCs were not reported in the published paper. 
This score was also developed specifically for postmenopausal women, and therefore may not 
be generalisable to a wider population. The cohort was large, which means there was high 
statistical power, and the score was validated with a cohort of 32,728 people. 
2.4.9 WHI 
The Women’s Health Initiative (WHI) developed an algorithm in 2007 to predict the 5-year 
risk of fracture in postmenopausal women. The purpose of the study was to develop a score 
using multiple risk factors for hip fracture in postmenopausal women. The cohort consisted of 
93,676 people living in the USA who were recruited from the WHI study exploring clinical 
interventions. There were a total of 1,132 (0.16%) hip fractures (102). 
Items included in the WHI algorithm were age, height, weight, ethnicity, previous fracture, 
parental history of fracture, alcohol consumption, medication use, self-reported health, and 
physical activity. The prediction model was developed using Cox proportional hazards 
models. The AUC for the entire cohort was 0.80 (95% CI: 0.77, 0.82). Models where some 
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variables were excluded were also explored. The AUC for the algorithm excluding active 
hormone therapy was 0.80 (95% CI: 0.77, 0.83), the AUC for the model excluding active 
dietary intervention was 0.78 (95% CI: 0.75, 0.81), and the algorithm excluding active 
calcium and vitamin D had an AUC of 0.81 (95% CI: 0.78, 0.83) (102). 
The WHI was developed for postmenopausal women and may not be generalisable to other 
populations. The algorithm was developed in a large cohort (93,676) but validated in a 
smaller cohort (10,750); the results of the validation cohort may not be as precise as they 
could be. The authors explored multiple different variations of the algorithm to test which of 
the scores had the highest AUC. 
2.4.10 FRAiL 
The Fracture Risk Assessment in Long-Term Care (FRAiL) model was developed using 
interRAI-LTCF data for older adults in US nursing homes in 2017. The purpose of the FRAiL 
study was to develop a hip fracture score for use with questions from the interRAI-LTCF 
assessment. The cohort consisted of 419,668 people with 299,794 females and 119,874 males. 
There were a total of 14,553 (3.5%) hip fractures (76). 
Questions used in the FRAiL model were age, race, cognitive performance score, ADL 
hierarchy scale (which is a measure of a person’s level of independence in performing 
personal hygiene activities, toilet use, locomotion, and eating), locomotion in room, bladder 
continence, previous fall, transfer performance, easily distracted, wandering, osteoarthritis, 
BMI, pressure ulcer, and diabetes. A competing risk model was used to develop the hip 
fracture scores. Initially, Berry et al. included medications in their model but removed them 
from the final model as they did not change the overall outcome of the score (76). Males and 
females had similar risk factors for hip fracture with the exception that diabetes was not 
statistically significant as a risk factor in males. Receiver operator characteristic (ROC) curves 
were created for the FRAiL model, and the area under the curve (AUC) were reported to 
assess how well the instrument predicts risk of fracture. The AUC reported for men was 0.67 
and for women was 0.69 (76). The FRAiL model was further validated and tested for 
prediction of hip and other fractures in 2019 in a retrospective cohort. All items in the initial 
version of the FRAiL model except for easily distracted remained significant for other non-
vertebral fractures (femur, pelvis, and upper arm). The AUC for the hip fracture only model 
was 0.68 in both males and females, and for other non-vertebral fracture the AUC was 0.65 in 
females and 0.66 in males (confidence intervals were not reported). 
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The FRAiL index was developed using a large cohort of 419,668 long-term care residents. It 
has also been successfully validated in three different instances showing that it is a good 
model for predicting hip fracture risk. The large cohort is a nationally representative sample 
of people living in US nursing homes receiving Medicare. It may not be generalisable outside 
of a US nursing home cohort. The cohort had high rates of mortality and a competing risk 
regression was employed to account for this where mortality was considered a competing 
event to hip fracture. 
2.4.11 FRS 
The Fracture Risk Scale (FRS) was developed using interRAI-LTCF data for 29,386 
individuals living in long-term care facilities in Ontario, Canada. A total of 1,553 (5.2%) of 
people had a hip fracture injury. The purpose of the study was to develop a hip fracture 
prediction model for use with interRAI long-term care data. Their final model calculated the 
1-year risk of hip fracture using eight questions from the long-term care interRAI assessment 
(LTC RAI-MDS version 2.0) (94). 
The variables used in the FRS to assess hip fracture risk were ability to walk in a corridor, 
BMI, previous fracture, wandering, age, transfer performance, and previous fracture (94). 
Decision tree analysis was used to predict hip fracture risk. The AUC in the FRS was 0.67 for 
the derivation set and 0.69 for the internal validation set, indicating the model had reasonable, 
but not great, predictability (165). Confidence intervals were not reported in the published 
paper. The FRS was validated in Ontario, British Columbia, and Manitoba. Discrimination 
among the provincial groups was similar with Ontario having an AUC of 0.67, British 
Columbia having an AUC of 0.64, and Manitoba having an AUC of 0.65 (168). 
This score was developed specifically for people living in long-term care facilities in Canada 
and may not be generalisable to people living in the community. The design of the tool makes 
it easy to use and could be integrated into the interRAI-LTCF instrument outcome scores and 
scales. However, this group is similar to that of Berry et al., which has a high mortality rate, 
and decision tree analysis does not account for death as a competing event. 
2.4.12 Summary of Hip Fracture Scores 
All scores reported above included age and weight as variables for assessing hip fracture. In 
some cases, weight was used as a part of the BMI information. Some of the scores found there 
were different risk profiles for male and females, and separate scores were developed for each 
sex. There were also some scores that were developed specifically for females, namely 
FRACTURE Index, FRAMO, and WHI. There were four scores that were developed for a 
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combined male and female cohort with sex being used as a variable in the model; in these 
cases all non-sex variables in the models will have the same impact on the calculated scores 
for males as they do for females. These models cannot capture cases where another variable 
may be more significant for males than females or vice versa. The FRS did not include sex as 
a part of the model. Four of the scores included previous fracture and six included falls 
information. While there are a large number of hip fracture prediction scores already 
developed, none have been developed for an interRAI-HC cohort, and none of the previously 
developed scores can be calculated using the interRAI-HC data as not all of the items are 





































































































Age ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Weight ✓ ✓ ✓a ✓a ✓a ✓a ✓ ✓ ✓ ✓a ✓ 
Height ✓  ✓a ✓a ✓a ✓a    ✓a ✓ 
Sex ✓ ✓ ✓  ✓ ✓      
Race/ Ethnicity   ✓   ✓     ✓ 
BMD ✓ ✓     ✓  ✓   
Previous fracture ✓ ✓  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Parental history of fracture ✓    ✓ ✓ ✓    ✓ 
Falls  ✓ ✓ ✓ ✓ ✓    ✓  
Smoking ✓    ✓ ✓ ✓   ✓ ✓ 
Alcohol ✓    ✓ ✓      
Osteoporosis ✓    ✓ ✓   ✓   
Rheumatoid Arthritis ✓    ✓ ✓      
Specific medications ✓  ✓  ✓ ✓    ✓ ✓ 
Cognitive Impairment   ✓ ✓        
ADL   ✓         
Locomotion in room   ✓         
Bladder continence   ✓         
Transfer performance   ✓ ✓        
Easily distracted   ✓         
Wandering   ✓ ✓        
Osteoarthritis   ✓         


































































































Diabetes   ✓  ✓ ✓     ✓ 
Walking in corridor    ✓        
Asthma     ✓ ✓      
Cardiovascular disease     ✓ ✓      
COPD      ✓      
Epilepsy      ✓      
Dementia      ✓   ✓   
Cancer      ✓      
Systemic lupus erythematosus      ✓      
Parkinson’s disease      ✓      
Chronic renal disease      ✓      
Care or nursing home residence      ✓      
Aid to get up from sitting       ✓ ✓    
Menopausal         ✓   
Back pain         ✓   
Self-reported health           ✓ 
Early menopause          ✓  
Chronic disease          ✓  
Central nervous system medication          ✓  
Physical activity           ✓ 
aCalculated together as BMI 
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There were 11 scores developed across six countries: USA, UK, Canada, Japan, Sweden, and 
Australia between 2001 and 2017. The cohort sizes ranged from 1,248 to 1,183,663 people. 
Six of the developed scores employed the Cox proportional hazards method. Other statistical 
methods used for development were Poisson regression, logistic regression, competing risks 
regression, and decision trees. More information about the statistical models can be found in 




Table 6 Summary of hip fracture scores including year developed, country of origin, cohort size, statistical technique used, and AUC 
Hip Score Year Country Cohort size Statistical Method AUC (95% CI) 
FRAX 2008 UK Unknown Poisson regression Unknown 
Garvan 2007 Australia 1,768 Cox proportional hazards model 0.85* 
Qfracture (Females) 2009 UK 1,183,663 Cox proportional hazards model 0.890 (0.786, 0.790) 
Qfracture (Males) 2009 UK 1,174,232 Cox proportional hazards model 0.856 (0.851, 0.860) 
Qfracture Updated (Females) 2012 UK 1,598,294 Cox proportional hazards model 0.893 (0.890, 0.896) 
Qfracture Updated (Males) 2012 UK 1,544,379 Cox proportional hazards model 0.875 (0.868, 0.883) 
FRACTURE 2001 USA 7,782 Logistic regression 0.714* 
FRAMO 2004 Sweden 1,248 Logistic regression 0.72 (0.64, 0.81) 
FRISC 2010 Japan 1,787 Poisson regression 0.727 (0.660, 0.794) 
Van Staa 2006 UK 366,104 Cox proportional hazards model 0.84* 
WHI 2007 USA 93,676 Cox proportional hazards model 0.80 (0.77, 0.82) 
FRAiL (Males) 2017 USA 119,874 Competing risk regression 0.692* 
FRAiL (Females) 2017 USA 299,794 Competing risk regression 0.711* 
FRS 2017 Canada 29,386 Decision tree 0.673* 




2.5 Statistical Models 
Several different statistical techniques were identified as being used in the literature for 
identifying risk factors for hip fracture and developing clinical prediction models from those 
risk factors. This section provides an overview of five different techniques that have been 
commonly employed for clinical prediction modelling. While this is not an exhaustive list of 
possible techniques to use, it represents many of the common techniques employed. The 
techniques discussed are logistic regression, Cox proportional hazards, competing risk 
regression, decision trees, and artificial neural networks. 
2.5.1 Logistic Regression 
A logistic regression model is used to find the best fitting, clinically-interpretable model to 
describe the relationship between an outcome variable, such as death, and several predictor 
variables. In the case of a binary logistic regression model, the outcome variable is 
dichotomous, with two mutually exclusive options. There are also an ordinal and multinomial 
logistic regression model. For example, when looking at mortality outcomes, the two possible 
outcomes are dead or still alive. A logistic regression model can be applied to other clinical 
data in this way. For example, in a study exploring the associations between different clinical 
items and hip fracture, the outcome variable would be hip fracture or no hip fracture (170). 
There is no time component or ability to include multi-level or mixed effects variables in this 
model. 
Logistic regression models are a simple-to-use model that can produce predictive estimates 
for any binary outcome. They are widely used so there is a large amount of literature detailing 
how to use logistic regression and describing how the model works (171). One downside of 
the logistic regression model is that there is no time-to-event component, and often studies 
identifying clinical outcomes such as hip fracture use a time-to-event analysis. The logistic 
regression is a simple model to use for developing a hip fracture score. However, a lot of 
clinical studies exploring specific effects can have competing outcomes. For example, death is 
a competing risk as once a person has died, they are no longer able to have a hip fracture. The 
logistic regression does not account for competing outcomes and it may be better to have a 
model that can account for competing factors. The interRAI-HC cohort has a high mortality 
rate, therefore for the purposes of this study, it would be better to use a model that included 
mortality as a competing event. 
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2.5.2 Cox Proportional Hazards 
A Cox proportional hazards model is the most popular model for analysing survival data. 
Survival analysis assess time-to-event information such as death. The Cox proportional 
hazards model is a survival model that associates the time that passes before an event of 
interest (hip fracture) occurs to one or more variables that may be associated with the event, 
particularly in relation to the amount of time it takes for the event to occur (172). Proportional 
hazards models have two main components. The first component is the hazard function, 
which describes how the risk of event per time unit changes over time at the baseline levels of 
the variables of interest. A clinical example would include variables such as assigned 
treatment, age, sex, and any other diseases that may relate to the outcome of interest. These 
variables are known as confounders. The second component is the proportional hazards. The 
proportional hazards assumption states that variables in the model are multiplicatively related 
to the hazard function (173). If the proportional hazards assumption holds, it is possible to 
estimate the effect parameters without consideration of the hazard function (174). 
The Cox proportional hazards model can be a good model to use when dealing with time-to-
event survival data. Cox proportional hazards models deal with only one outcome. Sometimes 
clinicians want to focus on relationships, for instance, testing a certain medication and 
whether it reduces the risk of heart attack. For this example, a Cox proportional hazards 
model the outcome of interest would be whether the individual has a heart attack or not. 
However, there is a competing risk as subjects may die during the study period. Methods 
traditionally used to deal with competing risks (for example, mortality) include censoring out 
anyone who dies. A recent paper by Szychowski et al. explored risk associated with entry to 
ARC facilities (175). Their study compared a Cox proportional hazards model where death 
was censored and a Fine and Gray model of competing risks regression that account for the 
competing event of death rather than censoring it to see if the results were similar. The study 
found that competing risk events affected the probability of the event of interest. This effect 
can be small, but when using a competing risk regression model there will be a reduction in 
bias (175). 
2.5.3 Competing Risk Regression 
The competing risk regression developed by Fine and Gray is a time-to-event regression 
model with multiple outcomes. Commonly there are three outcomes: the failure event of 
interest (for example, hip fracture), a competing event (usually this is death), and neither the 
failure event of interest nor the competing event have occurred (often this outcome is called 
“censored”) (176, 177). However, models have been extended to now include multiple 
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competing risks. The competing risk can have equal or more significant clinical importance 
than the primary outcome, and it affects the probability of the outcome of interest (178). 
Competing risk regression models are appropriate in cases where the cohort has high rates of 
mortality, such as in studies where the cohort is older in age (179). Their use is also beneficial 
for time-to-event data. For hip fracture risk, a competing risk of death should be considered 
for the interRAI-LTCF and HC cohorts because they have high rates of mortality. Competing 
risk regression models require more data than more simple models such as the logistic 
regression to provide meaningful results. A cohort of 5,000 people may be too small to 
employ competing risk regression models, particularly as there are competing events also. 
2.5.4 Decision Tree 
Classification and regression trees (CART) or decision trees use non-parametric methods to 
evaluate and divide data into subgroups based on the predictive independent variables (180). 
The significant variables and the order in which they should be split are determined by an 
underlying regression equation designed to maximise the predictive accuracy. Once the 
probabilities have been calculated, decision trees are created that follow different pathways to 
arrive at a predicted outcome for an individual, based on how they answered the questions 
(180). Figure 3 provides a visual example of a decision tree diagram where the answer to the 
first question dictates which question would be answered next. The tree diagram works as a 
flow chart that based on the answers to specific questions lead to a predicted outcome. 
 
















Decision trees provide an easily understood model that can be used easily in a clinical setting, 
as clinicians can follow the flow diagram produced by the tree to assess an individual’s 
outcome. However, decision trees can be less accurate than other prediction models, 
particularly because the nodes on the trees do not contain enough information to reliably 
predict outcomes (181, 182). Tree diagrams were developed by computer scientists rather 
than statisticians which makes them useful for large datasets. There is no way to deal with 
competing events using this method, so for a cohort with high mortality, it may not be an 
appropriate model. 
2.5.5 Artificial Neural Networks 
Artificial neural networks are a type of computer system based on biological neural networks 
that are commonly used in artificial intelligence, including for machine learning. Machine 
learning involves using sets of data to train a computer system to recognise patterns and 
perform analysis without having to specifically program that analysis into the computer 
system. A neural network can be trained to model a mathematical relationship between a 
series of variables of interest and the corresponding output. The predictor variables and the 
outcomes are input into the machine, which is configured with some quantity of adjustable 
internal processing steps. With iterative training, the neural network can develop a 
mathematical model to calculate the probability of a specific outcome. Multiple sets of the 
data can be input during training, and the more training data the neural network receives, the 
more sophisticated the internal arrangement of weightings can be made. The more data input 
into the machine, the more accurate the outcome data (180). Artificial neural networks can 
model complex relationships between variables. However, the structure of the model that a 
particular neural network embodies is unknown. Neural networks require large amounts of 
data for training purposes to try to avoid problems such as overfitting. Overfitting is where the 
model is developed to be tailored to one limited set of data, which can lead to the model 
performing poorly when used on a different dataset (183). 
Neural networks can require large amounts of computing power in the training stage to build 
an accurate prediction model. If large amounts of data and computing power are available, 
this allows for the modelling of more complex relationships between variables than is 
possible with more traditional techniques. However, in some contexts the complexity of the 
relationships may require more data to train a neutral network to model those relationships 




2.6 Potential Clinical Implications 
This thesis is novel as it is the first study internationally that uses the interRAI home care 
assessment to create a hip fracture risk score. The FRAiL model used competing risk 
regression, which is a recent technique for use in clinical analysis. Given the high rates of 
death in interRAI-HC and interRAI-LTCF cohorts, it is important for this study to also use 
competing risk regression and show more clinical researchers that it is a good statistical 
model to utilise when dealing with competing events in clinical cohorts. 
 
2.7 Concluding Statement 
This chapter explored the literature on risk factors for hip fracture, clinical prediction models 
for predicting hip fracture, and statistical techniques for developing clinical prediction 
models. Scores to identify those who are at risk of hip fracture are relatively common in 
medical settings. However, most of the clinically created risk factor scores are not suitable for 
those who are more frail, such as those in aged residential care facilities or still living at home 
but have more complex needs. The statistical technique best suited to the data is the 
competing risks regression model. The size of the cohort is too small for artificial neural 
networks to be a viable option. Time to event analysis is utilised and therefore regression 
models without a time component are not useful. Additionally, there is a high rate of mortality 
within the study cohort therefore the Cox Proportional Hazards model is not useful as it does 
not account for competing events. Based on a review of the literature, competing risk 
regression models will be used to develop a hip fracture prediction score. The next chapter 






3 Methodology and Methods 
The previous chapter was a survey of the literature regarding risk factors for hip fracture, hip 
fracture scores already developed, and statistical techniques for identifying and predicting hip 
fracture risk. This chapter provides a broad explanation of the methodology and methods used 
throughout this thesis including analytical techniques, data management, reporting methods, 
and ethics information. The specific methods used in each chapter will be presented in those 
chapters. The history of the interRAI was mentioned in section 1.5. Section 3.2.1 in this 
chapter provides information on how interRAI data are collected, and the format of the 
interRAI-HC assessment. 
 
3.1 Analytical Techniques 
3.1.1 Methods of Analysis 
This study used quantitative techniques to determine risk factors associated with hip fracture 
and to develop a hip fracture prediction score from those risk factors. The statistical technique 
employed was competing risk regression, which was described in detail in the previous 
chapter. For the purposes of developing a prediction model, there were two interRAI-HC 
datasets available; one was used for the initial creation and validation of the hip fracture 
prediction score and the second dataset was used to externally validate the hip fracture score 
and support generalisability of the model (184). External validation is important for assessing 
the accuracy of a prediction model because most prediction models perform better on the 
derivation dataset (185-188). 
The first dataset (original dataset) was obtained before analysis began and contained 
assessment records from September 2012 to June 2015 (all of the records available at the 
time), and the second dataset was obtained later and contained assessment records from July 
2015 to January 2018. Data collected before September 2012 was of an older version of the 
interRAI-HC and was incomplete on a national level. When predictive models are constructed 
using regression analysis, the performance of the model is better on the dataset it was 
developed from than for any other set of data, including test sets that contain people from the 
same population (189). This is a well-known statistical issue, and one way to address this is 
cross validation: randomly splitting the dataset into two (or more) parts and use one set of 
data (the test cohort) to develop the model and the other set(s) (validation cohort(s)) to assess 
the model’s performance. Using this approach, the model performance is tested on an 
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independent dataset with a similar cohort (189). Following this method, in order to more 
accurately test the predictability of the hip fracture risk score, the original dataset was 
randomly split into two datasets where two-thirds of the data was used as a test set to 
determine risk factors and construct a prediction model based on the regression analysis. The 
remaining one-third of the data was used to test the prediction model developed. In addition to 
this, the model was tested again using the second dataset from the later time period. This is 
conducted as a way of externally validating the data, by assessing the performance of the 
model with data that were not used in the initial creation and development (190). P-values of 
0.05 or less defined statistical significance. Figure 4 illustrates where the data came from and 
how it is related. 
 
Figure 4 interRAI-HC data and how it was split for analysis 
 
3.1.2 Target Population 
The study population are people aged 65 years and older living in New Zealand who had an 
interRAI-HC assessment between September 2012 and June 2015. Exclusions include anyone 
under the age of 65 years because older person’s health services in New Zealand are for those 
aged 65 years and older. Anyone who was listed as already living in an aged care facility were 
also excluded, because the focus of this study is on community-dwelling individuals. Anyone 
listed as having end-stage disease (less than 6 months to live) was omitted from the study 
because the score is for calculating the two-year risk of hip fracture and the life expectancy of 
the people with end-stage disease is six months. A comprehensive table outlining the 
exclusion criteria and the number of items removed can be found in Chapter Four, Figure 5. 
 




interRAI-HC 9.1 assessments 






3.2 Data Management 
This study utilises data from three different sources. These are the interRAI-HC assessment 
data, hospital admissions data, and mortality data. In New Zealand anyone who receives 
health care is assigned a national health index (NHI) number. The NHI is a unique identifier 
associated with a single individual that is permanently associated with them once assigned. 
The NHI is associated with information about that individual including their name, date of 
birth, address, and any health records (191). The NHI can be used to deterministically link the 
interRAI-HC dataset to any health datasets including mortality, hospital admissions, and 
pharmacy dispensing data. In this case, the NHI number was encrypted using a two-step 
encryption system where New Zealand’s Technical Advisory Service (TAS) provided the 
interRAI-HC data with encrypted NHI numbers, and the MoH provided the mortality and 
hospital admissions data with another encrypted NHI number. The MoH holds the encryption 
key and it is used to provide an extra protection to participants’ confidentiality. The key to 
linking these was provided by the MoH separately to other data. All data files from the MoH 
were in Microsoft Excel format. Only data relating to individuals who have consented for 
their data to be collected were provided for analysis, and all identifying information such as 
names and addresses were removed before the data was provided. Data matching was found 
to be highly reliable, with 0.2% of mortality records unable to be matched (192). 
3.2.1 interRAI-HC Dataset 
All interRAI assessments are performed by trained assessors. Every interRAI assessor is 
trained according to specific national level interRAI guidelines and is routinely re-tested to 
ensure a high standard of assessment is maintained (193). Assessors are usually nurses or 
social workers. In New Zealand, if a GP or hospital staff member believe that a patient 
requires home care services, they will refer the patient for an interRAI-HC assessment. The 
assessment is used to determine how much and what type of services the patient needs (194). 
Assessors will usually go to a person’s house and sit down with them to answer questions in 
the assessment. The assessors also use observations, interviews with family, and clinical 
records to obtain as much information as possible to complete the assessment (195). Most 
questions within the interRAI-HC assessment are mandatory, and all data is entered 
electronically and collected in an interRAI-HC database managed by TAS. Once an 
assessment has been completed by filling in the answers to all questions, outcome scores and 
outcome measures are calculated and triggered for specific areas of risk. Outcome scores 
include clinical assessment protocols (CAPs). CAPs are triggered and highlighted to the 
assessor to highlight key issues an individual may be having (196). For example, the 
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interRAI-HC has a Falls CAP that is triggered when an individual has any number of falls 
documented within the assessment (197). This suggests to the assessor that a falls prevention 
programme may be helpful to the individual. These scales and CAPs are used to guide the 
assessor on areas of health care support the individual may need. Outcome measures include 
such things as the BMI scale and CHESS. CHESS is a measure used to predict an individual’s 
mortality (198).  
A study conducted in 2008 asked assessors across twelve countries to conduct multiple 
assessments across five different interRAI assessment types (199). Each assessor received the 
same instructions on how to conduct the assessments and kappa measures, which are a 
measure of inter-rater reliability, were taken to see whether different assessors answered the 
same questions consistently. The results showed that the reliability of all questions present in 
multiple assessments (including some present in the home care assessment) exceeded the 
conventional cut-off point for reliability testing, with most items having a mean weighted 
kappa of 0.80 or better. Where a kappa value ≤ 0 is interpreted as no agreement, 0.01-0.20 is 
slight agreement, 0.20-0.40 is fair, 0.41-0.60 is moderate, 0.61-0.80 is substantial agreement, 
and 0.81-1.00 is almost perfect agreement (199). Some questions were the same across all five 
instruments and it was noted that questions shared across interRAI instruments retained their 
reliability across each instrument. This included questions such as Activities of Daily Living, 
understanding others, standing, and incontinence (200). Reliability between assessments in 
New Zealand was demonstrated by Schluter et al. who showed that inconsistencies between 
repeat interRAI assessments on the same individual being assessed were low in number and 
missing values were also rare (192).  
The interRAI-HC instrument is used under license to the MoH. It is a comprehensive clinical 
assessment tool consisting of 236 questions across 20 domains. Table 7 below lists the 




Table 7 Domains in interRAI-HC assessment 
Item 
A Identification Information 
B Intake and Initial History 
C Cognition 
D Communication and Vision 
E Mood and Behaviour 
F Psychosocial Well-Being 
G Functional Status 
H Continence 
I Disease Diagnoses 
J Health Conditions 
K Oral and Nutritional Status 
L Skin Condition 
M Medications 
N Treatment and Procedures 
O Responsibility 
P Social Supports 
Q Environmental Assessment 
R Discharge Potential and Overall Status 
S Discharge 
T Assessment Information 
 
3.2.2 Hospital Admissions Data 
The hospital admissions dataset was obtained from the National Minimum Dataset (NMDS) 
held by the MoH. The NMDS is a national collection of hospital discharge information for 
both public and private hospital care (201). The hospital admissions data has information on 
the accident date, discharge dates, diagnoses, hospital admission codes, and surgery dates. On 
admission to hospital each patient can have up to 20 different diagnoses. All diagnosis records 
are coded using ICD-10 AM. From the hospital admissions dataset, individuals who had a 
diagnosis of hip fracture in any of their up-to-20 diagnoses (ICD: S72.0, S72.1, S72.2, S72.3, 
S72.4, S72.8, S72.9) were extracted from the hospital admissions data. 
Several patients had multiple admissions for the same hip fracture event, which was 
confirmed by reference to the date of accident listed. Any admission with the same accident 
date was counted as the same injury. Transfers between different hospital services were 
counted as separate admissions. For example, a patient sustaining a hip fracture may first 
enter the accident and emergency department of a hospital, later they may be admitted to a 
different hospital department such as surgery, and each of these transfers between 
departments is counted as a separate admission in the records. Length of hospital stay and 
number of admissions for the same incident were calculated. Some patients had records of a 
second hip fracture; where this occurred the hip fracture that took place first within the 
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assessment period was used in the analysis. A cut-off date of 31 October 2015 was applied to 
the hospital admissions data; admissions that occurred after this date were excluded even if 
they related to a hip fracture that occurred within the study period. The cut-off date applied of 
31 October 2015 is three months prior to the end date of the available data; this date was 
chosen because it can often take up to three months for the data to be completed and 
confirmed as being accurate. The hip fracture admissions dataset was then deterministically 
matched with the interRAI home care assessment using the encrypted NHI number. NHI 
matching issues can arise when opening the data files in Microsoft Excel as some encrypted 
NHIs become formatted as dates automatically; additionally there can be some transcription 
errors, where some numbers are incorrectly typed into the database. 
3.2.3 Mortality Data 
Date of death information was extracted from the Mortality Collection (MORT) database 
provided by the MoH (202). Records for mortality were available up to 1 January 2016; to 
ensure mortality records for all individuals were complete, a cut-off date of 31 October 2015 
was applied. The mortality records consisted of the encrypted NHI and a date of death. 
 
3.3 Variable Recoding 
Using the risk factors associated with hip fracture outlined in Figure 2 of Chapter Two (Falls, 
Fractures, Environment, Cognition, Health, Age, Sex, Exercise, Lifestyle, BMI, and 
Ethnicity), questions of interest from the interRAI-HC were identified to ensure a wide 
variety of health questions were being assessed as potential risk factors. Decisions about what 
questions to include for initial analyses were based on the apposite literature pertaining to hip 
fracture risk factors as discussed in the literature review and clinical advice from 
gerontologists, physiotherapists, and other practising clinicians. Where reasonable, for 
variables with categories containing less than 5% of individuals, those categories were 
condensed into a smaller number of broader categories. Additionally, where disease diagnoses 
were concerned there were four response options, namely: 0 “Not present”, 1 “Primary 
diagnosis/diagnoses for current stay”, 2 “Diagnosis present, receiving active treatment”, 3 
“Diagnosis present, monitored but no active treatment”. These variables were collapsed into a 
dichotomos variable with the options “No diagnosis” (code 0) or “Diagnosis present” (codes 
1-3) for each disease diagnosis.  
The environment variable was created from three questions in the interRAI-HC assessment. 
The questions were: disrepair of the home, squalid conditions, and limited access to home or 
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rooms in home. Anyone who answered yes to one or more of the questions was coded as 
having some issue with their home environment. 
BMI was transformed into categorical values based on the the National Heart, Lung, and 
Blood Institute (NHLBI) classifications which are underweight (BMI < 18.5), Normal (BMI 
18.5-24.9), overweight (BMI 25.0-29.9), and obese (BMI ≥ 30.0)(98). Other than BMI, which 
can be calculated directly from height and weight data within the interRAI assessment, no 
outcome scores such as the CAPs were included in the analysis as they are calculated at the 
end of an assessment based on the answers given by the person being assessed. The final hip 
fracture score is designed to be similar to these outcome scores by being calculated at the end 
of an interRAI-HC assessment and, if triggered, the clinical assessor might then refer the 
patient to a hip fracture prevention program or further testing such as a bone mineral density 
assessment. Table 8 below outlines the questions selected for analysis, the domains within the 
assessment they belong to, the iCodes associated with each question, and how they were 
recoded. 
Ethnicity groups were Māori, Pacific people, Asian, European, and other. In the New Zealand 
version of the interRAI-HC assessment, individuals are allowed to select up to three different 
ethnicities. Where an individual had multiple ethnicities listed, priority coding was applied to 
give them one ethnicity for analysis purposes. Priorities are coded as outlined by the MoH 
policy on ethnicity data protocols to ensure consistency across New Zealand studies (203).The 
order of priority was Māori, Pacific people, Asian, European, and other. For instance, if 
someone identified as European and Māori, they would be listed as Māori for analysis 
purposes. Pacific people included anyone who identified as Samoan, Cook Island Māori, 
Tongan, Niuean, Tokelauan, Fijian, Other Pacific peoples, and Pacific peoples not further 
defined in the interRAI-HC assessment. Asian ethnicity included people who identified as 
Southeast Asian, Chinese, other Asian, and Asian not further defined as listed in the interRAI-
HC assessment. European included New Zealand European, other European, and European 
not further defined as listed in the interRAI-HC assessment. 
Each question used in an interRAI assessment is given an iCode. This is a value that 
corresponds uniquely to that specific question. For example, in the interRAI-HC assessment, 
question 1 from section C is given the iCode iC1. While it is question 1 of section C in the 
interRAI-HC, it may appear in a different section of another assessment. If the same question 
is used in multiple interRAI assessments, it will have the same iCode even if it appears in 
different sections in these assessments. Having the iCode means the question can quickly be 
identified across multiple assessments if needed. This also makes it easier to identify the same 
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question across different versions of the same assessment tool. The questions listed below are 
from the interRAI Home Care Assessment Form version 9.1 New Zealand Customisation. 
Towards the end of 2018, a small number of assessments included in the external validation 
dataset were conducted using version 9.3 of the interRAI-HC assessment. None of the 





Table 8 Variables assessed for their possible associations with hip fracture 
interRAI 
Domain 
Question iCode Recoding Area from 
literature 
A Identification Information  
 2 Gender iA2 Male = 0 
Female = 1 
Unknown = Missing 
Indeterminate = Missing 
Age, Sex 
 3 Age Group 
(in years) 
iA3 65-74 = 1 
75-84 = 2 
85-94 = 3 
95+ = 4 
Age, Sex 
 13a Lives iA12a Alone = 1 
With Others = 2,3,4,5,6,7,8 
Environment 







Māori = 1 
Pacific People = 2 
Asian = 3 
European = 4 
Other = 5 
Ethnicity 
C Cognitive/Functional  





iC1 0 = 0 Independent 
1,2 = 1 Minimal Independence 
3, 4 = 2 Moderate to Severe 
5 = 3 No discernible 
conscousness, coma 
Cognition 
 3a Easily 
Distracted 
iC3a 0 = 0 Not present 
1,2 = 1 Present 
Cognition 
 3c Mental 
Function 
Varies 
iC3c 0 = 0 Not present 
1,2 = 1 Present 
Cognition 
D Communication and Vision  
 3 Hearing iD3a 0 = 0 Adequate 
1,2 = 1 Minimal to moderate 
3,4 = 2 Severe to none 
Co-morbidities 
 4 Vision iD4a 0 = 0 Adequate 
1,2 = 1 Minimal to moderate 
3,4 = 2 Severe to none 
Co-morbidities 
E Mood and Behaviour  
 3a 
Wandering 
iE3a 0 = 0 Not present 






Question iCode Recoding Area from 
literature 
G Functional Status  
 2e Walking iG2e 0,1 = 0 Independent 
2, 3 = 1 Some assistance 
required 
4,5,6 = 2 Maximum 
assistance/dependent 




iG2f 0,1 = 0 Independent 
2,3 = 1 Some assistance 
4,5,6 = 2 Maximum 
assistance/dependent 
8 = Missing 
Co-morbidities 
 3a Primary 
mode of 
locomotion 
iG3 0 = 0 Walking, no assistive 
device 
1 = 1 Assisted walking 
2,3 = 2 Cannot walk 
Co-morbidities 
 3b Timed 4 
metre walk 
(seconds) 
iG12 1 = 0-15 
2 = 16-29 
3 = 30+ 
4= 77,88,99 = 4 Incomplete 
tests 
Co-morbidities 





iG6a 0,1 = 0 None/Less than 1 hour 
2,3 = 1 1-4 hours 
4 = 2 More than 4 hours 
Exercise 




out of the 
house 
iG6b 0,1 = 0 None 
2 = 1 1-2 days 
3 = 2 3 days 
Exercise 
H Continence  
 1 Bladder 
Continence 
iH1 0,1, - 1 Continent 
2,3,4,5 leave as is 
8 as missing 
Co-morbidities 
 3 Bowel 
Continence 
iH3 0,1, - 1 Continent 
2,3,4,5 leave as is 
8 as missing 
Co-morbidities 
I Disease Diagnoses  
 1a Previous 
hip fracture 
iI1a 0 = 0 No fracture 














iI1b 0 = 0 No fracture 





iI1h 0 = 0 Not present 




Ii1j 0 = 0 Not present 
1,2,3 = 1 Diagnosis present 
Co-morbidities 
 1L COPD iI1L 0 = 0 Not present 
1,2,3 = 1 Diagnosis present 
Co-morbidities 
J Health Conditions  
 1 Previous 
Fall 
iJ1 0 = 0 No falls 
1,2,3 = At least one fall 
Falls 
 3a Difficult 
or unable to 
move self to 
a standing 
position 
iJ2a 0,1 = 0 Not present 
2,3,4 = 1 Present 
Co-morbidities 
 3c Dizziness iJ2c 0,1 = 0 Not present 
2,3,4 = 1 Present 
Co-morbidities 
 3d Unsteady 
Gait 
iJ2d 0,1 = 0 Not present 
2,3,4 = 1 Present 
Co-morbidities 
 4 Dyspnoea 
(Shortness of 
Breath) 
iJ3 0 = 0 None 
1,2 = 1 Absent at rest 
3 = 2 Present at rest 
Co-morbidities 
 5 Fatigue iJ4 0 = 0 None 
1,2 = 1 Minimal to moderate 





iJ5a 0 =0 No pain 
1 =1 No pain in last 3 days 
2,3 = 2 At least once in last 3 
days 
Co-morbidities 
 6b Intensity 
of highest 
level of pain 
iJ5b 0 = 0 None 
1,2 = 1 Mild to moderate 





iJ5c 0,1 = 0 None to very little 
2 = 1 Intermittent 






Question iCode Recoding Area from 
literature 
 9a Smokes 
tobacco 
daily 
iJ8a 0 = 0 Non-smoker 
1,2 = 1 Smoker 
Lifestyle 
 9b Alcohol – 
highest 
number of 
drinks in any 
‘single 
sitting’ 
iJ8b 0 = 0 None 
1,2,3 = 1 At least 1 drink 
Lifestyle 
K Oral and Nutritional Status  
 BMI Scale_B
MI 
9- 18 Underweight 
18 -25 Normal 
26 – 30 Overweight 
31 – 41 Obese 
Missing/Unknown 
BMI 
 2a Weight 
loss of 5% or 
more 
iK2a 0 = 0 No 




iK2c 0 = 0 No 
1 = 1 Yes 
Co-morbidities 
 2e Decrease 
in amount of 
food or fluid 
usually 
consumed 
iK2g 0 = 0 No 
1 = 1 Yes 
Co-morbidities 
Q Environmental Assessment 
 1a Disrepair 











0 = 0 No 
1 = 1,2,3 Yes 
Environment 
 
3.3.1 Missing Data 
Within the interRAI-HC, all fields in assessments are required so there was very little missing 
data. In cases where there was missing data, the number of missing values have been reported 
in their respective descriptive tables. No imputation was done to fill in any missing data. The 
category with the largest number of missing variables was BMI. In the original dataset there 
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were 26,547 (39.4%) of people who were missing BMI information. These people were 
categorised as “Unknown” BMI for the purposes of complete-case analysis. Within the 
interRAI-HC assessment, gender can be reported as “male”, “female”, “unknown” and 
“indeterminate”. In the original interRAI-HC dataset, there were two people listed as 
indeterminate sex and two who were categorised as unknown, these four were excluded from 
further analysis. 
 
3.4 Reporting Methods 
3.4.1 RECORD Statement 
The reporting of results in this study (chapters 4, 5, 6, and 7) was informed by the Reporting 
of Studies Conducted using Observational Routinely-collected health Data (RECORD) 
statement (204). The RECORD statement is an extension of the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) (205) and is used to guide the reporting 
of observational studies that use routinely collected health data. The RECORD checklist 
contains 23 items to include when reporting the introduction, methods, results, and discussion 
sections of an analysis. A copy of the RECORD checklist can be found in Appendix A. 
3.4.2 Software 
Basic descriptive analysis, graphs, and data cleaning was undertaken using IBM SPSS version 
23 (206). Competing risks regression models were conducted using Stata SE version 15.0 
(207) as SPSS does not have this functionality. Graphs of the impact of risk factors were 
created using R version 3.6.1. 
 
3.5 Ethics 
All participants included in this study consented for their data to be used for planning and 
research purposes. Anyone who does not consent (approximately 7% of people undergoing an 
interRAI HC assessment (192)) is not included in the dataset when it is provided for research 
and planning, and for those people who do consent, all of their identifying information is 
removed. Ethics approval for this study was given by the Ministry of Health’s Health and 






Information bias may have occurred with the interRAI-HC data. Before the data were 
received, anyone who did not consent to have their data shared for research purposes were 
removed from the dataset; there may be health differences in this group that will go 
undetected. The interRAI-HC assessment is only used for people seeking publicly-funded 
health care services, and therefore, anyone who receives privately-funded home care services 
will not be included in this study. There are approximately 20% of people who are privately 
funded and do not have interRAI-HC information available (208). There will be bias as those 
who can afford private health care may have differing health needs. The results of this study 




4 Exploratory Analysis 
4.1 Introduction 
The previous chapter provided an overview of the methodology and general methods used 
throughout this thesis. This chapter focuses on presenting the basic descriptive information of 
the whole original interRAI-HC dataset before it was separated into test and validation 
datasets. The objective of this chapter is to explore the dataset and provide descriptive 





Participants included community-dwelling older adults aged 65 years and older who 
underwent an interRAI-HC assessment from 1 September 2012 to 30 June 2015. Where 
individuals had more than one interRAI-HC assessment, only the first assessment was 
included for analysis. Any further assessments of the same person were excluded to avoid 
having multiple records of the same person, which may affect the results. The first assessment 
was used because all individuals have a first assessment to decide what health services they 
require, if any. Not all people who are assessed, have subsequent assessments, and those who 
do have an additional assessment because their circumstances have changed; they potentially 
already have supports in place which may make differences to the cohort. The score 
developed in this study has been designed for use at a person’s first interRAI-HC assessment 
before they have any supports in place. A full list of the participant selection criteria is listed 
in Figure 4. 
4.2.2 Variables 
Demographic variables reported were sex, age, ethnicity, and living arrangement. Hip 
fractures were identified by the ICD-10-AM codes mentioned in the previous chapter. The 
Falls CAP is an outcome scale that is calculated at the end of an assessment to alert the 
clinical assessor if the individual is at a risk of having a fall (209). An individual is classed as 
having no to low risk of falls when they report no falls in the 90 days prior to the assessment, 
medium risk is when a person reports having a single fall in that time period, and high risk is 
when a person reports having multiple falls in that time period (197). Time-to-event status 
was determined as the first event occurring during the study period whether this was hip 
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fracture or death, where death was treated as a competing event. Anyone who did not have 
either event reported by the end of the study period was classified as alive with no fracture. 
4.2.3 Statistical Analysis 
Distributions of the demographic variables were reported overall and partitioned by outcome 
status at the end of the study period. The number and type of hip fractures were reported. 
Mortality figures were also reported. A log-rank test was conducted to assess if there was a 
difference between the two groups = those who had a hip fracture and those who did not. A 
cross-tabulation of hip fracture and Falls CAP was created to explore the number of people 
who had a hip fracture in each of the three Falls CAP risk groups. A ROC curve of the Falls 
CAP and how it predicts hip fracture was created and the AUC was reported. 
 
4.3 Results 
4.3.1 Participant Selection 
4.3.1.1 interRAI Data 
Participants of this study were those who underwent an interRAI-HC assessment in New 
Zealand from September 2012 to June 2015. The initial dataset consisted of 105,502 
assessments. Some encrypted NHIs did not have a corresponding NHI and could not be 
matched to hospital admissions or mortality data; they were removed from the analysis. 
Follow-up assessments were excluded from analysis to ensure only the first assessment of 
each participant was included. Anyone below the age of 65 years at the time of their 
assessment was excluded, and anyone who was listed as being in an ARC facility at time of 
assessment was also excluded. People who were in ARC at the time of their interRAI-HC 
assessment were excluded as previous studies have shown that people living in ARC have 
different risk profiles (51, 75, 105, 106), and this study focused on identifying risk factors for 
people living in the community. After additional tidying steps as detailed in Figure  below, a 




Figure 5 Participant exclusion criteria for the interRAI-HC assessments 
105,502 initial assessments 
Removed repeat (26,013) and unmatched (209) assessments 
26,222 removed 
Removed ≤ 64 years old 
3,634 removed 
Removed already living in ARC 
3,386 removed 
Removed assessment after 31 October 2015 
1,282 removed 
Removed if time to death ≤ 0 days from assessment 
24 removed 
Removed those who entered ARC  
≤ 30 days from assessment 
736 removed 
Participants eligible for analysis 
67,337 




4.3.1.2 Hospital Admissions Data 
The hospital admissions dataset consisted of 341,154 records of hospital admissions from 5 
January 2012 to 31 October 2015. There were 13,019 instances of hip fracture admission in 
the hospital admissions dataset. Additional considerations regarding the hospital admissions 
data were covered in Chapter Three. 
Length of hospital stay and number of admissions for the same incident were calculated. 
Where there were multiple records of hip fracture for one individual, the hip fracture that took 
place first within the assessment period (3 September 2012 to 31 October 2015) was used in 
the analysis. Multiple admissions for the same injury were removed from the dataset to obtain 
a dataset of 6,576 first hip fractures. These were identified by a column in the hospital 
admissions dataset labelled “accident date”, which details on which date the accident leading 
to the hospitalisation first occurred. The hip fracture admissions dataset was then matched 
with the interRAI home care assessment using an encrypted unique identifier. The date of 
assessment and the date of hip fracture admission were then used to determine who had a hip 
fracture before their assessment and those who had a hip fracture afterwards. A total of 4,317 
people had their only hip fracture before they had their first interRAI-HC 9.1 assessment, 
leaving a total of 2,259 people who had a hip fracture after their first assessment. Of those 
who had a hip fracture following their first assessment, 123 people who had a subsequent 
fracture. 
4.3.2 Demographic Information 
The mean age of individuals was 82.8 years with a range from 65 to 106 years, with 11,331 
(16.8%) aged 65-74 years, 27,703 (41.1%) 75-84 years, 26,058 (38.7%) aged 85-94 years, and 
2,245 (3.3%) aged 95 years and older. In comparison, the 2013 New Zealand census data 
reports the number of people aged 65-74 years were 346,134 (57.0%), 75-84 years were 
187,584 (30.9%), 85-94 years were 68,412 (11.3%), and 95+ were 4,902 (0.8%) (2, 192, 210). 
There were more females (61.6%) than males (38.4%). Within the study dataset, there were 
3,618 (5.4%) people who identified as Māori, 2,088 (3.1%) Pacific people, 1,548 (2.3%) 
Asian, 59,567 (88.5%) European, and 516 (0.7%) as other ethnicities. In comparison with the 
New Zealand 2013 census data 5.6% identified as Māori, 2.4% identified as Pacific people, 
4.7% identified as Asian and 87.8% of those aged over 65 years identified as European (2). 
Approximately half of individuals live alone (49.8%), while the 2013 census data reported 
28.8% of people aged 65 years and older living alone. Among individuals who had a fracture, 
there more females who had a fracture than males - 70.3% of fractures occurred in females. 
More fractures occurred in people ages 85-94 years than any other age groups. Among those 
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who had a hip fracture, 94.8% (2,142) occurred in those who identified as European. Māori 
had the next highest number of fractures with 41 people having a fracture. Across each of the 
three first events, living arrangement was split with approximately half of individuals living 
alone and half living with others. A summary of these results can be found in Table 9. The 
total person-time for this study was 86,296 years. The person-time that an individual 
contributes to the total is the time from their first assessment in the study period to the first 




Table 9 Distribution of demographic variables - total number and partitioned by outcome 
  First Event 
Variable names Total 
n (%) 






Sex     
Male 25,858 (38.4) 15,972 (61.8) 672 (2.5) 9,214 (35.7) 
Female 41,477 (61.6) 29,410 (70.9) 1,587 (3.8) 10,478 (25.3) 
Age Group (years)     
65-74 11,331 (16.8) 8,643 (76.3) 173 (1.5) 2,515 (22.2) 
75-84 27,703 (41.1) 19,659 (70.9) 817 (2.9) 7,227 (26.1) 
85-94 26,058 (38.7) 16,003 (60.4) 1,133 (4.3) 8,922 (34.2) 
95+ 2,245 (3.3) 1,080 (48.1) 136 (6.1) 1,029 (45.8) 
Ethnicity     
Māori 3,618 (5.4) 2,484 (68.7) 41 (1.1) 1,093 (30.2) 
Pacific 2,088 (3.1) 1,534 (73.5) 25 (1.2) 529 (25.3) 
Asian 1,548 (2.3) 1,155 (74.6) 33 (2.1) 360 (23.3) 
European 59,567 (88.5) 39,832 (66.9) 2,142 (3.6) 17,593 (29.5) 
Other 516 (0.8) 380 (73.6) 18 (3.5) 118 (22.9) 
Living Arrangement     
Lives alone 33,553 (49.8) 22,887 (68.0) 1,174 (3.5) 9,564 (28.5) 
Lives with others 33,784 (50.2) 22,498 (66.6) 1,085 (3.2) 10,129 (30.2) 
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4.3.3 Hip Fracture Incidence and Hospital Admissions 
Overall, there were a total of 2,259 hip fractures occurring after an interRAI-HC assessment. 
There are seven ICD-10AM codes for hip fracture. Most fractures were either fractures in the 
head and neck of femur (2,101, 48.7%) or pertrochanteric fractures (860, 38.1%), with 298 
(13.2%) fractures occurring in the other areas of the hip. Table 10 below shows the 
frequencies of the different types of hip fracture diagnosis.  
Table 10 Distribution of hip fractures partitioned by ICD-10-AM Code 
ICD Code Type of Fracture Number (%) 
S72.0 Head and neck of femur 1,101 (48.7) 
S72.1 Pertrochanteric fracture 860 (38.1) 
S72.2 Sub-trochanteric fracture 96 (4.2) 
S72.3 Fracture of shaft of femur 102 (4.5) 
S72.4 Fracture of lower end of femur 86 (3.7) 
S72.8 Other fracture of femur 9 (0.4) 
S72.9 Unspecified fracture of femur 5 (0.2) 
 
The amount of time spent in hospital for each hip fracture injury varied with individuals 
staying between 1 day and 387 days. The median length of stay was 20 days (Interquartile 
Range (IQR): 10 – 32 days). Where individuals stayed in hospital longer than 32 days (the 
75th percentile), they may have ended up in a care home that is also a hospital, or they may 
have had other further health complications leading to longer stays in hospital. Transfers 
between hospitals were initially listed as separate hospital admissions for the same event; 
where this was the case, admissions were condensed into one admission per hip fracture event 
(See Chapter 3 for more information on the cleaning process). The number of admissions per 
fracture event ranged from 1 to 7. Multiple admissions for single hip fracture events were 
typically due to transferring between different hospitals for surgery, recovery, and 
rehabilitation. In smaller hospitals, people stay in the same hospital for their surgery and 
rehabilitation and will only have one admission listed. In some bigger centres where there are 
multiple hospitals, the individual could have an admission to the acute hospital, then have 
another admission listed when they transfer to rehabilitation. Other reasons for multiple 
admissions listed could be that some centres have a temporary stay in the emergency 
department, people can get wound infections, they could become acutely unwell, or they may 
be transferred back to rehabilitation. The number of multiple admissions shows that hip 
fractures can be a burden for the patients and the hospital system. Table 11 below gives an 
overview of the number of transfers between hospital departments per patient. 
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Table 11 Number of hospital transfers for a hip fracture event 
Number of Transfers  Patients N (%) 
1 860 (38.1) 
2 942 (41.7) 
3 343 (15.2) 
4 88 (3.9) 
5 19 (0.8) 
6 6 (0.3) 
7 1 (0.0) 
 
4.3.4 Hip Fractures and Mortality 
By the end of the study period, there were a total of 20,711 (30.8%) people who had died. Of 
those who had a hip fracture after their first assessment, 736 (32.6%) died compared with 
19,975 (30.7%) of individuals who did not have a fracture after their first assessment. A log-
rank test showed there was a significant difference between the death rates of the fracture and 
non-fracture groups (χ2(1) = 59.1, p <0.01). In the first year of assessments, more people who 
did not have a hip fracture died than people who did have a fracture. After the one-year mark, 
more people who had a hip fracture died than those who did not have a hip fracture. 
4.3.5 Falls CAP 
The Falls CAP is an outcome score calculated at the end of a home care assessment. Within 
the cohort, more people triggered the low (39,978, 59.3%) falls risk group, and more of those 
people had a hip fracture than in the other two groups. Of those who were classified as high 
falls risk, 12.6% had hip fractures. 
Table 12 Contingency table of Falls CAP triggers and number of hip fractures 
 Low Medium High 
No fracture 38,628 (59.4%) 18,699 (28.7%) 7,751 (11.9%) 
Had hip fracture 1,350 (59.8%) 625 (27.7%) 284 (12.6%) 
 
The ROC curve for the Falls CAP can be found in Figure 6. The AUC was 0.540 (95% CI: 
0.527, 0.552). An AUC close to 0.5 suggests the model is marginally better than random 




Figure 6 ROC curve of Falls CAP and hip fractures 
 
4.4 Discussion 
4.4.1 Key Points 
A majority (41.1%) of people who had an interRAI-HC assessment were aged between 75 and 
94 years of age. Māori and Pacific people are over-represented, particularly in the 65-74 years 
and 74-85 years age groups compared to the general population of New Zealanders in those 
age groups (192). This over-representation is in part because Māori and Pacific people tend to 
have a poorer health status (211, 212). The percentage of people who live alone was far 
higher in the interRAI-HC cohort than in the national population. This is possibly because 
anyone undergoing an interRAI-HC assessment does so because they are seeking health care 
services; many people who live alone may be more likely to require home care services 
because they do not have someone at home to assist with their care needs. 
There was a total of 2,259 (3.4%) people who had a hip fracture after an interRAI-HC 
assessment. Most people who had a hip fracture had fractures of the head and neck of femur 
and the pertrochanteric region, with approximately 13% of fractures occurring in other parts 
of the hip. Length of hospital stay for those who have a fracture can be long with the median 
number of days being 20. Additionally, people can have between one and seven transfers 
between hospital wards, which may put extra stress on an already unwell individual. 
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By the end of the study period, 19,962 people had died. After hip fracture, there were a total 
of 736 people who died. Overall, there was a significantly higher percentage of people who 
died after hip fracture than people who did not have a hip fracture. After the one-year mark, 
more people who had a hip fracture died than those who did not have a hip fracture, but 
before that the no fracture group had a higher rate of mortality.  
The group who had the highest number of fracture within the falls CAP triggers were those 
who were considered to be low risk. A potential reason for this is that those who trigger the 
medium and high risk are given interventions. There may also be some people who do not 
trigger the falls CAP due to having more complex health needs such as limited mobility, 
which means they have less opportunity to fall. Alternatively, it can be noted that any older 
person that has falls at some point must have a first fall in their older age, and someone could 
have a hip fracture as a result of their first fall. Another explanation is that older people have a 
significant change of suddenly starting to have several falls after having had no falls in their 
recent history. One potential reason for this is when an older person is prescribed a 
medication that can cause dizziness as a side effect. The AUC was 0.540, which suggests the 
Falls CAP is slightly better than random chance at predicting who is likely to have a hip 
fracture. However, the Falls CAP was not designed to predict hip fracture, but rather to assess 
who is at high risk of having falls. The low AUC of the Falls CAP suggests it is worthwhile to 
develop a score similar to the CAPs but specifically for predicting who is likely to have a hip 
fracture. These results suggest there may be other factors that can lead to hip fractures than 
just falls. 
A Canadian study compared the Falls CAP with two other well-known fall screening tools, 
the Scott Fall Risk Screen (SFRS) and a Fall Risk Tool (FRT) that had been implemented as 
part of a Fall reduction strategy in Nova Scotia. The Falls CAP (C-statistic: 0.673) performed 
better at predicting an individual’s falls risk than the other two screening tools (C-statistic for 
SFRS: 0.529, C-statistic for FRT: 0.609). However, when other items such as Parkinson’s 
disease, multiple sclerosis (MS), Alzheimer’s disease, COPD, and cardiovascular disease 
were added to the Falls CAP, its predictability improved (C-statistic: 0.749) (213). The Falls 
CAP appears to be a good predictor of falls; however, there are no known published studies 
where the Falls CAP is used to predict hip fracture. 
4.4.2 Strengths and Limitations 
This was a largely descriptive and explorative chapter that provided insight into the basic 
demographic information of people in the dataset and the number and type of hip fractures. 
The dataset provides a good description of the New Zealand interRAI-HC cohort, but may not 
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be generalisable to the general population of people in New Zealand aged 65 years and older, 
particularly as those who undergo an interRAI-HC assessment have more complex health care 
needs. 
There is a large amount of data that can be used to explore how many people are having hip 
fractures and how those hip fractures impact mortality. Large data allows for high statistical 
power. 
4.4.3 Concluding Statement 
This chapter has provided a brief overview of the hip fracture dataset, including the data 
selection process and basic descriptive information. The next chapter will be an exploration of 
the home care data to assess risk factors for hip fracture that may be useful for creating a hip 




5 Risk Factors for Hip Fracture 
5.1 Introduction 
The previous chapter presented a general overview of the interRAI-HC assessment data, 
including how many people had fractures, how many died, and basic demographic 
information. This chapter presents the results for the first aim of the thesis: identifying risk 
factors for hip fracture. Risk factors will be explored for the whole group and will then be 
stratified by males and females to assess if there are any differences in risk profiles. The aim 
of this chapter is to identify risk factors for hip fracture within the interRAI-HC assessment 




Participants from the original interRAI-HC dataset of 67,337 individuals were split into two 
groups. Approximately two-thirds of the original dataset were randomly selected for the test 
dataset (45,046), and the remaining one-third (22,291) was set aside as a validation dataset. 
All analyses in this chapter employ the test dataset of 45,046. As the test dataset participants 
are a random subset of the participants featured in the previous chapter, their characteristics 
are still those who had an interRAI-HC assessment between 1 June 2012 and 30 June 2015, 
who were aged 65 years and older, and consented for their data to be used for research 
purposes. Figure 5 in Chapter 4 has a comprehensive breakdown of the participant selection 
criteria. 
5.2.2 Variables 
Variables used for analysis were derived from the interRAI-HC assessment and selected 
based on the literature outlined in Chapter 2. Groups from the literature were Falls, 
Environment, Cognition, Co-morbidities, Age, Sex, Exercise, Lifestyle, BMI, and Ethnicity. 
Medication was not included in analysis. There is medication information collected as part of 
an interRAI-HC assessment; however, the medication data received from TAS was of low 
quality with severe formatting errors and therefore unusable for analysis purposes. Previous 
studies relyng on New Zealand medication data sourced this from pharmacy data held by the 
MoH. This was not done on this occassion as all items considered for use in this analysis were 
taken from the interRAI-HC assessment only. This was to ensure the hip fracture prediction 
score could be easily calculated at the end of an interRAI-HC assessment without having to 
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find extra information external to what was available in the interRAI-HC assessment. 
Additionally, there are no general questions, for example, a question on number of 
medications. 
There are no questions in the interRAI-HC 9.1 assessment from the Bone category such as 
BMD, or whether the individual has a diagnosis of osteoporosis, so these risk factors were 
also excluded from analysis. A full description of the questions in the interRAI-HC 
assessment that were used in this analysis and the variable recoding applied for this purpose 
can be found in Chapter 3, Table 8. 
5.2.3 Statistical Analysis 
Basic descriptive information for the cohort was reported. This included the demographic 
variables and the variables of interest; the totals were reported alongside the numbers in each 
outcome group (Alive, no fracture, Fracture, and Death). Competing risk models using the 
Fine and Gray method (176) were utilised to determine risk factors for hip fracture. Hip 
fracture was the failure event and death was the competing event. Unadjusted models were 
constructed for each variable of interest. An adjusted model was then produced where all 
variables in the unadjusted models were included to ensure all potentially significant variables 
were found (214), with α = 0.05 defining statistical significance. Subhazard ratios (SHRs) and 
95% confidence intervals (CIs) were reported for each variable in the model. The relative 
importance of each significant variable was also assessed by calculating the percentage 
contribution of each variable to the model. The chi-square statistic minus the number of 
degrees of freedom (df) for each variable relative to the chi-square minus the number of 
degrees of freedom for the whole model was calculated. This information was presented as a 
graph. All analyses were conducted on the whole test dataset cohort and then repeated for 
males and females separately to determine if there were different risk profiles for each sex. 
Once significant variables were determined, new competing risk regression models were run 
containing only the significant variables. The competing risk regression model equation was 
extracted for each group to be used later in validating the risk factor score. The baseline 
cumulative incidence function (CIF) was also calculated for each model for a time of two 
years. The baseline CIF is calculated where the reference groups for all categorical variables 





5.3.1 Participant Information 
The mean age of the test cohort was 82.8 years (range 65 to 106 years). The cohort included 
17,339 (38.5%) males and 27,705 (61.5%) females. Most of the cohort identified as European 
ethnicity (88.2%) and most hip fractures were sustained by those of European ethnicity 
(94.9%). At the end of the study period, 1,475 (3.3%) people had sustained a hip fracture, 
13,167 (28.2%) had died without a hip fracture, and 30,404 (67.5%) were alive and had not 
had a hip fracture. Females had a higher rate of fracture (5.9%) than males (2.6%), and most 
fractures occurred in the 85-94 years age group. Of the males in the cohort, 35.7% died by 
end of the study period, compared to 25.2% of females. For living arrangement, 49.8% of 
individuals who lived alone. Over half (52.3%) of people had some level of cognitive 
impairment. Overall 70.7% of individuals had some level of fatigue: 12.1% of the cohort had 
severe fatigue, 50.1% had died by the end of the study period. This study had a total person-
time of 55,444 years. Table 13 below provides a summary of the descriptive information. All 




Table 13 Descriptive information of variables of interest for test cohort (n=45,046) with totals and partitioned by outcome 
 First Event 
Variable names Total 
n (%) 






Sex     
Male 17,339 (38.5) 10,710 (61.8) 444 (2.6) 6,185 (35.7) 
Female 27,707 (61.5) 19,692 (71.1) 1,031 (3.7) 6,982 (25.2) 
Age Group (years)     
65-74 7,574 (16.8) 5,780 (76.3) 109 (1.4) 1,685 (22.2) 
75-84 18,640 (41.4) 13,278 (71.2) 532 (2.9) 4,830 (25.9) 
85-94 17,315 (38.4) 10,613 (61.3) 742 (4.3) 5,960 (34.4) 
95+ 1,517 (3.4) 733 (48.3) 92 (6.1) 692 (45.6) 
Ethnicity     
Māori 2,487 (5.5) 1,724 (69.3) 26 (1.0) 737 (29.6) 
Pacific 1,430 (3.2) 1,043 (72.9) 19 (1.3) 368 (25.7) 
Asian 1,037 (2.3) 783 (75.5) 14 (1.4) 240 (23.1) 
European 39,732 (88.2) 26,584 (66.9) 1,400 (3.5) 11,748 (29.6) 
Other 360 (0.8) 270 (75.0) 16 (4.4) 74 (20.6) 
Living Arrangement     
Lives alone 22,423 (49.8) 15,242 (68.0) 741 (3.3) 6,440 (28.7) 
Lives with others 22,623 (50.2) 15,162 (67.0) 734 (3.2) 6,727 (29.7) 
Cognitive Skillsb 
Independent 21,505 (47.7) 15,293 (71.1) 590 (2.7) 5,622 (26.1) 
Minimal Dependence 16,512 (36.7) 11,039 (66.9) 588 (3.6) 4,885 (29.6) 
Moderate to Severe dependence 7,028 (15.6) 4,071 (57.9) 297 (4.2) 2,660 (37.8) 
Hearingc 
Adequate 23,142 (51.4) 16,399 (70.9) 691 (3.0) 6,052 (26.2) 
Minimal to moderate 20,056 (44.5) 13,011 (64.9) 709 (3.5) 6,336 (31.6) 
Severe to none 1,841 (4.1) 993 (53.9) 75 (4.1) 773 (42.0) 
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 First Event 
Variable names Total 
n (%) 







Adequate 32,013 (71.1) 22,281 (69.6) 948 (3.0) 8,784 (27.4) 
Minimal to moderate 11,863 (26.3) 7,429 (62.6) 477 (4.0) 3,957 (33.4) 
Severe to none 1,162 (2.6) 692 (59.6) 50 (4.3) 420 (36.1) 
Walkinga 
Independent 34,524 (76.6) 25,199 (73.0) 1,084 (3.1) 8,241 (23.9) 
Some assistance required 6,633 (14.7) 3,524 (53.1) 286 (4.3) 2,823 (42.6) 
Maximum Assistance/Dependent 2,336 (5.2) 995 (42.6) 82 (3.5) 1,259 (53.9) 
Locomotione 
Independent 35,033 (77.8) 25,572 (73.0) 1,097 (3.1) 8,364 (23.9) 
Some assistance required 6,228 (13.8) 3,274 (52.6) 273 (4.4) 2,681 (43.0) 
Dependent 2,971 (6.6) 1,233 (41.5) 90 (3.0) 1,648 (55.5) 
Primary Mode of Locomotionb 
Walking, no assistive device 14,486 (32.2) 11,225 (77.5) 411 (2.8) 2,850 (19.7) 
Assisted walking 28,367 (63.0) 18,201 (64.2) 1,029 (3.6) 9,137 (32.2) 
Unable to walk 2,192 (4.9) 977 (44.6) 35 (1.6) 1,180 (53.8) 
Timed 4 metre walk (seconds)f 
0-15 27,062 (60.1) 20,011 (73.9) 869 (3.2) 6,182 (22.8) 
16-29 3,927 (8.7) 2,603 (66.3) 146 (3.7) 1,178 (30.0) 
30+ 4,026 (8.9) 2,563 (63.7) 164 (4.1) 1,299 (32.3) 
Incomplete test 10,025 (22.3) 5,224 (52.1) 296 (3.0) 4,505 (44.9) 
Total hours of exercise or physical activityb 
None/Less than 1 hour 23,871 (53.0) 14,971 (62.7) 741 (3.1) 8,159 (34.2) 
1-4 hours 18,745 (41.6) 13,612 (72.6) 642 (3.4) 4,491 (24) 
4 hours or more 2,429 (5.4) 1,820 (74.9) 92 (3.8) 517 (21.3) 
Number of days left house in last 3 daysb     
None 14,987 (33.3) 8,037 (53.6) 514 (3.4) 6,436 (42.9) 
1-2 11,963 (26.6) 8,277 (69.2) 438 (3.7) 3,248 (27.2) 
3 18,095 (40.2) 14,089 (77.9) 523 (2.9) 3,483 (19.2) 
80 
 
 First Event 
Variable names Total 
n (%) 







Continent 28,200 (62.6) 19,706 (69.9) 867 (3.1) 7,627 (27.0) 
Infrequently incontinent 4,280 (8.5) 2,937 (68.6) 134 (3.1) 1,209 (28.2) 
Occasionally incontinent 4,079 (9.1) 2,668 (65.4) 162 (4.0) 1,249 (30.6) 
Frequently Incontinent 6,865 (15.2) 4,335 (63.1) 257 (3.7) 2,273 (33.1) 
Incontinent 1,586 (3.5) 742 (46.8) 53 (3.3) 791 (49.9) 
Bowel Continenceh 
Continent 37,767 (83.8) 26,519 (70.2) 1,216 (3.2) 10,032 (26.6) 
Infrequently incontinent 2,912 (6.5) 1,759 (60.4) 104 (3.6) 1,049 (36.0) 
Occasionally Incontinent 2,331 (5.2) 1,230 (52.8) 100 (4.3) 1,001 (42.9) 
Frequently Incontinent 1,089 (2.4) 502 (46.1) 34 (3.1) 553 (50.8) 
Incontinent 840 (1.9) 343 (40.8) 18 (2.1) 479 (57.0) 
Fatiguei 
None 13,194 (29.3) 9,928 (75.2) 399 (3.0) 2,867 (21.7) 
Minimal to Moderate 26,380 (58.6) 17,893 (67.8) 928 (3.5) 7,559 (28.7) 
Severe 5,469 (12.1) 2,581 (47.2) 148 (2.7) 2,740 (50.1) 
Difficult or unable to move self to standingi 
Not present 28,012 (62.2) 20,151 (71.9) 914 (3.3) 6,947 (24.8) 
Present 17,031 (37.8) 10,251 (60.2) 561 (3.3) 6,219 (36.5) 
Dizzinessi 
Not present 38,108 (84.6) 25,860 (67.9) 1,235 (3.2) 11,013 (28.9) 
Present 6,935 (15.4) 4,542 (65.5) 240 (3.5) 2,153 (31.0) 
Unsteady Gaiti 
Not present 21,569 (47.9) 15,416 (71.5) 669 (3.1) 5,484 (25.4) 
Present 23,474 (52.1) 14,986 (63.8) 806 (3.4) 7,682 (32.7) 
Previous Falli 
No Fall 26,889 (59.7) 18,936 (70.4) 792 (2.9) 7,161 (26.6) 
Had at least one fall 18,154 (40.3) 11,466 (63.2) 683 (3.8) 6,005 (33.1) 
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 First Event 
Variable names Total 
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Previous hip fracturea 
None 44,232 (98.2) 29,939 (67.7) 1,442 (3.3) 12,851 (29.1) 
Had previous fracture 812 (1.8) 464 (57.1) 33 (4.1) 315 (38.8) 
Previous Other fracturea 
None 43,704 (97.0) 29,576 (67.7) 1,414 (3.2) 12,714 (29.1) 
Had previous fracture 1,340 (3.0) 827 (61.7) 61 (4.6) 452 (33.7) 
Easily Distractedj 
Not present 34,633 (76.9) 23,621 (68.2) 1,051 (3.0) 9,961 (28.8) 
Present 10,400 (23.1) 6,779 (65.2) 424 (4.1) 3,197 (30.7) 
Mental function varies over the course of a dayj 
Not present 35,107 (77.9) 24,232 (69.0) 1,054 (3.0) 9,821 (28.0) 
Present 9,926 (22.0) 6,168 (62.1) 421 (4.2) 3,337 (33.6) 
Wanderingk 
Not Present 43,254 (96.0) 29,284 (67.7) 1,379 (3.2) 12,591 (29.1) 
Present 1,783 (4.0) 1,117 (62.6) 96 (5.4) 570 (32.0) 
Frequency of Paini 
No pain 18,291 (40.6) 11,960 (65.4) 632 (3.5) 5,699 (31.2) 
Not in last 3 days 4,573 (10.2) 3,160 (69.1) 172 (3.8) 1,241 (27.1) 
At least once in last 3 days 22,179 (49.2) 15,282 (68.9) 671 (3.0) 6,226 (28.1) 
Intensity of Highest level of Paini 
None 18,495 (41.1) 12,067 (65.2) 649 (3.5) 5,779 (31.2) 
Mild to Moderate 19,860 (44.1) 13,679 (68.9) 618 (3.1) 5,563 (28.0) 
Severe to Excruciating 6,688 (14.8) 4,656 (69.6) 208 (3.1) 1,824 (27.3) 
Consistency of Paini 
None/Very Little 19,792 (43.9) 12,972 (65.5) 683 (3.5) 6,137 (31.0) 
Intermittent 19,399 (43.1) 13,323 (68.7) 612 (3.1) 5,464 (28.2) 
Constant 5,852 (13.0) 4,107 (70.2) 180 (3.1) 1,565 (26.7) 
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Underweight 2,292 (5.1) 1,230 (53.7) 151 (6.6) 911 (39.7) 
Normal 13,538 (30.1) 9,064 (67.0) 498 (3.7) 3,976 (29.4) 
Overweight 7,480 (16.6) 5,559 (74.3) 162 (2.2) 1,759 (23.5) 
Obese 4,616 (10.0) 3,690 (79.9) 57 (1.2) 869 (18.8) 
Undetermined 17,237 (38.3) 10,861 (63.0) 607 (3.5) 5,652 (32.8) 
Smokes tobacco dailyi 
No 42,644 (94.7) 28,827 (67.6) 1,383 (3.2) 12,434 (29.2) 
Yes 2,399 (5.3) 1,575 (65.7) 92 (3.8) 732 (30.5) 
Consumes Alcoholi 
None 35,914 (79.7) 23,808 (66.3) 1,209 (3.4) 10,897 (30.3) 
At least one drink 9,129 (20.3) 6,594 (72.2) 266 (3.8) 2,269 (42.8) 
Weight Loss of 5% or morei 
No 38,317 (85.1) 26,807 (67.9) 1,220 (3.2) 10,290 (26.9) 
Yes 6,726 (14.9) 3,595 (53.4) 255 (3.8) 2,876 (42.8) 
Dehydratedi 
No 44,175 (98.1) 30,008 (67.9) 1,443 (3.3) 12,724 (28.8) 
Yes 868 (1.9) 394 (45.4) 32 (3.7) 442 (50.9) 
Decrease in food/fluid consumedi 
No 40,280 (89.4) 27,975 (69.5) 1,315 (3.3) 10,990 (27.3) 
Yes 4,763 (10.6) 2,427 (51.0) 160 (3.4) 2,176 (45.7) 
Parkinson’s Diseasea 
Not present 43,263 (96.0) 29,197 (67.5) 1,394 (3.2) 12,672 (29.3) 
Diagnosis present 1,781 (4.0) 1,206 (67.7) 81 (4.5) 494 (27.7) 
Stroke/CVAa 
Not Present 37,121 (82.4) 25,198 (67.9) 1,240 (3.3) 10,683 (28.8) 
Diagnosis Present 7,923 (17.6) 5,205 (65.7) 2,483 (31.3) 2,483 (31.3) 
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Not present 37,920 (84.2) 26,194 (69.1) 1,257 (3.3) 10,469 (27.6) 
Diagnosis present 7,124 (15.8) 4,209 (59.1) 218 (3.1) 2,697 (37.9) 
Dyspnoeai 
Not present 24,021 (53.3) 17,173 (71.5) 871 (3.6) 5,977 (24.9) 
Present 21,022 (46.7) 13,229 (62.9) 604 (2.9) 7,189 (34.2) 
Environmentd 
No 39,487 (87.7) 26,787 (67.8) 1,282 (3.2) 11,418 (28.9) 
Yes 5,551 (12.3) 3,611 (65.1) 193 (3.5) 1,747 (31.5) 
a2 values missing, b1 value missing, c7 values missing, d8 values missing, e814 values missing, f6 variables missing, g36 values missing, h107 values 




5.3.2 Competing Risks Regression 
5.3.2.1 Whole Test Cohort 
The risk factors for hip fracture identified by the model were age, sex, ethnicity, falls, mental 
function varies throughout the course of the day, wandering, tobacco use, BMI, and 
Parkinson’s disease. Dyspnoea (shortness of breath) was also associated with hip fracture, but 
those who suffered from dyspnoea were at a reduced risk of hip fracture (SHR 0.81 95% CI: 
0.72 to 0.91). For BMI, those who were underweight were at an increased risk of hip fracture 
(SHR 1.65 95% CI: 1.36 to 2.00) compared to individuals who had a normal BMI, and those 
who were overweight or obese had a reduced rate of hip fracture (Overweight SHR 0.67 95% 
CI: 0.56 to 0.81), Obese SHR 0.48 95% CI: 0.36 to 0.64). Table 14 presents the unadjusted 
and adjusted SHRs for each variable in the models. 
Table 14 Unadjusted and adjusted competing risk regression models for the whole cohort 
Variable Names Unadjusted Model 
SHR (95% CI) 
Adjusted* Model 
SHR (95% CI) 
Sex   
Male 1 (reference) 1 (reference) 
Female 1.46 (1.31, 1.64) 1.37 (1.21, 1.54) 
Age Group (years)   
65-74 1 (reference) 1 (reference) 
75-84 1.98 (1.61, 2.43) 1.83 (1.48, 2.27) 
85-94 2.96 (2.42, 3.62) 2.51 (2.00, 3.13) 
95+ 4.27 (3.23, 5.63) 3.25 (2.38, 4.43) 
Ethnicity   
Māori 0.30 (0.21, 0.45) 0.38 (0.25, 0.57) 
Pacific People 0.36 (0.23, 0.57) 0.49 (0.30, 0.79) 
Asian 0.38 (0.23, 0.65) 0.39 (0.22, 0.67) 
European 1 (reference) 1 (reference) 
Other 1.29 (0.79, 2.13) 1.42 (0.86, 2.34) 
Living Arrangement   
Lives alone 1 (reference) 1 (reference) 
Lives with others 0.98 (0.88, 1.08) 0.99 (0.89, 1.09) 
Cognitive Skills   
Independent 1 (reference) 1 (reference) 
Minimal Independence 1.32 (1.17, 1.47) 1.14 (1.00, 1.29) 
Moderate to Severe dependence 1.50 (1.31, 1.73) 1.16 (0.96, 1.40) 
Hearing   
Adequate 1 (reference) 1 (reference) 
Minimal to moderate 1.18 (1.06, 1.31) 0.98 (0.88, 1.10) 
Severe to none 1.35 (1.06, 1.71) 0.99 (0.77, 1.27) 
Vision   
Adequate 1 (reference) 1 (reference) 
Minimal to moderate 1.32 (1.18, 1.47) 1.15 (1.02, 1.29) 
Severe to none 1.37 (1.03, 1.82) 1.19 (0.89, 1.59) 
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Variable Names Unadjusted Model 
SHR (95% CI) 
Adjusted* Model 
SHR (95% CI) 
Walking   
Independent 1 (reference) 1 (reference) 
Some assistance required 1.34 (1.17, 1.52) 1.04 (0.76, 1.42) 
Maximum Assistance/Dependent 1.08 (0.86, 1.35) 1.21 (0.73, 2.00) 
Locomotion   
Independent 1 (reference) 1 (reference) 
Some assistance required 1.37 (1.20, 1.57) 1.07 (0.78, 1.47) 
Dependent 0.93 (0.75, 1.15) 0.89 (0.54, 1.47) 
Primary Mode of Locomotion   
Walking, no assistive device 1 (reference) 1 (reference) 
Assisted walking 1.24 (1.11, 1.39) 1.09 (0.95, 1.25) 
Unable to walk 0.52 (0.37, 0.73) 0.73 (0.41, 1.32) 
Timed 4 metre walk (seconds)   
0-15 1 (reference) 1 (reference) 
16-29 1.07 (0.90, 1.28) 1.00 (0.83, 1.20) 
30+ 1.13 (0.95, 1.33) 1.04 (0.88, 1.24) 
Incomplete test 0.86 (0.76, 0.99) 0.88 (0.75, 1.03) 
Total hours of exercise or physical activity   
None/Less than 1 hour 1 (reference) 1 (reference) 
1-4 hours 1.06 (0.95, 1.17) 1.04 (0.93, 1.17) 
4 hours or more 1.05 (0.84, 1.30) 1.11 (0.89, 1.40) 
Number of days left house in last 3 days   
None 1 (reference) 1 (reference) 
1-2 1.08 (0.95, 1.22) 1.18 (1.02, 1.37) 
3 0.86 (0.77, 0.98) 1.03 (0.88, 1.20) 
Bladder Continence   
Continent 1 (reference) 1 (reference) 
Infrequently incontinent 1.03 (0.86, 1.24) 0.94 (0.78, 1.13) 
Occasionally incontinent 1.29 (1.09, 1.52) 1.09 (0.92, 1.30) 
Frequently Incontinent 1.20 (1.05, 1.38) 1.07 (0.92, 1.30) 
Incontinent 1.04 (0.79, 1.37) 1.27 (0.91, 1.76) 
Bowel Continence   
Continent 1 (reference) 1 (reference) 
Infrequently incontinent 1.11 (0.90, 1.35) 0.98 (0.79, 1.21) 
Occasionally Incontinent 1.31 (1.07, 1.61) 1.10 (0.87, 1.38) 
Frequently Incontinent 0.93 (0.66, 1.31) 0.83 (0.57, 1.21) 
Incontinent 0.64 (0.40, 1.03) 0.84 (0.47, 1.49) 
Fatigue   
None 1 (reference) 1 (reference) 
Minimal to Moderate 1.18 (1.05, 1.32) 1.16 (1.02, 1.31) 
Severe 0.89 (0.73, 1.07) 0.89 (0.72, 1.11) 
Difficult or unable to move self to standing   
Not present 1 (reference) 1 (reference) 
Present 1.00 (0.90, 1.12) 0.98 (0.86, 1.11) 
Dizziness   
Not present 1 (reference) 1 (reference) 
Present 1.06 (0.93, 1.22) 1.08 (0.93, 1.25) 
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Variable Names Unadjusted Model 
SHR (95% CI) 
Adjusted* Model 
SHR (95% CI) 
Unsteady Gait   
Not present 1 (reference) 1 (reference) 
Present 1.10 (0.99, 1.21) 1.01 (0.89, 1.14) 
Previous Fall   
No Fall 1 (reference) 1 (reference) 
Had at least one fall 1.30 (1.17, 1.44) 1.14 (1.02, 1.28) 
Previous hip fracture   
None 1 (reference) 1 (reference) 
Had previous fracture 1.22 (0.86, 1.72) 0.90 (0.62, 1.29) 
Previous Other fracture   
None 1 (reference) 1 (reference) 
Had previous fracture 1.44 (1.11, 1.86) 1.05 (0.80, 1.38) 
Easily Distracted   
Not present 1 (reference) 1 (reference) 
Present 1.34 (1.20, 1.50) 1.10 (0.96, 1.27) 
Mental function varies over the course of a day   
Not present 1 (reference) 1 (reference) 
Present 1.39 (1.24, 1.56) 1.16 (1.01, 1.34) 
Wandering   
Not Present 1 (reference) 1 (reference) 
Present 1.68 (1.37, 2.07) 1.40 (1.02, 1.77) 
Frequency of Pain   
No pain 1 (reference) 1 (reference) 
Not in last 3 days 1.13 (0.96, 1.34) 1.36 (1.01, 1.83) 
At least once in last 3 days 0.89 (0.80, 1.00) 1.12 (0.81, 1.52) 
Intensity of Highest level of Pain   
None 1 (reference) 1 (reference) 
Mild to Moderate 0.91 (0.81, 1.01) 
 
0.69 (0.50, 0.95) 
Severe to Excruciating 0.91 (0.78, 1.06) 0.76 (0.53, 1.09) 
Consistency of Pain   
None/Very Little 1 (reference) 1 (reference) 
Intermittent 0.94 (0.85, 1.05) 1.21 (0.93, 1.57) 
Constant 0.89 (0.76, 1.05) 1.25 (0.93, 1.69) 
Body Mass Index (BMI)   
Underweight 1.81 (1.51, 2.17) 1.65 (1.36, 2.00) 
Normal 1 (reference) 1 (reference) 
Overweight 0.59 (0.49, 0.70) 0.67 (0.56, 0.81) 
Obese 0.34 (0.26, 0.45) 0.48 (0.36, 0.64) 
Undetermined 0.93 (0.82, 1.04) 0.99 (0.87, 1.12) 
Smokes tobacco daily   
No 1 (reference) 1 (reference) 
Yes 1.21 (0.98, 1.49) 1.55 (1.24, 1.95) 
Consumes Alcohol   
None 1 (reference) 1 (reference) 
At least one drink 0.87 (0.76, 0.99) 0.90 (0.78, 1.03) 
Weight Loss of 5% or more   
No 1 (reference) 1 (reference) 
Yes 1.19 (1.04, 1.37) 1.08 (0.93, 1.25) 
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Variable Names Unadjusted Model 
SHR (95% CI) 
Adjusted* Model 
SHR (95% CI) 
Dehydrated   
No 1 (reference) 1 (reference) 
Yes 1.12 (0.79, 1.59) 0.82 (0.56, 1.20) 
Decrease in food/fluid consumed   
No 1 (reference) 1 (reference) 
Yes 1.05 (0.89, 1.23) 0.95 (0.79, 1.15) 
Parkinson’s Disease   
Not present 1 (reference) 1 (reference) 
Diagnosis present 1.37 (1.09, 1.71) 1.46 (1.15, 1.86) 
Stroke/CVA   
Not Present 1 (reference) 1 (reference) 
Diagnosis Present 0.87 (0.76, 1.00) 0.92 (0.79, 1.06) 
COPD   
Not present 1 (reference) 1 (reference) 
Diagnosis present 0.92 (0.80, 1.06) 1.14 (0.79, 1.06) 
Dyspnoea   
Not present 1 (reference) 1 (reference) 
Present 0.80 (0.72, 0.89) 0.81 (0.72, 0.91) 
Environment   
No 1 (reference) 1 (reference) 
Yes 1.05 (0.90, 1.22) 1.10 (0.94, 1.29) 
*Adjusted variables: age, sex, ethnicity, living arrangement, cognitive impairment, hearing, 
vision, walking, locomotion, primary mode of locomotion, timed 4 metre walk, exercise 
hours, left house in last 3 days, bladder continence, bowel continence, fatigue, difficulty 
standing, dizziness, unsteady gait, falls, previous hip fracture, previous other fracture, easily 
distracted, mental function varies, wandering, frequency of pain, intensity of pain, consistency 
of pain, BMI, tobacco use, alcohol consumption, weight loss, dehydration, decrease in food 
consumption, Parkinson’s disease, stroke, COPD, dyspnoea, environment, and living 
arrangement. 
 
5.3.2.2 Males and Females 
Adjusted competing risk regression models were run for males and females separately. These 
models are presented in Table 15 below. The variables associated with hip fracture for males 
were age, Parkinson’s disease and Dyspnoea. Dyspnoea was associated with a reduced risk of 
fracture for males (SHR 0.78 95% CI: 0.63 to 0.97). For the females only group the 
significant variables were age, ethnicity, wandering, BMI, tobacco use, and dyspnoea. High 
BMI (Overweight SHR 0.60 95% CI 0.47 to 0.76), Obese SHR 0.47 95% CI 0.34 to 0.66), 
and dyspnoea (SHR 0.82 95% CI: 0.71, 0.94) were associated with a reduced rate of hip 
fracture. The variables for the whole group and the female cohort were similar, but falls, 
mental function varies throughout the day, and Parkinson’s disease were not associated risk 
factors for the female cohort. 
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Table 15 Adjusted competing risk regression models for male and female groups 
Variable names Males Adjusted* 
Analysis 
SHR (95% CI) 
Females Adjusted* 
Analysis 
SHR (95% CI) 
Age Group (years)   
65-74 1 (reference) 1 (reference) 
75-84 2.11 (1.47, 3.03) 1.69 (1.29, 2.22) 
85-94 2.42 (1.65, 3.54) 2.49 (1.89, 3.28) 
95+ 3.43 (1.86, 6.32) 3.13 (2.17,4.53) 
Ethnicity   
Māori 0.36 (0.16, 0.82) 0.38 (0.23, 0.60) 
Pacific People 0.57 (0.25, 1.29) 0.45 (0.25, 0.81) 
Asian 0.58 (0.26, 1.29) 0.30 (0.14, 0.64) 
European 1 (reference) 1 (reference) 
Other 1.75 (0.76, 4.00) 1.26 (0.67, 2.38) 
Living Arrangement   
Lives alone 1 (reference) 1 (reference) 
Lives with others 0.84 (0.69, 1.01) 1.06 (0.93, 1.20) 
Cognitive Skills   
Independent 1 (reference) 1 (reference) 
Minimal Independence 1.18 (0.94, 1.48) 1.11 (0.95, 1.30) 
Moderate to Severe 
dependence 
1.06 (0.74, 1.51) 1.20 (0.96, 1.50) 
Hearing   
Adequate 1 (reference) 1 (reference) 
Minimal to moderate 1.04 (0.85, 1.29) 0.96 (0.84, 1.10) 
Severe to none 1.17 (0.78, 1.76) 0.91 (0.66, 1.25) 
Vision   
Adequate 1 (reference) 1 (reference) 
Minimal to moderate 1.52 (0.93, 1.42) 1.15 (1.00, 1.32) 
Severe to none 1.16 (0.66, 2.03) 1.19 (0.85, 1.68) 
Walking   
Independent 1 (reference) 1 (reference) 
Some assistance required 0.97 (0.58, 1.63) 1.08 (0.73, 1.58) 
Maximum 
Assistance/Dependent 
0.78 (0.37, 1.64) 1.19 (0.79, 2.80) 
Locomotion   
Independent 1 (reference) 1 (reference) 
Some assistance required 1.12 (0.66, 1.89) 1.05 (0.71, 1.55) 
Dependent 1.37 (0.68, 2.74) 0.73 (0.38, 1.41) 
Primary Mode of Locomotion  
Walking, no assistive 
device 
1 (reference) 1 (reference) 
Assisted walking 1.11 (0.87, 1.42) 1.08 (0.92, 1.28) 
Unable to walk 0.66 (0.24, 1.83) 0.78 (0.38, 1.60) 
Timed 4 Metre walk   
0-15 seconds 1 (reference) 1 (reference) 
16-29 seconds 0.90 (0.64, 1.26) 1.05 (0.84, 1.29) 
30+ seconds 1.02 (0.74, 1.41) 1.05 (0.86, 1.30) 
Incomplete test 0.75 (0.55, 1.02) 0.94 (0.78, 1.14) 
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Variable names Males Adjusted* 
Analysis 
SHR (95% CI) 
Females Adjusted* 
Analysis 
SHR (95% CI) 
Total hours of exercise or physical activity  
None/Less than 1 hour 1 (reference) 1 (reference) 
1-4 hours 1.07 (0.87, 1.32) 1.03 (0.90, 1.18) 
4 hours or more 0.88 (0.56, 1.38) 1.22 (0.93, 1.58) 
Number of days left house in last 3 days  
None 1 (reference) 1 (reference) 
1-2 days 1.29 (0.98, 1.71) 1.14 (0.96, 1.35) 
3 days 1.02 (0.77, 1.36) 1.03 (0.85, 1.23) 
Bladder Continence   
Continent 1 (reference) 1 (reference) 
Infrequently incontinent 0.84 (0.58, 1.23) 0.98 (0.79, 1.22) 
Occasionally incontinent 1.03 (0.73, 1.46) 1.12 (0.91, 1.37) 
Frequently Incontinent 0.86 (0.61, 1.21) 1.14 (0.95, 1.36) 
Incontinent 1.58 (0.95, 2.62) 1.13 (0.73, 1.75) 
Bowel Continence   
Continent 1 (reference) 1 (reference) 
Infrequently incontinent 0.87 (0.58, 1.31) 1.05 (0.82, 1.34) 
Occasionally Incontinent 1.03 (0.67, 1.59) 1.14 (0.86, 1.50) 
Frequently Incontinent 0.66 (0.32, 1.37) 0.94 (0.60, 1.48) 
Incontinent 0.95 (0.41, 2.21) 0.73 (0.33, 1.65) 
Fatigue   
None 1 (reference) 1 (reference) 
Minimal to Moderate 1.33 (1.04, 1.70) 1.10 (0.95, 1.28) 
Severe 1.27 (0.87, 1.85) 0.75 (0.57, 0.99) 
Difficult or unable to move self to standing  
Not present 1 (reference) 1 (reference) 
Present 0.94 (0.74, 1.18) 1.00 (0.85, 1.17) 
Dizziness   
Not present 1 (reference) 1 (reference) 
Present 1.08 (0.83, 1.40) 1.08 (0.91, 1.29) 
Unsteady Gait   
Not present 1 (reference) 1 (reference) 
Present 1.04 (0.82, 1.32) 0.99 (0.86, 1.15) 
Previous Fall   
No Fall 1 (reference) 1 (reference) 
Had at least one fall 1.17 (0.82, 1.32) 1.13 (0.98, 1.29) 
Previous hip fracture   
None 1 (reference) 1 (reference) 
Had previous fracture 0.88 (0.41, 1.91) 0.88 (0.58, 1.33) 
Previous Other fracture   
None 1 (reference) 1 (reference) 
Had previous fracture 1.48 (0.83, 2.64) 0.97 (0.71, 1.33) 
Easily Distracted   
Not present 1 (reference) 1 (reference) 
Present 1.07 (0.83, 1.38) 1.11 (0.94, 1.31) 
Mental Function Varies over the course of a day  
Not present 1 (reference) 1 (reference) 
Present 1.26 (0.98, 1.63) 1.12 (0.94, 1.33) 
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Variable names Males Adjusted* 
Analysis 
SHR (95% CI) 
Females Adjusted* 
Analysis 
SHR (95% CI) 
Wandering   
Not Present 1 (reference) 1 (reference) 
Present 1.14 (0.74, 1.77) 1.54 (1.16, 2.05) 
Frequency of Pain   
No pain 1 (reference) 1 (reference) 
Not in last 3 days 1.40 (0.84, 2.34) 1.34 (0.93, 1.94) 
At least once in last 3 days 1.35 (0.78, 1.77) 1.03 (0.71, 1.53) 
Intensity of Highest level of Pain  
None 1 (reference) 1 (reference) 
Mild to Moderate 0.63 (0.36, 1.10) 0.72 (0.48, 1.07) 
Severe to Excruciating 0.76 (0.41, 1.43) 0.78 (0.50, 1.21) 
Consistency of Pain   
None/Very Little 1 (reference) 1 (reference) 
Intermittent 0.97 (0.63, 1.48) 1.31 (0.94, 1.81) 
Constant 0.97 (0.57, 1.63) 1.37 (0.94, 1.97) 
BMI   
Underweight 1.54 (0.97, 2.44) 1.67 (1.35, 2.06) 
Normal 1 (reference) 1 (reference) 
Overweight 0.81 (0.61, 1.07) 0.60 (0.47, 0.76) 
Obese 0.48 (0.28, 0.82) 0.47 (0.34, 0.66) 
Undetermined 0.98 (0.78, 1.23) 0.99 (0.86, 1.15) 
Smokes tobacco daily   
No 1 (reference) 1 (reference) 
Yes 1.31 (0.87, 1.97) 1.70 (1.30, 2.23) 
Consumes Alcohol   
None 1 (reference) 1 (reference) 
At least one drink 0.84 (0.67, 1.06) 0.93 (0.78, 1.11) 
Weight Loss of 5% or more   
No 1 (reference) 1 (reference) 
Yes 1.25 (0.96, 1.64) 1.01 (0.84, 1.21) 
Dehydrated   
No 1 (reference) 1 (reference) 
Yes 0.54 (0.24, 1.22) 0.95 (0.62, 1.45) 
Decrease in food/fluid consumed  
No 1 (reference) 1 (reference) 
Yes 0.93 (0.66, 1.32) 0.96 (0.77, 1.20) 
Parkinson’s Disease   
Not present 1 (reference) 1 (reference) 
Diagnosis present 1.53 (1.10, 2.13) 1.37 (0.96, 1.95) 
Stroke/CVA   
Not Present 1 (reference) 1 (reference) 
Diagnosis Present 1.08 (0.86, 1.37) 0.84 (0.70, 1.01) 
COPD   
Not present 1 (reference) 1 (reference) 
Diagnosis present 1.18 (0.89, 1.56) 1.11 (0.91, 1.35) 
Dyspnoea   
Not present 1 (reference) 1 (reference) 
Present 0.78 (0.63, 0.97) 0.82 (0.71, 0.94) 
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Variable names Males Adjusted* 
Analysis 
SHR (95% CI) 
Females Adjusted* 
Analysis 
SHR (95% CI) 
Environment   
No 1 (reference) 1 (reference) 
Yes 1.02 (0.69, 1.01) 1.14 (0.95, 1.38) 
*Adjusted variables: age, ethnicity, living arrangement, cognitive impairment, hearing, vision, 
walking, locomotion, primary mode of locomotion, timed 4 metre walk, exercise hours, left 
house in last 3 days, bladder continence, bowel continence, fatigue, difficulty standing, 
dizziness, unsteady gait, falls, previous hip fracture, previous other fracture, easily distracted, 
mental function varies, wandering, frequency of pain, intensity of pain, consistency of pain, 
BMI, tobacco use, alcohol consumption, weight loss, dehydration, decrease in food 
consumption, Parkinson’s disease, stroke, COPD, dyspnoea, environment, and living 
arrangement. 
 
5.3.3 Explanatory Variables 
5.3.3.1 Whole Test Cohort 
Figure 7 below is a graph of all significant risk factors associated with hip fracture for the 
whole test cohort and the percentage they contribute to the model. Age was the most 
influential variable and it accounted for almost 50% of the predictive power of the model. 
BMI was the least explanatory variable included in the analysis. 
 





Figure 8 presents the three risk factors associated with hip fracture in males and the 
percentage of the model they explained. As was the case for the whole cohort, age had the 
highest percentage contribution to the model. Dyspnoea had the lowest percentage 
contribution to the males-only model. 
 
Figure 8 Percentage of the model explained by each variable for the males only model 
 
5.3.3.3 Females 
Figure 9 presents the percentage contribution to the model of each risk factor associated with 
hip fracture in females. Again, age had the highest percentage contribution. For the females, 
wandering had the next highest percentage contribution, followed by ethnicity. The lowest 




Figure 9 Percentage of the model explained by each variable for the females only model 
 
5.3.4 Model Coefficients 
The coefficients of the variables associated with hip fracture risk for the whole cohort, the 
males-only model, and the females-only model are listed below in Table 16. The coefficients 
are derived from the model and multiplied by their corresponding variable as part of the 
whole model calculation. For the males and females models, any variable not used in the 
model was listed as N/A (Not applicable). The baseline CIF at two years for the whole cohort 
was 0.0160; the baseline CIF for the males cohort was 0.0150, and for females was 0.0263. 
















Age Group    
65-74 0 (Reference) 0 (Reference) 0 (Reference) 
75-84 0.62 (0.42, 0.83) 0.77 (0.43, 1.12) 0.56 (0.30, 0.82) 
85-94 0.94 (0.73, 1.15) 1.02 (0.68, 1.37) 0.94 (0.68, 1.19) 
95+ 1.23 (0.95, 1.52) 1.41 (0.85, 1.98) 1.21 (0.87, 1.54) 
Sex    
Male 0 (Reference) N/A N/A 
Female 0.34 (0.23, 0.46) N/A N/A 
Ethnicity    
Māori -0.920 (-1.31, -0.53) N/A -0.90 (-1.35, -0.45) 
Pacific People -0.726 (-1.18, -0.27) N/A -0.80 (-1.35, -0.24) 
Asian -0.914 (-1.44, -0.39) N/A -1.11 (-1.81, -0.41) 
European 0 (Reference) N/A 0 (Reference) 
Other 0.327 (-0.17, 0.82) N/A 0.23 (-0.40, 0.86) 
Falls    
None 0 (Reference) N/A N/A 
Had at least one fall 0.16 (0.06, 0.26) N/A N/A 
Mental Function Varies    
No 0 (Reference) N/A N/A 
Yes 0.25 (0.13, 0.37) N/A N/A 
Wandering    
No 0 (Reference) N/A 0 (Reference) 
Yes 0.42 (0.20, 0.64) N/A 0.69 (0.44, 0.94) 
BMI    
Underweight 0.49 (0.31, 0.68) N/A 0.52 (0.32, 0.73) 
Normal 0 (Reference) N/A 0 (Reference) 
Overweight -0.39 (-0.57, -0.21) N/A -0.51 (-0.75, -0.28) 
Obese -0.74 (-1.02, -0.47) N/A -0.76 (-1.10, -0.43) 
Undetermined -0.03 (-0.15, 0.82) N/A -0.003 (-0.14, 0.14) 
Tobacco use    
No 0 (Reference) N/A 0 (Reference) 
Yes 0.46 (0.24, 0.68) N/A 0.55 (0.29, 0.81) 
Parkinson’s Disease    
No diagnosis 0 (Reference) 0 (Reference) N/A 
Diagnosis Present 0.44 (0.21, 0.66) 0.56 (0.25, 0.87) N/A 
Dyspnoea    
No 0 (Reference) 0 (Reference) 0 (Reference) 
Yes -0.16 (-0.26, -0.05) -0.18 (-0.37, 
0.003) 






5.4.1 Key Findings 
The variables associated with hip fracture were age, sex, ethnicity, falls, mental function 
varies throughout the course of the day, wandering, BMI, tobacco use, Parkinson’s disease, 
and dyspnoea. Males and females had different risk profiles; this may have been due to the 
lower number of males making it more difficult to detect small effects in that population. The 
risk factors associated with hip fracture for males were age, Parkinson’s disease, and 
dyspnoea. The females-only model included age, ethnicity, wandering, BMI, tobacco use, and 
dyspnoea as factors relating to hip fracture. 
For each of the three risk factor models, age contributed the most to hip fracture risk. This is 
reflected in previous studies on hip fracture risk, particularly with all hip fracture scores in 
Table 5 of Chapter 2 including age as a variable (49-52, 76, 84, 92, 102, 166, 167, 169). This 
is because as age increases, so does the chance of sustaining a hip fracture (60, 61, 89).  
Previous hip fracture was included in nine out of the 11 models (FRAiL and Qfracture did not 
find this to be a significant risk factor) but was not found to be associated with hip fracture for 
this cohort. 
Falls are a significant risk factor associated with hip fracture and was included in six out of 
the 11 models in Table 5. In this cohort, when examining the whole group, falls were 
significantly associated with hip fracture, but they were not when the data was stratified by 
sex. This is possibly due to a loss of power when separating the model into males- and 
females-only cohorts. 
Most of the risk factors identified in this study were included in at least one of the hip fracture 
scores listed in Table 5. Mental function varies throughout the course of the day was not 
specifically found to be associated with hip fracture risk; however, in this case, it could be a 
proxy for cognitive impairment, which was found in two fracture scores (FRAiL and FRS). 
Dyspnoea was not included in any of the scores and has not been explicitly studied in the 
literature; in this study, it was noted that people with dyspnoea were likely to be at a reduced 
risk of fracture, possibly due to the inability to move around without becoming short of 
breath. 
5.4.2 Strengths and Limitations 
Most variables in the cohort had very little missing information, except for BMI where 38.3% 
of assessments did not have a value recorded. This is likely due to the difficulty of measuring 
the height and weight of people with limited mobility. All other variables had consistently 
96 
 
low missing data rates, which allows for higher quality results. The less data that is missing, 
the less impact that any systematic bias can have on the model. 
The medication data within the interRAI-HC was not in a format that could be used for 
analysis. As detailed in the literature review, people who are prescribed certain medications 
such as corticosteroids are at an increased risk of osteoporotic fractures, including hip fracture 
(51, 81, 139). However, Berry et al. examined medications and their association with hip 
fracture for individuals who underwent an interRAI-LTCF assessment and found there was 
little association between medications and hip fractures (76). 
Falls are a significant factor associated with hip fracture as the majority of hip fracture 
sustained by older adults are the result of a fall (20, 215). Falls appear to be less of a 
contributing factor to this model (see 5.3.3) than other variables. A potential explanation for 
this is that those who are frequent fallers within this cohort are captured by the Falls CAP and 
interventions are put in place for those individuals, and those who do not trigger the Falls 
CAP are sustaining more fractures. 
The New Zealand version of the interRAI-HC 9.1 no longer has osteoporosis diagnosis 
information; therefore, it was unable to be included in the analysis. Osteoporosis diagnosis 
could be an important risk factor for hip fracture as noted in the literature. 
5.4.3 Concluding Statement 
Risk factors for hip fracture in the New Zealand interRAI-HC cohort were identified and 
analysed in this chapter. These results were similar to those of previous studies discussed in 
the literature review. The next chapter will utilise the results from this chapter to calculate and 




6 Hip Fracture Score 
6.1 Introduction 
The previous chapter contained an exploration of the test dataset (two-thirds of the original 
dataset) to determine risk factors for hip fracture. Competing risk regression models were 
conducted to assess which variables were associated with hip fracture. In the data, several risk 
factors were found to be significantly associated with hip fracture for males, but were not 
found to be significantly associated with hip fracture for females and vice versa. Further 
analysis of the combined male and female cohort was not performed. Both males and females 
had different risk profiles, which suggests that separate hip fracture prediction models would 
need to be developed for each group. In additon, Berry et al. also chose to develop separate 
hip fracture prediction scores for males and females (76). 
For males, the risk factors found to be associated with hip fracture were age, previous hip 
fracture, Parkinson’s disease, and dyspnoea. For females, the associated risk factors were age, 
ethnicity, falls, previous hip fracture, wandering, BMI, tobacco use, and dyspnoea. In this 
chapter, two hip fracture scores will be validated using the results from the previous chapter; 
one score for males and one for females. The aim of this chapter is to assess how well the hip 
fracture scores can identify individuals at an elevated risk of hip fracture using the validation 




Participants were those in the validation dataset, the remaining one-third from the original 
interRAI-HC dataset of 67,331 individuals, after two-thirds were randomly selected as the test 
dataset. The validation dataset used in this analysis consisted of 22,291 people. Figure 5 in 
Chapter Three provides a breakdown of the participant selection criteria. 
6.2.2 Variables 
The variables utilised for this analysis were those that were determined to be significantly 
associated with hip fracture in the previous chapter. These variables were age, ethnicity, falls, 
mental function varies throughout the course of the day, wandering, BMI, tobacco use, 
Parkinson’s disease, and dyspnoea. A description of the variables listed here can be found in 
Chapter Three, Table 8. 
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6.2.3 Statistical Analysis 
Basic descriptive information of the cohort including numbers of the variables of interest were 
reported. Hip fracture scores were calculated for each member of the test and validation 
datasets using Equation 1 below and the coefficients listed in section 5.3.4. Separate scores 
were calculated for the male cohort and the female cohort for both the test dataset and the 
validation dataset for comparative purposes. A cumulative distribution plot was created for 
each of the male and female scores. In this instance, CIF is the hip fracture risk. 
𝐶𝐼𝐹 = 1 − 𝑒−𝜆10(𝑡) ∗ 𝑒(∑𝛽𝑥𝑖) 
Equation 1 Equation to calculate the CIF to determine risk of hip fracture 
Where λ10(t) is the baseline cumulative hazard, the baseline cumulative hazard is when each 
variable in the equation is set to zero at time t. For this model, when time is two years, the 
baseline cumulative hazard is 0.0150 for males, and 0.0263 for females. The sum of the β 
coefficients (Σβxi) is calculated by using the β coefficient as given by the model multiplied by 
the participant characteristic (xi). The β coefficients used to calculate the relative risk for each 
characteristic were listed in Table 16. Graphs of the distribution of each score were produced. 
ROC curves were created for each score and the AUC reported.  
Cut-off points were established for each model to suggest when an individual has a high 
probability of receiving a correct positive or negative result. In this instance, a true positive is 
when an individual is at an elevated risk of hip fracture and actually sustained a hip fracture, 
and a true negative is when an individual is not at an elevated risk of hip fracture and they do 
not have a hip fracture by the end of the study period. Sensitivity is the true positive rate of a 
test; for example, it is how accurately the hip fracture score determines an individual’s risk of 
hip fracture. In cases where there are large numbers of people who do not have the disease or, 
in this instance, are not at an elevated risk of hip fracture, a test that has high specificity could 
be a useful measure. Specificity is a measure of how accurately the test identifies individuals 
who are not at risk; for example, how many people with a negative test result did not have a 
hip fracture. A perfect test would have a sensitivity and specificity of 1. 
It is common in medical tests to have a range of values that a patient can score, and some of 
these scores suggest the patient is free from the issue, while other scores suggest the 
individual may have the specific medical issue. Often, it can be clear whether a patient has a 
negative result or a positive (216). For example, the hip fracture score developed in this 
chapter ranges from 0 to 1. A patient with a score close to 0 would not be deemed to be at an 
elevated risk of hip fracture, and a patient with a score close to 1 would be determined to be at 
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an elevated risk of hip fracture. The problem lies in the middle of this score where it is unclear 
whether the individual is at an elevated risk of hip fracture or not. 
There are multiple ways of determining and assessing cut-off points for tests. One way to 
establish a cut-off point and assess the predictability of a test is by examining ROC curves. 
ROC curves provide a visual representation of the test values among patients based on their 
sensitivity and specificity. Additionally, the AUC for a ROC curve can be calculated to 
determine how accurately the score itself can predict between positive and negative subjects. 
When examining a ROC curve, the closer to the diagonal line the ROC curve is the less 
accurate the model is, and the closer to the point (0,1) at the top left-hand corner of the graph, 
the more accurate the model is. The diagonal line represents random chance. 
Additionally, clinical judgment can help to identify the best cut-off point. In cases where it 
would be important to make sure positive test results are identified early, a cut-off point with 
a high sensitivity may be more important (216, 217).  
Six cut-off points were explored for each hip fracture score, to determine where the best cut-
off point might be. The first cut-off point was determined by calculating the closest point on 
the ROC curve to (0,1). Cut-off points two, three, and four were based on high sensitivity, and 
were established by choosing the co-ordinates on the graph where sensitivity was 
approximately 75%, 85%, and 95% respectively. Cut-off points five and six were based on 
high specificity and were established by choosing the co-ordinates on the graph where 1-
specificity was approximately 5% and 15% (specificity of 95% and 85%) respectively. 
The validity of each cut-off point was assessed by calculating the sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) for the test. The PPV is 
used to assess how likely it is that an individual that receives a positive result is truly positive. 
The NPV measures how likely it is that an individual is that receives a negative result is truly 
negative (216, 218). Sensitivity, specificity, PPV, and NPV for a test can be calculated with a 
contingency table. A contingency table is a 2x2 table that displays the number of people who 
tested positive, broken down into those who actually had the outcome as predicted and those 
who did not, and the people who tested negative, broken down into those who did had the 





6.3.1 Score calculation for test dataset 
For comparative purposes, the male and female scores were calculated using the test datasets 
of 17,339 males and 27,707 females mentioned in Chapter Five. By the end of the study 
period, 44 (2.5%) males had sustained a hip fracture and 6,185 (35.7%) had died. For the 
females, 1,031 (3.7%) sustained a hip fracture and 6,982 (25.2%) had died by the end of the 
study period. The ROC for the male score is displayed in Figure 10, and the AUC was 0.617 
(95% CI: 0.577, 0.657). The ROC for the females score can also be found in Figure 10 and 
the AUC was 0.645 (95% CI: 0.629, 0.661). 
 
Figure 10 ROC curves of male and female hip fracture scores developed from the test cohort 
 
6.3.2 Participant Information 
The internal validation dataset consisted of 22,291 people with a mean age of 82.8 (range 65 
to 105 years). There were 8,519 (38.2%) males and 13,770 (61.8%) females. Within the 
cohort, a total of 784 (3.5%) people sustained a hip fracture, and 6,526 (29.3%) people died 





Table 17 Descriptive information of significant variables for validation cohort with totals and partitioned by outcome 
  First Event 
Variable names Total 
n (%) 
Alive, no fracture Fracture Death 
Sex     
Male 8,519 (38.2) 5,262 (61.8) 228 (2.7) 3,029 (35.6) 
Female 13,770 (61.8) 9,718 (70.6) 556 (4.0) 3,496 (25.4) 
Age Group (years)     
65-74 3,757 (16.9) 2,863 (76.2) 64 (1.7) 830 (22.1) 
75-84 9,063 (40.7) 6,381 (70.4) 285 (3.1) 2,397 (26.4) 
85-94 8,743 (39.2) 5,390 (61.6) 391 (4.5) 2,962 (33.9) 
95+ 728 (3.3) 347 (47.7) 44 (6.0) 337 (46.3) 
Ethnicity     
Māori 1,131 (5.1) 760 (67.2) 15 (1.3) 356 (31.5) 
Pacific 658 (3.0) 491 (74.6) 6 (0.9) 161 (24.5) 
Asian 511 (2.3) 372 (72.8) 19 (3.7) 120 (23.5) 
European 19,835 (89.0) 13,248 (66.8) 742 (3.7) 5,845 (29.5) 
Other 156 (0.7) 110 (70.5) 2 (1.3) 44 (28.2) 
Previous Fall     
No Falls 13,085 (58.7) 9,125 (69.7) 383 (2.9) 3,577 (27.3) 
Had at least one fall 9,206 (41.3) 5,856 (63.6) 401 (4.4) 2,949 (32.0) 
Wanderingb     
Not Present 21,322 (95.7) 14,396 (67.5) 727 (3.4) 6,199 (29.1) 
Present 965 (4.3) 585 (60.6) 57 (5.9) 323 (33.5) 
BMI     
Underweight 1,208 (5.4) 645 (53.4) 92 (7.6) 471 (39.0) 
Normal 6,658 (29.9) 4,420 (66.4) 256 (3.8) 1,982 (29.8) 
Overweight 3,601 (16.2) 2,692 (74.8) 84 (2.3) 825 (22.9) 
Obese 1,945 (8.7) 1,498 (77.0) 28 (1.4) 419 (21.5) 
Undetermined 8,879 (39.8) 5,726 (64.5) 324 (3.6) 2,829 (31.9) 
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  First Event 
Variable names Total 
n (%) 
Alive, no fracture Fracture Death 
Smokes tobacco dailya     
No 21,067 (94.5) 14,162 (67.2) 739 (3.5) 6,166 (29.3) 
Yes 1,223 (5.5) 818 (66.9) 45 (3.7) 360 (29.4) 
Parkinson’s Disease     
Not present 21,439 (96.2) 14,421 (67.3) 752 (3.5) 6,266 (29.2) 
Diagnosis present 852 (3.8) 560 (65.7) 32 (3.8) 260 (30.5) 
Dyspnoeaa     
Not present 11,985 (53.8) 8,610 (71.8) 455 (3.8) 2,920 (24.4) 
Present 10,305 (46.2) 6,370 (61.8) 329 (3.2) 3,606 (35.0) 




6.3.3 Internal Validation Hip Fracture Scores 
The hip fracture scores were calculated using the β coefficients from Table 16. The 
cumulative distribution plot shows the cumulative percentage of the hip fracture score for 
both males and females (Figure 11). 
 
Figure 11 Cumulative distribution of male and female hip fracture scores 
 
The ROC curves for the male and female scores are shown in Figure 12. For males, the AUC 
was 0.586 (95% CI: 0.548, 0.625), and for females, the AUC was slightly better with 0.615 
(95% CI: 0.593, 0.637). However, the 95% CIs overlap, which suggests the two scores may 
be similar when predicting hip fracture risk. An AUC of between 0.5 and 0.7 suggests there is 
some discrimination, but an AUC greater than 0.7 is a more acceptable range according to 


























Figure 12 ROC curves of male and female hip fracture scores developed from the internal validation cohort 
 
The cut-off points for the hip fracture scores were explored. For the males-only score, cut-off 
points one and two had the same values. The most ideal cut-off point would have high 
sensitivity and specificity. In cases where the sensitivity is high, but the specificity is low, 
there are large numbers of people who are at an elevated risk of hip fracture. With a high 
specificity, the focus is more on correctly identifying those who are not likely to have a hip 
fracture, which leaves a smaller pool of people who have an elevated risk of hip fracture. As 
health care resources are limited, it is better, in this instance, to focus on narrowing down the 
pool of people who are at an elevated risk of hip fracture by focusing on a higher specificity. 
Cut-off point six is the best cut-off point to use based on this criteria because while it does not 
have the highest specificity, the sensitivity is higher than for cut-off point five (which has the 
highest specificity), making it a more balanced score because there is a higher sensitivity 





Table 18 Summary of all cut-off points for males only internal validation cohort 
Cut-off Point Sensitivity Specificity PPV NPV 
COP 1 = 0.0624* 73.7% 34.9% 3.1% 98.0% 
COP 2 = 0.0624* 73.7% 34.9% 3.1% 98.0% 
COP 3 = 0.0414 86.4% 19.1% 2.9% 98.0% 
COP 4 = 0.0137 95.2% 6.0% 2.7% 97.8% 
COP 5 = 0.3269 7.9% 96.5% 5.8% 97.4% 
COP 6 = 0.2567 32.9% 77.3% 3.8% 97.7% 
*Cut-off point 1 and 2 are the same value because they were both calculated using different 
calculation methods, but both methods rendered the same cut-off point.  
 
For the females only score, cut-off point six appears to be the best cut-off point according to 
the criteria described above. While cut-off point five has the highest specificity (95.1%), it 
also has the lowest specificity (8.6%). Cut-off point six has a specificity of 84.0% suggesting 
that there is an 84% chance the hip fracture score will correctly identify people who are not at 
an elevated risk of hip fracture. Table 19 below, outlines all six cut-off points and the 
sensitivity, specificity, PPV, and NPV of each one. 
Table 19 Summary of all cut-off points for females only internal validation cohort 
 Sensitivity Specificity PPV NPV 
COP 1 = 0.0910 61.9% 54.3% 5.4% 97.1% 
COP 2 = 0.0764 71.0% 83.7% 5.2% 97.4% 
COP 3 = 0.0637 85.8% 56.3% 4.9% 98.1% 
COP 4 = 0.0170 95.7% 12.3% 4.4% 98.5% 
COP 5 = 0.5243 8.6% 95.1% 6.9% 96.1% 
COP 6 = 0.3533 24.6% 84.0% 6.1% 96.4% 
 
6.4 Discussion 
6.4.1 Key Findings 
The hip fracture scores for males and females were validated in a smaller set of 22,291 
people. The female score had slightly better predictability with an AUC of 0.615 (95% CI: 
0.593, 0.637) compared to 0.586 (95% CI: 0.548, 0.625) for males. Both AUC values suggest 
the models have better predictability than random chance, but there is room for improvement. 
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When compared to the hip fracture scores outlined in Table 20, both the males and females 
scores have low AUCs. No scores published had an AUC below 0.67, which means they are 
much stronger at predicting hip fracture than the interRAI-HC models. A full discussion of 




Table 20 Summary of hip fracture scores including year developed, country of origin, cohort size, statistical technique used, and AUC updated with interRAI-HC scores 
Hip Score Year Country Cohort Statistical Method AUC (95% CI) 
FRAX 2008 UK Unknown Poisson regression Unknown 
Garvan 2007 Australia 1,768 Cox proportional hazards model 0.85* Δ 
Qfracture (Females) 2009 UK 1,183,663 Cox proportional hazards model 0.890 (0.786, 0.790) 
Qfracture (Males) 2009 UK 1,174,232 Cox proportional hazards model 0.856 (0.851, 0.860) 
Qfracture Updated (Females) 2012 UK 1,598,294 Cox proportional hazards model 0.893 (0.890, 0.896) 
Qfracture Updated (Males) 2012 UK 1,544,379 Cox proportional hazards model 0.875 (0.868, 0.883) 
FRACTURE 2001 USA 7,782 Logistic regression 0.714* Δ 
FRAMO 2004 Sweden 1,248 Logistic regression 0.72 (0.64, 0.81) Δ 
FRISC 2010 Japan 1,787 Poisson regression 0.727 (0.660, 0.794) 
Van Staa 2006 UK 366,104 Cox proportional hazards model 0.84* Δ 
WHI 2007 USA 93,676 Cox proportional hazards model 0.80 (0.77, 0.82)  
FRAiL (Males) 2017 USA 119,874 Competing risk regression 0.692*Δ 
FRAiL (Females) 2017 USA 299,794 Competing risk regression 0.711* Δ 
FRS 2017 Canada 29,386 Decision tree 0.687* 
Internal males 2019 NZ 8,521 Competing risks regression 0.586 (0.548, 0.625) 
Internal females 2019 NZ 13,770 Competing risks regression 0.615 (0.593, 0.637) 




Various cut-off points for each model were also explored. When trying to determine which 
would be the best cut-off point, one with a high specificity and high NPV was preferable. 
There would be fewer individuals who have a fracture than not. As resources for hip fracture 
prevention programs are limited, it is a better use of health resources to concentrate on 
correctly identifying low risk individuals and have a smaller number of people being provided 
with support and interventions. One benefit of a greater focus on high sensitivity, would be 
that more individuals are identified who have an elevated risk of fracture. A consequence of 
this would be people who are genuinely at elevated risk not receiving the preventive medicine 
or other measures that they should. There would be limited resources being spread among a 
larger population of people who were not at an elevated risk and would not benefit as 
significantly from those interventions. 
6.4.2 Strengths and Limitations 
The cross-validation method is good for assessing how the hip fracture score can predict hip 
fractures in a dataset that was not used for creating the model. Only the variables that were 
determined to be statistically significant were included in the hip fracture score model. If 
more variables had been included in the hip fracture prediction scores, there would be more 
information to base a prediction on. Perhaps future work could explore including a large array 
of variables available in the interRAI-HC assessment to compare how well that model can 
predict hip fracture risk. 
The internal validation dataset is a small cohort compared to the test cohort and there are very 
small numbers of people who have fractures, particularly in the males-only score. This 
suggests the results have low statistical power. The results may not be as strong as they could 
be because of these small numbers. 
6.4.3 Concluding Statement 
Hip fracture scores were validated using the remaining one-third of the data from the original 
interRAI-HC dataset. The next chapter will repeat the analysis conducted here, but with a 
separate cohort of New Zealand interRAI-HC data from assessments performed later in time. 
This is to evaluate how well the hip fracture score can predict hip fractures in a dataset 




7 External Validation 
7.1 Introduction 
The previous chapter contained information on the development of the hip fracture score 
using two different models: one for a male cohort and one for a female cohort. Various cut-off 
points were assessed to find which cut-off point was the best at identifying individuals at an 
elevated risk of fracture. In this chapter, the same analyses performed in the previous chapter 
is repeated using a more recent interRAI-HC dataset. This is to assess how well the hip 
fracture score can predict hip fractures in a dataset that was not part of the development 
dataset, nor part of the internal validation which was taken from the original dataset. This is 
advantageous as it allows the score to be used in other cohorts, not just the one it was 
developed for. The aim of this chapter is to assess how the scores that were developed in the 




Participants of the study were selected using the same exclusion criteria as applied to the 
original dataset as outlined in 4.3.1. Participants included community-dwelling adults aged 65 
years and over who had an interRAI-HC assessment from 1 November 2015 to 1 June 2018. 
Where individuals had more than one HC assessment, only the first one was included. 
7.2.2 Variables 
Variables used for analysis were those used for creation of the hip fracture scores and the sex 
variable. These variables were age, ethnicity, falls, wandering, BMI, tobacco use, Parkinson’s 
disease, and dyspnoea. All variables were recoded using the methods outlined in section 3.3. 
7.2.3 Statistical Analysis 
Descriptive information about the cohort was reported. Hip fracture scores were calculated for 
both male and female cohorts using Equation 1. A cumulative frequency distribution plot of 
the scores and ROC curves were created for each group. The AUC values were reported for 
each ROC curve. The cut-off points determined in section 6.3 were explored for the external 
validation cohort. The cut-off point that suggests an individual is at an elevated risk of hip 
fracture was 0.2567 or higher for males and 0.3533 or higher for females. Sensitivity, 





7.3.1 Participant Selection 
7.3.1.1 interRAI Data 
The initial interRAI dataset received contained home care, long-term care (LTCF), palliative 
care (PC), and palliative care hospice supplement (PCH) assessments. The LTCF, PC, and 
PCH assessments were removed from the dataset, leaving only the HC assessments. Only 
assessments undertaken after 31 October 2015 were included. There were a total of 62,678 
interRAI-HC assessments for analysis. The figure below (Figure 13) details the data selection 




Figure 13 Participant selection criteria for the external validation cohort 
Removed Gender is Unknown (74) or Indeterminate (2) 
76 removed 
Removed those with end-stage disease 
2,527 removed 
Removed already living in ARC 
925 removed 
Removed if time to death ≤ 0 days from assessment 
42 removed 
Removed ≤ 64 years old 
3,825 removed 
Removed any HC assessments before 31 October 2015 
103,266 removed 
Removed repeat (19,886) and unmatched (65) assessments 
19,951 removed 
Removed all LTCF, PC, and PCH assessments  
206,694 removed 
399,987 initial assessments 










7.3.1.2 Hospital Admissions Data 
The hip fracture hospital admissions were processed  in the same manner described in section 
3.3. The hospital admissions dataset consisted of 549,319 records of patient hospital 
admissions from 14 October 2015 to 17 July 2018. There were 19,238 instances of hip 
fracture admissions; however, several patients had multiple admissions listed for the same 
event, and this was confirmed in the dataset by the event date column. Some people had 
multiple hip fracture events, and the first event after 31 October 2015 was used for analysis. 
After condensing the dataset, there were a total of 4,392 first hip fractures. Anyone who had a 
hip fracture before their interRAI-HC assessment was not counted as having a hip fracture; 
this left a total of 2,836 participants with a hip fracture. 
7.3.2 Participant Characteristics 
The external validation dataset consisted of 62,728 interRAI-HC assessments. It was similar 
in size to the original dataset before it was partitioned for cross-validation purposes. 
Participants had a mean age of 82.5 years (range 65 to 109 years) and there were 37,685 
(60.1%) females. The mean age and sex distributions were similar to the original dataset 
(mean age: 82.8 years, 61.6% female). The ethnic distributions were similar to that of the 
original dataset. Within the external cohort 2,836 (4.5%) people had a hip fracture, and 20,324 
(32.4%) had died. There was a smaller percentage of people with an undetermined BMI in the 
external cohort (16,436, 26.2%) than in the original cohort (26,116, 38.8%). There was a 
slightly higher percentage of people who had a hip fracture in this cohort (4.5%) compared 
with the original cohort (3.4%), and there was a slightly higher percentage of deaths (32.4%) 
than in the original cohort (29.2%). Table 21 below lists the frequencies for all variables used 




Table 21 Descriptive information of significant variables for external validation cohort with totals and partitioned by outcome 
  First Event 
Variable names Total 
n (%) 
Alive, no fracture Fracture Death 
Sex     
Male 24,917 (39.8) 14,368 (36.4) 947 (33.4) 9,602 (47.3) 
Female 37,761 (60.2) 25,150 (63.5) 1,889 (66.6) 10,722 (52.7) 
Age Group (years)     
65-74 12,279 (19.6) 8,929 (22.6) 298 (10.5) 3,052 (15.0) 
75-84 26,353 (42.0) 17,460 (44.2) 1,075 (37.9) 7,818 (38.5) 
85-94 22,493 (35.9) 12,469 (31.6) 1,366 (48.2) 8,658 (42.6) 
95+ 1,553 (2.5) 660 (1.7) 97 (3.4) 796 (3.9) 
Ethnicity     
Māori 3,838 (6.1) 2,539 (6.4) 63 (2.2) 1,236 (6.1) 
Pacific 2,191 (3.5) 1,524 (3.9) 35 (1.2) 632 (3.1) 
Asian 1,823 (2.9) 1,295 (3.3) 53 (1.9) 475 (2.3) 
European 54,201 (86.5) 33,701 (85.3) 2,654 (93.6) 17,846 (87.8) 
Other 625 (1.0) 459 (1.2) 31 (1.1) 135 (0.7) 
Previous Falla     
No Fall 36,664 (58.5) 24,298 (61.5) 1,444 (50.9) 10,922 (53.7) 
Had at least one fall 26,013 (41.5) 15,219 (38.5) 1,392 (49.1) 9,402 (46.3) 
Wanderingb     
Not Present 59,932 (95.6) 37,963 (96.1) 2,657 (93.7) 19,312 (95.1) 
Present 2,734 (4.4) 1,553 (3.9) 179 (6.3) 1,002 (4.9) 
BMI     
Underweight 3,784 (6.0) 1,791 (4.5) 284 (10.0) 1,709 (8.4) 
Normal 22,156 (35.3) 13,447 (34.0) 1,237 (43.6) 7,472 (36.8) 
Overweight 12,916 (20.6) 8,887 (22.5) 446 (15.7) 3,583 (17.6) 
Obese 7,386 (11.8) 5,504 (13.9) 157 (5.5) 1,725 (8.5) 
Unknown 16,436 (26.2) 9,889 (25.0) 712 (25.1) 5,835 (28.7) 
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  First Event 
Variable names Total 
n (%) 
Alive, no fracture Fracture Death 
Smokes tobacco dailya     
No 59,400 (94.8) 37,444 (94.8) 2,680 (94.5) 19,276 (94.8) 
Yes 3,277 (5.2) 2,073 (5.2) 156 (5.5) 1,048 (5.2) 
Parkinson’s Diseasea     
Not present 60,149 (96.0) 37,907 (95.9) 2,679 (94.5) 19,563 (96.3) 
Diagnosis present 2,528 (4.0) 1,610 (4.1) 157 (5.5) 761 (3.7) 
Dyspnoeaa     
Not present 31,909 (50.9) 21,814 (55.2) 1,579 (55.7) 8,516 (41.9) 
Present 30,768 (49.1) 17,703 (44.8) 1,257 (44.3) 11,808 (58.1) 




7.3.3 External Validation Hip Fracture Scores 
Hip fracture scores for both males and females were calculated using the β coefficient from 
Table 16. The cumulative distribution plot (Figure 14) shows the cumulative percentage of 
each hip fracture score.  
 
Figure 14 Cumulative distribution of male and female hip fracture scores in the external validation cohort 
 
The ROC curves for the male and female scores can be found in Figure 15. For males, the 
AUC was 0.611 (95% CI: 0.594, 0.629) and for females the AUC was 0.624 (95% CI: 0.612, 
0.636). These AUCs suggest the models are better than random chance at predicting hip 
fracture risk in older adults, but a value closer to 1 would be better (219). 
 


























The cut-off points of 0.2567 or higher for males and 0.3533 or higher for females determined 
in Chapter Six were used to indicate whether a person was at an elevated risk of hip fracture 
or not. For the males score, the sensitivity was 28.0% and the specificity was 82.6%. The 
females had slightly lower sensitivity (24.2%), but a higher specificity (85.5%). 
Table 22 Sensitivity, specificity, PPV, and NPV of males and females external validation scores 
Cohort Sensitivity Specificity PPV NPV 
Males 28.0% 82.6% 6.0% 96.7% 
Females 24.2% 85.5% 8.1% 95.5% 
 
7.3.4 Summary of Hip fracture scores 
The AUCs for the test scores (original dataset) were the highest (0.617 for males, 0.645 for 
females). Overall, the females score had higher AUCs suggesting it was better at predicting 
hip fracture risk in the interRAI-HC cohort. The internal validation cohort had the lowest 
AUCs with 0.586 for males (95% CI: 0.548, 0.637) and 0.615 (95% CI: 0.593, 0.637) for 
females. Table 23 below provides a summary of each of the AUCs for each cohort. 
Table 23 Summary of AUCs for the test cohort, internal validation cohort, and external validation cohort 
Cohort Male AUC (95% CI) Female AUC (95% CI) 
Test 0.617 (0.577, 0.657) 0.645 (0.629, 0.661) 
Internal validation 0.586 (0.548, 0.637) 0.615 (0.593, 0.637) 
External validation 0.611 (0.594, 0.629) 0.624 (0.612, 0.636) 
 
The sensitivity, specificity, PPV, and NPV appear to be similar between the two females 
scores with sensitivity of 24.6% for the internal cohort and 24.2% for the external cohort. The 
specificity is also similar at 84.0% for the internal cohort and 85.5% for the external cohort. 
There are more differences between the males, but they still appear similar. Table 24 provides 
a summary of each of the hip fracture risk scores and their corresponding sensitivity, 
specificity, PPV, and NPV. 
Table 24 Summary of sensitivity, specificity, PPV, and NPV for the internal validation cohort, and external 
validation cohort 
Cohort Sensitivity Specificity PPV NPV 
Internal Males 32.9% 77.3% 3.8% 97.7% 
Internal Females 24.6% 84.0% 6.1% 96.4% 
External Males 28.0% 82.6% 6.0% 96.7% 





7.4.1 Key Findings 
Both the males and females scores performed better than they did with the internal validation 
cohort. This is likely due to the smaller cohort sizes in the internal validation cohort. The 
AUC for the males external score was 0.611 (95% CI: 0.594, 0.629) compared to the internal 
score of 0.586 (0.548, 0.625). The females external score was 0.624 (95% CI: 0.612, 0.636) 
and the internal score was 0.615 (0.593, 0.637). All four of the scores had AUCs that were 
better than random chance (0.5 or lower); however, they would all be considered to have 
moderate predictability, which suggests there is room for improvement with these hip fracture 
scores. 
Both male scores had similar sensitivity, specificity, PPV, and NPV to each other, as did the 
female scores. The higher levels of specificity indicate there is a higher level of accuracy 
concerning people who are less likely to be at risk of having a hip fracture. If there was a 
focus on sensitivity, there would be larger numbers of people who would be classified as 
being at an elevated risk of hip fracture, and as resources are limited, it would be more 
difficult to decide who should be referred for hip fracture prevention programmes. 
7.4.2 Strengths and Weaknesses 
The external validation dataset was large, which allowed for a strong analysis of the hip 
fracture score; the AUCs were higher than in the internal validation set, possibly because of 
these larger numbers. 
Both the original and the external cohorts are from New Zealand and were similar cohorts, so 
the results of the external validation cohort were similar to the test and internal validation 
cohorts. However, the score may not perform as well in a cohort from another country where 
there may be differences between the characteristics of people who undergo interRAI-HC 
assessments from those countries. 
7.4.3 Concluding Statement 
The females hip fracture score was a better predictor of hip fracture risk than the males score. 
External validation for the model was good, and the hip fracture scores performed better than 
they did with the internal validation cohort. The next chapter provides an extended discussion 
about the results of the whole study, including the interpretation of all results, and the 





8.1 Key Findings 
Risk factors for hip fracture for the entire interRAI-HC cohort were age, sex, ethnicity, 
previous falls, mental function varies throughout the course of the day, wandering, BMI, 
tobacco use, Parkinson’s disease, and dyspnoea. Sex differences were assessed, and it was 
noted that males and females had different risk profiles. The risk factors associated with hip 
fracture for males were age, Parkinson’s disease, and dyspnoea, and for females, the 
associated risk factors were age, ethnicity, wandering, BMI, tobacco use, and dyspnoea. 
Hip fracture scores were developed for male and females separately. The males-only score 
(AUC: 0.586, 95% CI: 0.548, 0.625) performed worse than the females-only score (AUC: 
0.615, 95% CI: 0.593, 0.637) in the internal validation dataset, but both had some 
predictability. The scores were also tested on an external validation set and the male scores 
(AUC: 0.611, 95% CI: 0.594, 0.629) and the female scores (AUC: 0.624, 95% CI: 0.612, 
0.636) performed better than they did with the internal validation cohort. The hip fracture 
scores had higher AUCs than the Falls CAP (AUC: 0.540, 95% CI: 0.527, 0.552), which 
suggests both scores are better at predicting hip fracture risk than the Falls CAP. 
 
8.2 Integration with the Literature 
8.2.1 Falls 
It is well documented in the literature that falls are a leading cause of fractures in older adults 
(15, 74-76, 79). It was not surprising that, for the whole cohort, falls were significantly 
associated with hip fracture. However, when the cohort was separated into males and females, 
falls were not associated with hip fracture. This is possibly due to the reduced number of 
people in each cohort and less statistical power when developing the predictive models than 
when the whole cohort was used. Additionally, the Falls CAP is triggered in those people who 
are consistently having falls, and it was noted in section 4.3.5 that those who did not trigger 
the Falls CAP had a higher number of hip fractures than those who triggered the medium and 
high risk categories - where 59.7% (2,259) of hip fractures were sustained by those who did 
not trigger the falls CAP. This suggests the possibility that falls prevention programs may be 
put in place for those who do trigger the Falls CAP and this could possibly reduce their risk of 
falling in future and sustaining a hip fracture. 
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Five of the hip fracture prediction tools discussed in the literature review did not include falls 
as an item in the model. The FRAX tool did not include falls as a measure and did not assess 
whether this would improve their model. Kanis et al. acknowledged that other studies had 
included a question on falls, but no explanation was given as to why they opted not to include 
falls in their tool (161). Neither the FRISC nor the WHI included falls as an item either, and 
falls as a risk factor for hip fracture was not mentioned (102, 167). Both the FRACTURE and 
the FRAMO scores explored falls as a potential risk factor to include in their prediction 
models. Both found falls were not significantly associated with hip fracture and so were 
omitted from the final prediction models (84, 166). A potential explanation for these findings 
was that both studies had very small numbers with 7,782 people included in the FRACTURE 
score (30.2% of people reported having a fall), and 1,248 people included in the FRAMO 
score (33.3% of people reported having a fall). 
8.2.2 Fractures 
Neither previous hip fracture nor previous other fracture were associated with hip fracture. 
Both the FRAiL and the FRS scales which were developed using interRAI-LTCF data 
explored associations between hip fracture and previous hip fracture. Berry et al. found 
previous hip fracture was not associated with an increased risk of hip fracture either (76). 
However, Ioannidis et al. found those who had a previous hip fracture were at an elevated risk 
of sustaining a subsequent fracture (94). These differences may have occurred from the way 
that previous fracture was calculated. Berry et al. took previous hip fracture information from 
Medicare information and linked it with interRAI data, and Ioannidis et al. had previous 
fracture information from the last 180 days in the interRAI-LTCF, whereas the New Zealand 
interRAI-HC data only contains information on previous fractures within the last 30 days 
prior to assessment. The shorter time frame of the New Zealand data reduced the time-frame 
available for identifying individuals who have had a previous hip or other fracture. 
Nine of the eleven hip fracture prediction models mentioned in Table 5 included previous hip 
fracture. The FRAiL model explored previous hip fracture but found it was not significantly 
associated with hip fracture (76). The Qfracture did not contain the variable previous hip 
fracture, but the Updated Qfracture study explored previous fracture information and added it 
to the updated model (51, 92). 
8.2.3 Age and Sex 
Demographic differences such as age, sex, and ethnicity are all commonly known risk factors 
for hip fracture (60). As age increases, the likelihood of a hip fracture increases (60, 89). 
Unsurprisingly, the results of this study showed that age was significantly associated with hip 
120 
 
fracture risk, where those in the higher age groups were more likely to sustain a hip fracture 
than those in the lower age groups. Age was also a key risk factor that explained more of the 
models than any other variable. As an individual ages, they are likely to have more health 
issues such as impaired vision, low BMD, muscle weakness, and balance issues, which can all 
lead to an increase in hip fracture risk (15, 60, 89, 91). 
Females are known to have a higher risk of hip fracture than males as they are more likely to 
develop osteoporosis and have lower bone mineral density (61, 68, 84, 85). In this study, 
females had a higher number of significant risk factors than did men suggesting there are 
more risks common to females, therefore there is a higher chance that females will sustain a 
hip fracture. However, these findings could also be related to the larger cohort size for the 
females or a combination of both. Additionally, there was less data available for males; 
therefore, the statistical power is lower. Males and females were found to have different risk 
factors profiles. However, the FRAiL study found that males and females had almost identical 
risk factor profiles except that diabetes was significantly associated with fracture risk in 
females but not males (76). A potential explanation is that their study had larger cohorts, 
which would lead to more statistical power, or the LTCF cohort may have more similar risk 
profiles for males and females than in the HC cohort. A German study identified that males 
have a higher falls incidence in nursing homes leading to similar risk of hip fracture in aged 
care facilities (220). 
All of the hip fracture prediction models mentioned in Table 5 included age as an item. The 
FRACTURE, FRAMO, FRISC, Van Staa, and WHI prediction models were developed for 
women only, so sex was not included in these models (52, 84, 102, 166, 167). Of the 
remaining prediction models, only the FRS did not include sex as an item for calculating risk 
prediction. 
8.2.4 Ethnicity 
People with different ethnic backgrounds have differing risks for hip fracture in the current 
study and in previous hip fracture risk studies (106, 221, 222). This study found that those of 
European ethnicity were deemed to be at a high risk of hip fracture compared to Māori, 
Pacific people, and Asians. There is a large amount of literature identifying that those who are 
white or European have higher rates of hip fracture than other ethnic groups (20, 69, 92, 222). 
Additionally, studies have noted that individuals who identify as Hispanic have similar hip 
fracture rates to those of white/European ethnicity (221, 222). Berry et al. and Robbins et al. 
noted that Native American individuals had a higher risk of sustaining a hip fracture than 
white individuals (76, 102). 
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An earlier New Zealand study noted that Māori males are less likely to have a hip fracture 
than non-Māori and female Māori (30). In this study, after adjusting for age and sex, Māori 
and Asian participants had the lowest risk of hip fracture, followed by Pacific people; 
individuals who were classified as other ethnicities had the highest risk of fracture but the 
group was small and diverse, therefore, no substantial conclusions can be made about that 
group. People who identified as European had the highest number of fractures and, after the 
ethnic group “other”, were more likely to sustain a hip fracture. These results are similar to 
earlier findings in New Zealand where Europeans are more likely to have fractures than Māori 
or Pacific people (20, 30).  
8.2.5 Cognition 
Wandering was found to be associated with hip fracture risk for this cohort; these results were 
also found among interRAI-LTCF cohorts, and wandering was included in both the FRAiL 
and FRS models (76, 94). A study by Stolee et al. did not examine the effect of wandering on 
hip fracture risk in the Canadian interRAI-HC cohort (75). None of the non-interRAI hip 
fracture prediction models identified in Table 6 included wandering as an item. 
Cognitive impairment was not associated with hip fracture. All three of the other interRAI 
cohort studies used the CPS as a measure of cognitive impairment. For all three studies, CPS 
was found to be associated with hip fracture (75, 76, 94). The CPS was not specifically 
explored in this study as it is an outcome scale calculated at the end of an assessment (95). 
However, the question regarding cognitive skills for daily decision making is an item in the 
CPS, and this was used as one of the primary measures for cognitive impairment within this 
study. It was not found to be associated with hip fracture risk. Mental function varies 
throughout the course of the day was associated with hip fracture risk for the whole cohort, 
but it was not associated with hip fracture risk in either the male or female cohorts. This item 
was not noted to be examined in any of the other known studies but is a measure of cognitive 
impairment within the interRAI-HC assessment. 
Dementia was not included in this study based on research conducted by Berry et al. and 
Ioannidis et al. (76, 94). Berry et al. did not include dementia diagnosis as a variable of 
interest however, Ioannidis et al. included dementia diagnosis as a variable of interest in their 
study but found it was not associated with hip fracture (94). Bohlken et al., however, found 
that individuals with dementia who lived in care homes were more likely to sustain a hip 
fracture than those who did not have a diagnosis of dementia (96). Their study had a large 
number of individuals with dementia (53,156 people), which may have allowed them more 
statistical power than Ioannidis’ (16,778 individuals with dementia). Both the QFracture 
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Updated and the FRISC hip fracture prediction models included dementia as an item (92, 
167). 
8.2.6 BMI 
Those with a low BMI are more likely to have a hip fracture than those who have a normal 
BMI, and those overweight or obese had a lowered risk for hip fracture. These findings are 
consistent with the literature (66, 68, 99, 100). Typically, older people who are underweight 
tend to be frailer than those who have a BMI in the normal or overweight categories (223). 
They are also more likely to fracture their bones than those who are overweight or obese 
because they have a lower body fat percentage, and less padding around the hip areas. 
Therefore, when they fall and land on the hip, the impact is less cushioned (67, 224). 
Many studies have also identified those who have a high BMI are at a reduced risk of fracture 
(99, 103, 104, 225, 226). Studies have examined the relationship between high BMI and 
BMD and discovered that some individuals with a high BMI are also likely to have a high 
BMD (103, 104). Although a recent study conducted by Greco et al. found that some 
individuals with a high BMI had lower-than-expected lumbar BMD suggesting that it is still 
important to test an individual’s BMD when they have a high BMI (227). 
All of the hip fracture prediction models previously discussed included weight as a 
component of their scores. The FRAiL, FRS, Qfracture, Qfracture Updated, and Van Staa 
included weight information as a BMI calculation. WHI and FRAX included both height and 
weight information independently, and the other scores did not include height as a variable in 
their prediction models. 
8.2.7 Lifestyle Factors 
Smoking tobacco has been associated with hip fracture risk in previous studies (75, 228, 229), 
and this study also found that those who smoked tobacco were at an increased risk of 
sustaining a hip fracture. Kanis et al. found that non-smokers had the lowest risk of sustaining 
a hip fracture and current smokers had a higher risk of hip fracture than people who were 
smokers but had since quit (228). Tobacco smoking was included in six of the eleven fracture 
risk prediction models. The FRAiL and the FRS did not include smoking as there is no 
question on tobacco use in the interRAI-LTCF assessment (230). Nguyen et al. chose not to 
include smoking as a measurement as this would be reflected in the BMD measurement (169, 
231). Both the FRAMO and FRISC included smoking status in their initial research but 
excluded it from their final models as they did not find a strong association between smoking 
and hip fracture for their cohorts (166, 167), although both had sample sizes below 2,000 and 
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may not have had the statistical power to detect associations between hip fracture and tobacco 
smoking. 
Alcohol consumption was not associated with hip fracture for this cohort, though there have 
been a number of studies identifying alcohol as a risk factor for hip fracture (61, 65, 115, 117, 
118). A potential reason for this could be because the cohort may be less likely to drink 
alcohol, therefore they are less likely to be impaired from the alcohol, reducing their falls risk. 
The questions in the interRAI-HC are also based on the reports of the person being assessed, 
any family members present at the time of the assessment, and medical records where needed. 
For topics such as alcohol use, it may be difficult to tell precisely how much alcohol a person 
consumes as they may not wish to disclose the true amount they drink from a possible fear of 
criticism or judgement. The alcohol consumption question itself is also vague and asks for the 
highest number of drinks in any “single setting” in the 14 days prior to assessment. The term 
“single setting” is vague and may result in unclear answers. 
Alcohol information was only included in the FRAX, Qfracture, and Qfracture Updated 
prediction models (50, 51, 92). There is no question within the interRAI-LTCF assessment on 
alcohol consumption so this item was not included in the FRAiL or FRS models (230). 
Similar to tobacco use, alcohol consumption was not included in the Garvan as it is believed 
to be reflected in the patient’s BMD (231). Robbins et al. found alcohol consumption was 
statistically significantly associated with hip fracture risk but did not affect the AUC of the 
model and so was not included in their final risk prediction model (102). 
8.2.8 Co-Morbidities 
Within this study Parkinson’s disease and Dyspnoea were the co-morbidities associated with 
hip fracture risk. Other co-morbidities such as Stroke/CVA, COPD, and incontinence were 
explored but were not significantly associated with hip fracture. Parkinson’s disease has 
previously been found to be associated with hip fracture (232-236). Parkinson’s disease was a 
significant risk factor for hip fracture in the whole cohort and the males-only cohort, but not 
for females. This may be because males are more commonly diagnosed with Parkinson’s 
disease than females (237). Parkinson’s disease is a neurodegenerative disorder that can lead 
to impaired motor-skills, which can lead to falls (237). The Qfracture Updated score was the 
only hip fracture model to include Parkinson’s disease as an item (92). The FRS study 




Dyspnoea was associated with hip fracture for the whole cohort and for females. Those who 
had shortness of breath were less likely to have a hip fracture. This is possibly because the 
people with dyspnoea are unable to move around without feeling short of breath, and are 
unlikely to be mobile enough to have falls. No hip fracture prediction models mentioned in 
the literature include dyspnoea, and it does not appear to be considered as a risk factor in 
other hip fracture studies. Within the body of literature, dyspnoea appears to be discussed as 
an issue that arises after an individual sustains a hip fracture, rather than as a potential risk 
factor (238-241). 
A total of thirteen co-morbidities were included among the hip fracture prediction models. 
The Qfracture Updated score included items such as COPD, epilepsy, cancer, systemic lupus 
erythematosus, Parkinson’s disease, and chronic renal disease (92). None of these items were 
included in any other hip fracture models; however, Hippisley-Cox et al. had the largest 
cohort (3,142,673), which gave them greater statistical power. Cardiovascular issues were 
included in both the Qfracture and the Qfracture Updated and were analysed by Tanaka et al. 
but were not deemed significant (51, 92, 167). 
Diabetes was included in the FRAiL, Qfracture, and Qfracture Updated models (51, 76, 92). 
Ioannidis et al. included diabetes in their initial analyses, but found it was not associated with 
hip fracture (94). Osteoarthritis was included in the FRAiL model; no other study explored 
osteoarthritis (76). However, FRAX, Qfracture, and Qfracture Updated models included 
rheumatoid arthritis (51, 92, 161). Tanaka et al. examined rheumatoid arthritis as a potential 
risk factor for hip fracture but found it was not statistically significant (167). A low cohort 
size (1,787) could be the reason for their lack of findings. Asthma was included in the 
Qfracture and Qfracture Updated models, and no other scores included asthma or COPD in 
their studies (51, 92). The Van Staa model included an item labelled “chronic disease” which 
was consisted of any recent GP visits or hospitalisation for COPD, asthma, cerebrovascular 
accident, heart failure, rheumatoid arthritis, or inflammatory bowel disease (52). 
8.2.9 Exercise 
Several studies have shown that individuals who do not engage in regular exercise are at an 
increased risk of hip fracture (68, 86, 102, 145, 146). This study did not find exercise to be 
significantly associated with hip fracture. Multiple studies have noted that exercise in early 
life is important for reaching peak bone mass, which results in stronger bones in older age 
(154-157). There is currently only one question about physical activity in the interRAI-HC 
assessment, which asks the individual for the total hours of exercise or physical activity in the 
three days prior to their assessment. This question includes activities such as walking, but the 
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intensity of the exercise is not recorded. Including a question about activity level in early 
adulthood may serve as a proxy for estimating an individual’s bone strength or BMD. 
WHI was the only hip fracture prediction model that included an item about physical activity 
as part of their prediction model (102). Participants in the study reported their physical 
activity and this was converted to a Metabolic Equivalent Task (MET) by Robbins et al. A 
MET is a measure of the intensity and energy expenditure of an activity (242). In this 
instance, a MET score of 7 or higher was considered to be strenuous activity, 4-6 was 
moderate, and 3 was considered a low intensity activity, such as walking (102). There was 
only one other hip fracture score that explored physical activity as a possible risk factor. The 
FRACTURE index included a question on whether participants went for a walk, and this was 
not found to be statistically significant (84). All other scores did not include exercise as a 
possible risk factor; however, the Qfracture, Van Staa, and FRAMO acknowledged the lack of 
information about exercise was a limitation with their studies (51, 52, 166). Using a more 
specific measure of the intensity of exercise within the interRAI-HC assessment could give 
more information about the physical capability of an individual, and may be a significant 
predictor for hip fracture. 
Figure 16 below, shows an updated conceptual framework diagram of the risk factors 
associated with hip fracture derived from the literature review (Figure 2). The dark grey items 
were items that were unavailable for use in the model, and the light grey items were not 




















8.2.10 Comparison with Other Hip Fracture Scores 
There were some similarities across several of the hip fracture scores developed in the 
literature, and the two scores derived from the interRAI-HC 9.1 assessment data. All hip 
fracture scores included age as a variable. Only the males-only hip fracture score derived from 
the interRAI-HC 9.1 did not contain weight as a variable. Both Parkinson’s disease and 
dyspnoea were not included in any other hip fracture score. People who had dyspnoea had a 
reduced risk of hip fracture compared to those who did not; perhaps the other hip fracture 
scores were interested in items that, when present, were more likely to increase the risk of hip 
fracture than reduce it. 
The two hip fracture scores created for interRAI assessments (FRAiL and FRS) used some 
variables that were consistent with the variables found in the hip fracture score developed in 
this study. The two previously published hip fracture scales were developed for the LTCF 
assessment, which is a different cohort to those undergoing the HC assessment, therefore not 
all risk factors will be the same. The score developed by Berry et al. consisted of 15 items, 
and six of those items were included in the HC score. These items were age, sex, 
ethnicity/race, previous falls, wandering, and BMI (76). Previous falls was not used in the 
male- and female-only cohorts, but it was significantly associated with hip fracture for the 
whole cohort. 
The fracture risk score developed by Ioannidis et al. included eight items and five of these 
were also in the HC score; the items in common were age, BMI, previous falls, wandering, 























































































































Age ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Weight ✓ ✓ ✓a ✓a  ✓a ✓a ✓a ✓ ✓ ✓ ✓a ✓ 
Height ✓  ✓a ✓a  ✓a ✓a ✓a    ✓a ✓ 
Sex ✓  ✓    ✓ ✓      
Race/ Ethnicity      ✓  ✓     ✓ 
BMD ✓ ✓       ✓  ✓   
Previous fracture ✓ ✓  ✓    ✓ ✓ ✓ ✓ ✓ ✓ 
Parental history of fracture ✓      ✓ ✓ ✓    ✓ 
Falls  ✓ ✓ ✓   ✓ ✓    ✓  
Smoking ✓     ✓ ✓ ✓ ✓   ✓ ✓ 
Alcohol ✓      ✓ ✓      
Osteoporosis ✓      ✓ ✓   ✓   
Rheumatoid Arthritis ✓      ✓ ✓      
Specific medications ✓  ✓    ✓ ✓    ✓ ✓ 
Cognitive Impairment   ✓ ✓          
ADL   ✓           
Locomotion in room   ✓           
Bladder continence   ✓           
Transfer performance   ✓ ✓          
Easily distracted   ✓           
Wandering   ✓ ✓  ✓        
Osteoarthritis   ✓           





















































































































Diabetes   ✓    ✓ ✓     ✓ 
Walking in corridor    ✓          
Asthma       ✓ ✓      
Cardiovascular disease       ✓ ✓      
COPD        ✓      
Epilepsy        ✓      
Dementia        ✓   ✓   
Cancer        ✓      
Systemic lupus erythematosus        ✓      
Parkinson’s disease     ✓   ✓      
Chronic renal disease        ✓      
Care or nursing home residence        ✓      
Aid to get up from sitting         ✓ ✓    
Menopausal           ✓   
Back pain           ✓   
Self-reported health             ✓ 
Early menopause            ✓  
Chronic disease            ✓  
Central nervous system medication            ✓  
Physical activity             ✓ 
Dyspnoea     ✓ ✓        
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The test cohort had the highest AUC (males: 617 95% CI: 0.577, 0.657; females: 0.645 95% 
CI: 0.629, 0.661) of any of the interRAI-HC scores, which is to be expected because the score 
was developed for that cohort, therefore it would be expected that it would be the most 
accurate at identifying people at an elevated risk of fracture. The external validation cohort 
had a higher AUC than those in the internal validation cohort, possibly due to the low 
numbers of people and therefore lower statistical power in the internal cohort. 
None of the scores mentioned in the literature review had an AUC below 0.67, suggesting 
they are much stronger at predicting hip fracture than the interRAI-HC models. All models 
developed for use with interRAI assessments had the lowest AUCs (FRAiL females: 0.711, 
FRAiL males: 0.692, FRS: 0.673). A potential explanation is that these people have more 
complex health care needs than those in the other cohorts. Due to their complex health needs, 
there may be other competing issues or underlying health concerns that make it harder to 
predict hip fracture in this population.  
Those who undergo an interRAI-HC assessment may have greater heterogeneity than other 
cohorts. This means these individuals have a wider range of health issues than more specific 
populations so it may be harder to predict who in the group is likely to have a hip fracture. 
Another example of a national cross-sectional (like the population in this thesis) population 
with greater heterogeneity is in a recent study by Schluter et al. which aimed to evaluate how 
well preschool development indicators measured within a comprehensive assessment could 
screen for early literacy interventions. Their study identified strong associations between 
variables within the cohort, but had a low AUC (0.624, 95% CI: 0.618, 0.629) (243). 
The highest AUC of any score was the female’s Qfracture Updated score with an AUC of 
0.893 (0.890, 0.896); it also had the largest development cohort (1,598,294), which would 
have allowed for greater statistical power when exploring the associations to hip fracture. 
Additionally, the Qfracture and Qfracture updated scores included a high numbers of items 
used to calculate their scores (14 for Qfracture and 24 for Qfracture updated). One way to 
improve prediction of a model is to include a high number of variables. This study aimed to 
characterise risk factors in addition to developing a prediction score, which meant there were 
less items used in the final prediction model, which could lead to a lower AUC. The selection 
criteria of variables in the model was based on which variables were statistically associated 
with hip fracture similar to the methods used by Berry et al. (76). 
There were some studies with smaller cohorts (<2,000) that had higher AUCs such as the 
FRAMO (AUC: 0.72 95% CI: 0.64, 0.81) and the FRISC (0.727 95% CI: 0.660, 0.794). This 
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is most likely due to the cohort being a less heterogeneous group - for instance, both scores 
were developed for postmenopausal women, a group that is likely to have similar health 
issues compared to a more heterogeneous group as the interRAI-HC cohort. When the group 
is likely to be similar, the risk factors for hip fracture will also be similar and therefore easier 
to predict the likelihood of fracture. 
Table 26 provides a summary of all hip fracture scores mentioned in section 2.4 and those 




Table 26 Summary of hip fracture scores including year developed, country of origin, cohort size, statistical technique used, and AUC updated with interRAI-HC scores 
Hip Fracture Score Year Country Cohort Statistical Method AUC (95% CI) 
FRAX 2008 UK Unknown Poisson regression Unknown 
Garvan 2007 Australia 1,768 Cox proportional hazards model 0.85* 
Qfracture (Females) 2009 UK 1,183,663 Cox proportional hazards model 0.890 (0.786, 0.790) 
Qfracture (Males) 2009 UK 1,174,232 Cox proportional hazards model 0.856 (0.851, 0.860) 
Qfracture Updated (Females) 2012 UK 1,598,294 Cox proportional hazards model 0.893 (0.890, 0.896) 
Qfracture Updated (Males) 2012 UK 1,544,379 Cox proportional hazards model 0.875 (0.868, 0.883) 
FRACTURE 2001 USA 7,782 Logistic regression 0.714* 
FRAMO 2004 Sweden 1,248 Logistic regression 0.72 (0.64, 0.81) 
FRISC 2010 Japan 1,787 Poisson regression 0.727 (0.660, 0.794) 
Van Staa 2006 UK 366,104 Cox proportional hazards model 0.84* 
WHI 2007 USA 93,676 Cox proportional hazards model 0.80 (0.77, 0.82) 
FRAiL (Males) 2017 USA 119,874 Competing risk regression 0.692* 
FRAiL (Females) 2017 USA 299,794 Competing risk regression 0.711* 
FRS 2017 Canada 29,386 Decision tree 0.673* 
Test cohort males 2019 NZ 17,339 Competing risks regression 0.617 (0.577, 0.657) 
Test cohort females 2019 NZ 27,707 Competing risks regression 0.645 (0.629, 0.661) 
Internal males 2019 NZ 8,521 Competing risks regression 0.586 (0.548, 0.625) 
Internal females 2019 NZ 13,770 Competing risks regression 0.615 (0.593, 0.637) 
External males 2019 NZ 24,917 Competing risks regression 0.611 (0.594, 0.629) 
External females 2019 NZ 37,761 Competing risks regression 0.624 (0.612, 0.636) 





8.3 Strengths and Limitations 
The data arises from a national interRAI-HC cohort in New Zealand, which has distinct 
demographic characteristics. This allows scores derived from this cohort to potentially be 
more applicable to the population of New Zealanders with complex needs than other scores 
are. For example, the FRAX score is used to determine the ten-year probability of hip 
fracture, but among New Zealand individuals having an interRAI-HC assessment from July 
2012 to June 2014, approximately 30% had died by the end of the 2-year period (192), 
suggesting ten years may be an unsuitable time period to estimate fracture risk in New 
Zealand. Conversely, the results from this study may not be as generalisable to international 
interRAI-HC users as some questions such as ethnicity have been specially tailored for a New 
Zealand cohort. 
This is the first study to explore the development of a hip fracture risk score for use with the 
interRAI-HC cohort. The high quality source of data available in New Zealand and the ability 
to match to external datasets such as mortality records and hospital admissions presents a 
great opportunity to develop a hip fracture score and include mortality as a competing risk, 
which is important for cohorts with high mortality rates such as the interRAI-HC cohort. 
The format of the medications data in the interRAI-HC assessments was such that it could not 
be easily extracted for analysis. However, the medications data obtained from the external 
validation dataset was in a different format to the original data, which after a considerable 
amount of tidying could possibly have been used for analysis. The literature indicates that 
medications are a significant risk factor for hip fracture, but this had to be excluded from the 
analysis. Berry et al. initially included medications in their interRAI-LTCF hip fracture 
prediction measure but found there was almost no difference when medications were included 
so opted not to include medications in the final model (76). 
One limitation of this study is that the interRAI-HC 9.1 assessment does not have a question 
relating to osteoporosis so cannot be used to identify those who may be at risk of a severe 
injury. Osteoporosis is strongly associated with hip fracture risk in the literature (61). A 
question in the interRAI-HC assessment on osteoporosis may be helpful to make decisions 
about hip fracture risk. 
While the initial dataset had large numbers, once it was divided for the purposes of cross-
validation, and then again separated into male and female groups, there were small numbers 
of hip fractures available for analysis. This was especially true for the internal validation 
dataset, where the results were not as high as those found in the external validation dataset. 
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For instance, falls, which are the main cause of hip fracture in older adults, were considered to 
be statistically significant in the whole cohort model; however, they were not considered 
statistically significant in the males- and females-only cohorts, this may be due to low 
numbers. Additionally, the AUCs for the internal validation cohort were lower than those of 
the external validation cohort, which is unusual but is most likely due to the very low number 
of fractures in the internal validation cohort. 
The New Zealand interRAI-HC assessment is for older people who are frailer and more 
vulnerable than the general population of older people in New Zealand; these people are 
therefore more likely to be at high risk of falls and hip fractures. 
The time between an individual having an interRAI-HC assessment and a subsequent hip 
fracture event varies, and any changes to a person’s health or any of the characteristics used in 
the hip fracture score between the two events are unknown. 
This whole study explores main effects of specific risk factors for hip fracture. There may be 
interactions between various risk factors that were not explored in this thesis. For example, 
the risk factors BMI, alcohol, and sex may have interactions that can lead to hip fractures. 
 
8.4 Implications/Recommendations 
Based on the analysis in this study, the hip fracture risk scores have a modest ability to predict 
hip fracture risk in older adults undergoing an interRAI-HC assessment. The results of this 
analysis set the foundations for developing a hip fracture score that can be used clinically in 
the interRAI-HC assessment. The ROCs are not sufficient to include as an outcome score 
within the interRAI-HC at present. Additionally, there is strict criteria for including prediction 
tools in an interRAI assessment. Therefore, further work should be undertaken to optimise the 
scores by aiming to increase the sensitivity and specificity, where they are accurate enough to 
be adopted for clinical use. In addition to this, further external validation should be done 
using interRAI-HC assessments from other countries such as Canada or Belgium to test how 
well the hip fracture score can predict hip fractures outside of New Zealand. 
Practical application of the hip fracture scores could be tested, where, at the end of an 
interRAI-HC assessment, the score is calculated, and the assessor uses this information to 
assess whether the individual should be referred to hip fracture prevention programs. 
In the literature it was noted that there are differences in hip fracture incidence among 
different ethnic groups. Further research could be undertaken to explore whether there are 
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different risk profiles among different ethnic groups. Unfortunately, there are exceptionally 
low numbers of hip fracture for non-European groups, therefore analysis of the smaller ethnic 
groups would be unlikely to produce meaningful results. It is likely that part of the predictive 
power of ethnicity results from it acting as a proxy for socioeconomic status. The MoH track 
socioeconomic status by meshblock (a grouping of physical addresses that roughly 
correspond to street blocks) and interRAI-HC assessment data includes address information. 
Future studies could use this data to evaluate socioeconomic status more directly as a risk 
factor for hip fracture.  
Additional items could be added to the interRAI-HC assessment to improve its ability to 
produce a more accurate risk prediction model. For instance, osteoporosis is an important risk 
factor for assessing hip fracture scores, and, therefore, it would be helpful to include as part of 
the interRAI-HC assessment. A question about whether an individual has a diagnosis of 
osteoporosis was included in older versions of the interRAI-HC in New Zealand, but for an 
unknown reason, it was removed. Berry et al. included osteoarthritis in their LTCF hip 
fracture prediction tool (76). This item is unavailable in the New Zealand interRAI-HC 
assessment and could be a risk factor for hip fractures in the New Zealand home care cohort. 
The medications data extracted from the interRAI-HC assessment could be better formatted 
for analysis. Initially, the data was received in a broken and unusable format, but the external 
validation dataset had the medications listed in a separate spreadsheet. While this was a better 
format, the medication names were included in a column that also contained dosage 
information for each medication; this would require a significant amount of tidying to be 
usable for analysis. If the data were listed with the medication name in its own data column, it 
would be easier to analyse. Additionally, the medications data is currently entered into the 
interRAI-HC assessment form via a drop-down menu or by typing the medication information 
directly into the electronic form (195). This can lead to inconsistencies in medication names; a 
better method would be to only allow medications information to be inserted from a drop-
down menu, which would reduce the spelling errors and make it easier to find certain 
medications. 
There is an opportunity to explore the incidence of hip fracture across different regions of 
New Zealand. The external validation interRAI-HC dataset specifies which DHB administers 
the hospital that each patient was initially admitted to. An exploration into whether there were 
regional differences in the rate of hip fracture could be undertaken. 
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The literature indicates that hip fracture and other osteoporotic fractures have similar risk 
profiles. In future studies this novel methodology could be applied to further data to assess to 
what degree hip fracture scores can be used to predict the risk of other osteoporotic fractures 
such as humeral fractures and pelvic fractures. 
It may be possible to utilise the medications data available from the MoH to test for 
relationships between medication and hip fracture instead of relying on data in the 
assessments. Where medication data from both a source like the MoH and the assessment is 
available, an opportunity exists for comparative analysis looking at which source of 
medication data can be used to produce the most predictive model, and to see how much 
improvement is made by using both sources together.   
There is value in developing a hip fracture prediction model for the interRAI-LTCF cohort in 
New Zealand. There is already international work being undertaken to develop hip fracture 
scores for the interRAI-LTCF in the United States (76) and Canada (94); collaborative efforts 
could be made to develop a score that predicts hip fracture well for the same interRAI 
assessment across multiple countries. Additionally, the hip fracture score developed for the 
interRAI-HC could be tested and further developed across multiple countries where the 
interRAI-HC is already in use. The interRAI-HC assessment is used extensively around the 
world in populations similar to the New Zealand population. 
 
8.5 What Could Have Been Done Differently 
Some DHBs in New Zealand have a policy where some people aged between 50 and 65 years 
are eligible for older people’s health services including interRAI-HC. For instance, the 
Canterbury District Health Board has a policy titled Assessing “Close in Age and Need” 
Guidelines which states that older persons health (which the interRAI-HC assessment is a part 
of) is a service available to people aged 65 years and older with disabilities, Māori and Pacific 
people aged 50 years and older with disabilities, and people aged 50 years and older with a 
confirmed dementia with disabilities (244). Studies following on from this one could include 
interRAI-HC assessment for Māori and Pacific people and people with a diagnosis of 
dementia who are 50 years and older. 
Further studies could explore other methods of analysis such as artificial neural networks to 
see if the results produced using the competing risk regression model are similar to those 
developed by a neural network. Additionally, as there were small numbers of people in the 
internal validation cohort, another method of selecting a dataset for validation, such as 
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bootstrapping, could have been employed instead. Bootstrapping is a technique where a 
dataset is created by randomly selecting individuals one at a time to be part of the dataset. 
After each person is selected, they are added back into the selection dataset so they could be 
selected again. In this way a dataset is created that is similar to the original one that was used 
for developing the hip fracture score (245). 
The size of the cohorts appeared to limit the predictive power of the models produced from 
this analysis. When working with a demographically distinct population as small as the one of 
New Zealand, it may be valuable to perform analyses over cohorts drawn from broader time 
periods to increase the sample size available. 
 
8.6 Concluding Statement 
This thesis identified risk factors associated with hip fracture and found that males and 
females had different risk profiles. Scores were developed for males and females individually, 
and both scores performed better than random chance but could be improved. Further work on 
optimising the scores could be undertaken to produce scores that may one day be used to 
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